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1. PREAMBLE and INTRODUCTION
1.1. Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
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and therapies in the management or prevention of disease
states. Rigorous and expert analysis of the available data
documenting relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve
the effectiveness of care, optimize patient outcomes, and
favorably affect the overall cost of care by focusing
resources on the most effective strategies. 
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged in
the production of such guidelines in the area of cardiovascu-
lar disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines, whose charge
is to develop and revise practice guidelines for important
cardiovascular diseases and procedures. Experts in the sub-
ject under consideration are selected from both organiza-
tions to examine subject-specific data and write guidelines.
The process includes additional representatives from other
medical practitioner and specialty groups where appropriate.
Writing groups are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against a particular treatment or procedure, and include esti-
mates of expected health outcomes when data exist. Patient-
specific modifiers, comorbidities, and issues of patient pref-
erence that might influence the choice of particular tests or
therapies are considered, as well as frequency of follow-up
and cost-effectiveness. When available, information from
studies on cost will be considered; however, review of data
on efficacy and clinical outcomes will be the primary basis
for preparing recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual or potential conflicts of inter-
est that might arise as a result of an outside relationship or
personal interest of a member of the writing panel.
Specifically, all members of the writing panel are asked to
provide disclosure statements of all such relationships that
might be perceived as real or potential conflicts of interest.
These statements are reviewed by the parent task force,
reported orally to all members of the writing panel at the first
meeting, and updated as changes occur. The relationships
with industry information for the writing committee mem-
bers is posted on the ACC (www.acc.org) and AHA
(www.americanheart.org) World Wide Web sites with the
full-length version of the update (Appendix 1), along with
names and relationships with industry of the peer reviewers
(Appendix 2). 
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range
of generally acceptable approaches for the diagnosis, man-
agement, or prevention of specific diseases or conditions.
These guidelines attempt to define practices that meet the
needs of most patients in most circumstances. The ultimate
judgment regarding care of a particular patient must be made
by the healthcare provider and patient in light of all of the
circumstances presented by that patient. 
The ACC/AHA 2004 Guideline Update for CABG was
approved for publication by the ACCF Board of Trustees in
March 2004 and the AHA Science and Advisory
Coordinating Committee in June 2004. The summary article,
describing the major areas of change reflected in the update,
is published in the August 31, 2004 issue of Circulation and
the September 1, 2004 issue of the Journal of the American
College of Cardiology. The full-text guideline is posted on
the ACC (www.acc.org) and the AHA (www.american-
heart.org) World Wide Web sites. These guidelines will be
reviewed 1 year after publication and yearly thereafter and
considered current unless the Task Force on Practice
Guidelines revises or withdraws them from circulation.
Elliott M. Antman, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1.2. Introduction
The ACC/AHA Task Force on Practice Guidelines was
formed to make recommendations regarding the appropriate
use of diagnostic tests and therapies for patients with known
or suspected cardiovascular disease. Coronary artery bypass
graft (CABG) surgery is among the most common opera-
tions performed in the world and accounts for more
resources expended in cardiovascular medicine than any
other single procedure. Since the initial guidelines for
CABG surgery were updated and published in 1991 (1),
there has been additional evolution in the surgical approach
to coronary disease while at the same time there have been
significant advances in preventive, medical, and percuta-
neous catheter approaches to therapy. 
The current Writing Committee was charged with updating
the guidelines published in 1999 (1a). The Committee
reviewed pertinent publications, including abstracts, through
a computerized search of the English literature since 1999
and performed a manual search of final articles. Special
attention was devoted to identification of randomized trials
published since the original document. A complete listing of
all publications covering coronary bypass surgery in the past
4 years is beyond the scope of this document. However, evi-
dence tables were updated to reflect major advances over
this time period. Inaccuracies or inconsistencies present in
the original publication were identified and corrected when
possible. Recommendations provided in this document are
based primarily on published data. Because randomized tri-
als are unavailable in many facets of coronary artery disease
(CAD) treatment, observational studies and, in some areas,
expert opinion form the basis for recommendations that are
offered. In each section of the Indications (Section 9), the
relative levels of evidence favoring the Class I, II, and III
indications were noted. 
All of the recommendations in this guideline update have
been written in full sentences that express a complete
thought, such that a recommendation, even if separated and
presented apart from the rest of the document, would still
convey the full intent of the recommendation. It is hoped that
this will increase readers’ comprehension of the guidelines.
Also, the level of evidence, either an A, B, or C, for each rec-
ommendation is now provided. 
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Classification of Recommendations and Level of Evidence
are expressed in the ACC/AHA format as follows and
described in more detail in Table 1.
Classification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or 
treatment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or
treatment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well
established by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
Level of Evidence
Level of Evidence A: Data derived from multiple ran-
domized clinical trials or meta-analyses.
Level of Evidence B: Data derived from a single ran-
domized trial, or nonrandomized studies. 
Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care. 
The Committee consists of acknowledged experts in car-
diac surgery, interventional cardiology, general cardiology,
and family practice. The Committee included representa-
tives from the American Academy of Family Physicians
(AAFP) and the Society of Thoracic Surgeons (STS). Both
academic and private practice sectors were represented. The
document was reviewed by 3 outside observers nominated
by the ACC, 3 outside reviewers nominated by the AHA, and
outside reviewers nominated by STS and the Society of
Cardiovascular Anesthesiologists. This document was
approved by the American College of Cardiology
Foundation’s Board of Trustees and the American Heart
Association’s Science Advisory and Coordinating
Committee, as well as endorsed by the American
Association for Thoracic Surgery and the Society of
Thoracic Surgeons. 
These guidelines overlap several previously published
ACC/AHA guidelines, including those for the management
of acute myocardial infarction (MI), for the management of
stable angina, for percutaneous coronary intervention (PCI),
and for exercise testing. For each of these guidelines, an
analysis of overlap or contradiction has been explored by the
Committee with attempts to create consensus in each
instance. Finally, it is acknowledged that no guideline can
take into account all of the various parameters that must be
part of the individual decision to recommend CABG for a
single patient. However, this entire report is intended to pro-
vide a framework that healthcare providers can use in com-
bination with other types of knowledge and patient prefer-
ences to make rational decisions about treatment.
2. GENERAL CONSIDERATIONS AND
BACKGROUND
Surgical revascularization for atherosclerotic heart disease is
one of the great success stories in medicine. Relief of angi-
na after revascularization, improvement in exercise toler-
ance, and the realization of survival benefit have attended
the operation since the early stages of development. The
evolution of coronary surgery is a story of focused thought,
dedication, courage, collaboration, and serendipity. 
Alexis Carrel (1872 to 1944) understood the association
between angina pectoris and coronary stenosis (2). Before
World War I, he had developed a canine model of aortocoro-
nary anastomosis using carotid arteries as a conduit. For his
seminal work in the development of cardiovascular surgical
techniques, he was awarded the Nobel Prize. Carrel’s contri-
butions lay fallow, as he had predicted, until a time when
advances in technology would allow safe application to
humans. 
Carrel and the aviator Charles Lindbergh collaborated in
the 1930s in developing a primitive heart-lung machine
intended to allow direct cardiac operation. Lindbergh was
driven to this project by the desire to save a family member
dying of valvular heart disease. The project did not produce
a clinically useful device, but it did make incremental
progress toward the ultimate goal (3). Over a professional
lifetime of intense dedication, John Gibbon developed a
clinically useful cardiopulmonary bypass (CPB) technology
and applied it successfully to a patient in 1953 (4). 
With direct coronary operation awaiting advancing tech-
niques, surgical efforts to relieve angina pectoris in the mid-
20th century included suppression of metabolic stimulation
through thyroidectomy and augmentation of noncoronary
flow to the myocardium through creation of pericardial or
omental adhesions. Attempts to create an artificial collateral
by implantation of the internal mammary artery (IMA) into
the myocardium, the Vineberg procedure, met with limited
success (5). 
Coronary surgery moved into the modern era in the 1950s.
It is not entirely clear to whom credit should be given for the
first coronary bypass. The first direct surgical approach to
the coronary circulation in a patient was likely performed by
William Mustard in 1953 in Toronto, who used a carotid-to-
coronary bypass. The patient did not survive the operation. 
The first clinical use of the IMA to graft a coronary vessel
appears to have been in response to an intraoperative misad-
venture. William Longmire applied the technique of coro-
nary endarterectomy in a series of patients in 1958. A right
coronary artery disintegrated during one of these operations,
and an IMA was placed as a direct graft to restore flow. In
retrospect, the surgeon thought it to be a good operation (2).
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Michael DeBakey and Edward Garrett had a similar expe-
rience with a left anterior descending (LAD) coronary
endarterectomy in 1964 (6). This situation was salvaged by
an aortocoronary saphenous vein graft (SVG). The patient
did well and had a patent aortocoronary SVG when restud-
ied 8 years later. This experience was subsequently recorded
and recognized as the first successful clinical aortocoronary
SVG. An aortocoronary SVG operation by David Sabiston at
Duke in 1962, involving an anastomotic end-to-end tech-
nique done without the use of CPB, was the first planned
saphenous vein operation but was complicated by an early
fatal outcome (7,8). 
Mason Sones showed the feasibility of selective coronary
arteriography and amassed a large library of cineangiograms
that were studied in depth by Rene Favaloro (9). Sones and
Favaloro formed an innovative team that demonstrated the
efficacy and safety of SVG interposition and aortocoronary
SVGs for single-vessel, left main, and multivessel coronary
disease. An explosive growth in the application of these
techniques ensued, such that within a decade, coronary
bypass operation became the most frequent surgical proce-
dure in the United States. 
Recognition of the value of the IMA (also known as the
internal thoracic artery) as a conduit came slowly. V.I.
Kolessov, working in the 1960s at the Pavlov Institute in
Leningrad, described a series of patients in whom the IMA
was used for coronary revascularization without the aid of
routine arteriography or CPB (10,11). Frank Spencer devel-
oped extensive experimental experience with the IMA to the
coronary circulation in canine models. After preliminary
animal and cadaveric work with microscopic methods,
George Green brought this technique to successful clinical
application. Floyd Loop and colleagues at the Cleveland
Clinic incorporated the IMA into the coronary operation in a
large series of patients and subsequently published the land-
mark article demonstrating the powerful survival benefit
afforded by use of the IMA for LAD coronary distribution
revascularization (12). 
The 1970s, the first full decade of CABG, helped to define
its appropriate role relative to medical therapy. Coronary
bypass was found to consistently relieve angina and improve
the quality of life in symptomatic patients. Three large,
prospectively randomized, multicenter trials, The Coronary
Artery Surgery Study (CASS), The Veteran’s Administration
Coronary Artery Bypass Trial, and the European Coronary
Artery Bypass Trial, were conducted. These trials and sever-
al smaller studies helped to define subsets of patients likely
to benefit from coronary bypass surgery in terms of prolon-
gation of life and specifically identified patients with more
advanced disease as those most appropriate for application
of the operation for survival benefit. In addition to patients
with triple-vessel disease and left main disease, patients with
ischemic left ventricular (LV) dysfunction were found to
benefit from the operation relative to medical therapy. These
results led to the application of coronary bypass to progres-
sively sicker patients in the 1980s. 
Improvements in operative techniques and new technolo-
gies have allowed increasingly difficult patients to be
approached with success. Improvements in cardiac anesthe-
sia have paralleled improvements in operative techniques.
Operation on complex patients became routine as sophisti-
cated perioperative monitoring techniques, such as Swan-
Ganz pulmonary artery catheters and intraoperative trans-
esophageal echocardiography (TEE), were applied to specif-
ic problem situations. Anesthetic techniques, CPB technolo-
gy, and most important, methods of myocardial protection
were refined and successfully applied to specific problem
situations. Close collaboration between the surgeon, the
anesthesiologist, the perfusionist, and the intensive care
team has been critically important to these advances. These
refinements, discussed in Section 6, have led to an expected
30-day mortality of less than 1% in patients receiving elec-
tive coronary bypass who are less than 65 years of age and
who have no severe LV dysfunction or congestive heart fail-
ure (CHF). Even in otherwise uncomplicated patients aged
less than 65 years and with an ejection fraction (EF) of 0.25
to 0.35, first-time coronary bypass has an operative mortali-
ty risk of less than 5%. 
In addition to improvements in short-term outcomes,
evolving technology has contributed to improved long-term
results. The widespread use of the IMA, the use of other
arterial conduits, long-term antiplatelet therapy, and lipid
management are discussed in later sections of these guide-
lines. Progress has also been significant in the moderation of
perioperative morbidity. Central nervous system (CNS)
injury, the systemic insults of CPB, infection, and bleeding
are addressed in subsequent discussions. Finally, the appli-
cation of CABG without CPB and through limited incisions
has presented the prospect of further reductions in perioper-
ative morbidity. 
3. OUTCOMES
3.1. Hospital Outcomes
3.1.1. Introduction
As the clinician and the patient consider the decision for
CABG, an understanding of probable immediate outcomes
(events that occur during the immediate hospitalization or
within 30 days of operation) is of paramount importance. In
particular, it is important to be able to predict the hospital
mortality of the procedure and the risk of the major compli-
cations of coronary bypass, including cerebrovascular acci-
dents, major wound infection, and renal dysfunction. 
3.1.2. Predicting Hospital Mortality
Class IIa
It is reasonable that statistical risk models be used to
obtain objective estimates of CABG operative mortal-
ity. (Level of Evidence: C)
The risk of death with CABG has been the focus of numer-
ous studies in the last 2 decades. Although early reports were
e219
Eagle and Guyton et al. 2004
ACC/AHA Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
useful in correlating patient factors with outcomes such as
in-hospital mortality (13), they were inadequate in their abil-
ity to risk stratify (14,15). Subsequently, a number of large
single-center and multicenter cardiac surgical databases
were established (13,16,17). From these databases, risk
stratification models were created to better understand the
variation in institutional and surgeon performance and to
provide a more accurate risk prediction of mortality for
patients facing CABG. Although all data sets identified
patient and disease characteristics that consistently predict-
ed mortality, the inclusion or exclusion of certain variables,
variations in definitions of the same variables, and institu-
tional and regional differences in practice styles have made
it difficult to compare results across data sets. A review of 7
large data sets, representing more than 172 000 patients who
underwent surgery between 1986 and 1994, was carried out
to find the predictive power of certain preoperative variables
(18). Seven core variables (i.e., urgency of operation, age,
prior heart surgery, sex, LVEF, percent stenosis of the left
main coronary artery, and number of major coronary arteries
with more than 70% stenosis) were found to be predictive of
mortality after CABG in all 7 data sets. Variables relating to
the urgency of operation, age, and prior coronary bypass sur-
gery were found to have the greatest predictive power, while
variables describing coronary anatomy had the least predic-
tive power. Besides these 7 core variables, 13 “level 1” vari-
ables were identified that, when added to the core variables,
had a modest influence on the predictive capability of the
model. These level 1 variables included the following:
height; weight; PCI during index admission; recent (less
than 1 week) MI; history of angina, ventricular arrhythmia,
CHF, or mitral regurgitation (MR); comorbidities including
diabetes, cerebrovascular disease, peripheral vascular dis-
ease (PVD), and renal dysfunction; and creatinine level.
While the level 1 variables carry predictive power, their
addition beyond these 7 core variables has been found to
have a minimal impact on predictability (18). 
While Jones and others have attempted to develop a com-
mon risk stratification language, general application of risk
stratification models across populations must be done with
caution. Although it may be possible to generalize the rela-
tive contribution of individual patient variables, rules must
be calibrated to regional mortality rates and should be updat-
ed periodically to maximize accuracy (19,20). Table 2 com-
pares the relative risk of the 7 core variables identified by
Jones et al (18) as being most predictive of mortality as
reported by 6 data sets.
Age has consistently predicted mortality after CABG
(16,21), with advancing age associated with higher mortali-
ty. Assuming that age less than 65 years carries a relative risk
of 1, Tu et al (22) found that the relative risk increased to
2.07 for patients between 65 and 74 years old and to 3.84 for
those older than 75 years. Despite this increased short-term
risk of mortality after CABG treatment, long-term results
remain encouraging. When patients less than 50 years of age
are compared with those 70 years and older and are matched
by age to a population that did not undergo CABG, the older
patients experience a longer hospitalization and higher hos-
pital mortality, although their long-term survival more close-
ly matches the general population compared with their
younger counterparts. While elderly patients face an
increased likelihood of morbidity after CABG and a partic-
ularly high incidence of stroke compared with the general
population (23,24), age itself should not exclude a patient
from being offered treatment with CABG, assuming that
there is no prohibitive comorbidity. A careful quality of life
and longevity assessment should be made in the oldest age
groups.
Sex also predicts early mortality after CABG, with females
facing an increased risk. Reported relative risks have ranged
from 1.5 to 2.0. Smaller body size (25), smaller diameter of
coronary arteries (26), increased age, and comorbidity status
(27) have all been suggested as explanations for this
increased risk. Another study based on the STS national
database shows that female gender is an independent risk
factor of operative mortality in low- and moderate-risk sub-
sets but not in high-risk populations (28). Despite the
increased risk, long-term results appear similar to those of
males (29). 
Having had previous open heart surgery adds considerable
risk for patients having subsequent coronary artery surgery.
The relative risk of early mortality appears to be around 3.0
compared with first-time CABG patients (16). An addition-
al factor that further increases risk in this subset appears to
be whether reoperation is carried out within 1 year of the pri-
mary operation (30). Despite the significant increased risk,
long-term results after reoperative CABG are encouraging
(31). 
Coronary artery surgery in the presence of or immediately
after an acute MI is controversial. Despite optimistic reports
of low mortality if the operation is carried out within 6 hours
of the onset of chest pain (32), many authors have found this
approach to carry excessive mortality (33-35). Fibrinolytic
therapy and/or PCI appears to be the preferable first-line
therapy in the presence of an evolving MI. CABG surgery is
reserved for patients with evidence of ongoing ischemia
despite these interventions, or it may be performed coinci-
dent with repair directed at mechanical complications of
infarction (i.e., ventricular septal defect or papillary muscle
rupture). It also may benefit patients with shock complicat-
ing a recent acute MI, as demonstrated in the Should We
Emergently Revascularize Occluded Coronaries for
Cardiogenic Shock (SHOCK) trial (35a).
The presence of comorbidities is also related to survival
after CABG. Though not identified by Jones et al (18) as a
core variable, treated diabetes (36), the presence of PVD
(37), renal insufficiency (38), and COPD have all been
shown to have a negative impact on outcome after CABG.
An intraoperative variable that seems to have both a short-
term and a long-term impact on survival is the use of the
IMA as a bypass conduit. Loop, Lytle, and others have
reported that use of the IMA is an independent predictor of
survival 10 to 20 years after CABG (39,40). Hospital mor-
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tality after CABG has also been reported to be lower when
the IMA is used (41,42). 
In summary, early mortality after CABG is associated par-
ticularly with advancing age, poor LV function, and the
urgency of operation. Additional coronary anatomic and
comorbid conditions further influence risk. If overall risk for
an institution or region is known, then a general estimate for
the individual patient can be rendered preoperatively by
using mathematical models, as illustrated in Table 3 and
Figure 1. This application may find utility as patients and
their physicians weigh the potential benefits versus risks of
proceeding with bypass surgery. 
3.1.3. Morbidity Associated With CABG:
Adverse Cerebral Outcomes
Class I
Significant atherosclerosis of the ascending aorta
mandates a surgical approach that will minimize the
possibility of arteriosclerotic emboli. (Level of
Evidence: C)
Neurological abnormalities after CABG are a dreaded
complication. The reported incidence ranges from 0.4% to
nearly 80%, depending on how the deficit is defined (43-45).
Neurological derangement after CABG has been attributed
to hypoxia, emboli, hemorrhage, and metabolic abnormali-
ties (46,47). Despite the many advances made in cardiac sur-
gery, postoperative stroke remains a problem. 
Postoperative neurological deficits have been divided into
2 types: type 1 deficits are those associated with major, focal
neurological deficits, stupor, and coma; type 2 deficits are
characterized by deterioration in intellectual function or
memory. Roach et al (48) reported on a multi-institutional
prospective study aimed at determining the true incidence of
both stroke (type 1 deficits) and encephalopathy (type 2
deficits) after CABG. In this study, 2108 patients operated
NNE indicates Northern New England Cardiovascular Disease Study Groups; VA, Veterans Affairs cardiac surgical database; STS, Society for Thoracic Surgery
national cardiac surgical database; NYS, New York State cardiac surgery reporting systems; CC = Cleveland Clinic; AGH = Allegheny General Hospital; LMD,
left main disease; Vol, voluntary; reg, regional; Man, mandatory; nat, national; state, single state; SI, single institution; NA, not available; and mult reops, mul-
tiple reoperations.
The relative risk coefficient for age indicates the additional mortality risk per year of age greater than 50 years.
*Urgent indicates patients are required to stay in the hospital but may be scheduled and operated on within a normal scheduling routine; Emergent, ongoing refrac-
tory cardiac compromise, unresponsive to other forms of therapy except for cardiac surgery; and Salvage, ongoing cardiopulmonary resuscitation en route to the
operating room.
Table 2. Relative Mortality Risk: Core CABG Variables for 6 Data Sets
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Definitions:
Obesity: Find the approximate height and weight in the table below
to classify the person as obese or severely obese. Obesity: BMI 31-
36. Severe obesity: BMI greater than or equal to 37.
Example: A patient is 5’7” and weighing 200 lbs. is classified obese.
If the patient weighed 233 lbs. or more, he/she would be classified
severely obese.
Diabetes: Currently treated with oral medications or insulin.
COPD (chronic obstructive pulmonary disease): treated with bron-
chodilators or steroids.
PVD (peripheral vascular disease): Cerebrovascular disease,
including prior CVA, prior TIA, prior carotid surgery, carotid 
stenosis by history or radiographic studies, or carotid bruit. Lower-
extremity disease including claudication, amputation, prior lower-
extremity bypass, absent pedal pulses or lower-extremity ulcers.
Dialysis: Peritoneal or hemodialysis-dependent renal failure. 
MI less than 7 days: The development of a) new Q wave on EKG or
b) new ST-T changes with a significant rise (defined locally) in 
CPK with positive (defined locally) isoenzymes.
EF less than 40% (left ventricular ejection fraction): The patient’s 
current EF is less than 40%.
WBC greater than 12K (white blood cells greater than 12 000):
Use the patient’s last preoperative measurement of WBC taken 
before the procedure.
Urgent: Medical factors require patient to stay in hospital to have 
operation before discharge. The risk of immediate morbidity and 
death is believed to be low.
Emergency: Patient’s cardiac disease dictates that surgery should be 
performed within hours to avoid unnecessary morbidity or death.
Data set and definitions for dependent variables:
The regression models that generated the scores for these prediction
rules were based on 14 971 patients receiving isolated CABG surgery
between 1999 and 2002. The dependent variables and observed event
rates are as follows: inhospital mortality (2.5%); cerebrovascular
accident, defined as a new focal neurologic event persisting at least
24 hours (1.6%); and mediastinitis during the index admission
defined by positive deep culture and/or gram stain and/or radiograph-
ic findings indicating infection and requiring reoperation (1.0%).
Northern New England Cardiovascular Disease Study Group 4/03.
BMI indicates body mass index; CVA, cerebrovascular accident; LM,
left main; TIA, transient ischemic attack; EKG, electrocardiogram.
Calculation of Mortality Risk: An 80-year-old female, with an EF less
than 40% who is having elective CABG surgery, has had no prior CABG
surgery and has no other risk factors. Her total score = 6.5 (age greater than
or equal to 80) + 2 (EF less than 40%) = 10.5. Since her total score equals
10.5, round up to 11; her predicted risk of mortality = 4.0%.
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on at 24 institutions were observed for signs of neurological
dysfunction after CABG. Adverse cerebral outcomes
occurred in 129 patients (6.1%) and were evenly distributed
between type 1 (3.1%) and type 2 (3.0%) deficits. The influ-
ence of these complications included a 21% mortality for
those with type 1 deficits and a 10% mortality for those with
type 2 deficits. In addition, patients with neurological com-
plications had, on average, a 2-fold increase in hospital
length of stay and a 6-fold likelihood of discharge to a nurs-
ing home. 
Independent risk factors were identified for both type 1
and type 2 deficits (48). Predictors of both types of cerebral
complications included advanced age, especially age greater
than or equal to 70 years, and a history or the presence of
significant hypertension. Both of these variables have previ-
ously been reported to be associated with adverse cerebral
outcomes after CABG (49,50). 
Predictors of type 1 deficits included the presence of prox-
imal aortic atherosclerosis as defined by the surgeon at the
time of surgery (odds ratio [OR] 4.52), a history of prior
neurological disease (OR 3.19), use of the intra-aortic bal-
loon pump (IABP; OR 2.60), diabetes (OR 2.59), a history
of hypertension (OR 2.31), a history of unstable angina (OR
1.83), and increasing age (OR 1.75 per decade).
Perioperative hypotension and the use of ventricular venting
were also weakly associated with this type of outcome. 
Proximal aortic atherosclerosis has been reported to be the
strongest predictor of stroke after CABG, supporting the
theory that liberation of atheromatous material during
manipulation of the aorta is the main cause of this compli-
cation (49). Although palpation of the aorta has traditionally
been used by surgeons to identify patients with atheroma-
tous disease of the ascending aorta and to find “soft spots”
for cannulation or cross-clamping, the use of ultrasound has
been suggested as a more accurate means of assessing the
aorta (51). Duda et al (51) have suggested that once aortic
atherosclerosis is identified, alternative strategies to prevent
mobilization of aortic atheroma should be considered,
including techniques such as groin or subclavian placement
of the aortic cannulas, fibrillatory arrest without aortic cross-
clamping, use of a single cross-clamp technique, modifying
the placement of proximal anastomoses, or all-arterial revas-
cularization in cases of severe aortic involvement. Other
authors recommended ascending aortic replacement under
circulatory arrest as the best means of minimizing this com-
plication (52,53). 
A history of previous neurological abnormality or the pres-
ence of diabetes is also a predictor of type 1 CNS complica-
tions. These are likely markers for patients with marginal
cerebral blood flow, alterations in CNS vasomotor autoregu-
latory mechanisms, or diffuse atherosclerosis. The need for
an IABP is likely correlated with a higher risk of atheroma-
tous emboli and is often required in patients with systemic
hypoperfusion, each of which may cause stroke after CABG.
The fact that use of an LV vent—or other devices that have
potential for introducing air into the arterial circulation—has
been associated with stroke suggests air emboli as the cause
and argues for meticulous technique when placing these
devices to prevent this complication. 
Figure 1. Event curves. For calculation of risk score, see Table 3.
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Factors predictive of type 2 neurological deficits include a
history of alcohol consumption, dysrhythmia (including atri-
al fibrillation), hypertension, prior CABG, PVD, or CHF.
Because aortic atherosclerosis is not a strong predictor of
type 2 complications, encephalopathic changes may be relat-
ed not only to microemboli but also to the brain’s microcir-
culation. Type 2 complications are more likely to occur after
periods of hypotension or inadequate perfusion. 
Off-pump coronary artery bypass (OPCAB) avoids both
aortic cannulation and cardiopulmonary bypass.
Accordingly, one would expect postoperative neurological
deficits to be reduced in patients undergoing OPCAB. Three
randomized controlled trials (54-56) have not firmly estab-
lished a significant change in neurological outcomes
between OPCAB patients and conventional CABG patients.
Each trial demonstrates problems inherent with small patient
cohorts, differing definitions, and patient selection. At this
point, there is insufficient evidence of a difference in neuro-
logical outcomes for patients undergoing OPCAB compared
with those undergoing conventional CABG (57).
Individual patient counseling regarding postoperative
stroke risk represents an important opportunity to assist
patients as they weigh the risks and benefits of elective
CABG. Although postoperative stroke rates may vary
between hospitals or regions, if local rates are known, then
these may be used to assist the patient in appreciating the
general risk of this dreaded complication. Strategies to
reduce the risk of postoperative neurological complications
are discussed in depth in Section 4.1.1.
3.1.4. Morbidity Associated With 
CABG: Mediastinitis
Deep sternal wound infection has been reported to occur in
1% to 4% of patients after CABG and carries a mortality rate
of nearly 25% (58,59). Studies have consistently associated
obesity and reoperation with this complication, while other
risk factors such as use of both IMAs, duration and com-
plexity of operation, and the presence of diabetes have been
reported inconsistently. Most studies examining deep sternal
wound infection have been single-center, retrospective
reviews, and variation in wound surveillance techniques and
the definition of deep sternal wound infection limit compar-
isons. 
Obesity is a strong correlate of mediastinitis after CABG
(60). In one report of 6459 patients undergoing CABG at a
single institution, Milano et al (61) found obesity to be the
strongest independent predictor of mediastinitis (OR 1.3). In
a prospective multi-institutional study, the Parisian
Mediastinitis Study Group also found obesity to carry the
greatest association with the development of postoperative
mediastinitis (OR 2.44) (62). The mechanism by which obe-
sity leads to this complication is poorly understood but is
likely multifactorial. Perioperative antibiotics may be poor-
ly distributed in adipose tissue, skin folds present a special
challenge in maintaining sterility, and large regions of adi-
pose tissue serve as an ideal substrate for bacteria and repre-
sent a clinical challenge for diagnosis when early infection
occurs. 
Another patient characteristic that has been associated
with postoperative mediastinitis is the presence of diabetes
(55,57), especially in patients requiring regular insulin (58).
In addition to the microvascular changes seen in diabetic
patients, elevated blood glucose levels may impair wound
healing. The use of a strict protocol aimed at maintaining
blood glucose levels less than or equal to 200 mg/dL by the
continuous, intravenous infusion of insulin has been shown
to significantly reduce the incidence of deep sternal wound
infection in patients with diabetes (58a,314).
Prior cardiac surgery is another factor associated with the
development of mediastinitis (61-63). Reoperation requires
additional dissection, necessitates longer operative and/or
perfusion times, produces more bleeding, and results in a
higher likelihood of needing transfusion, variables that have
all been linked to this complication. 
Operator-dependent variables may also contribute to the
development of deep sternal wound infection. These include
the use of both IMAs for bypass conduits and excessive use
of electrocautery for hemostasis (61,320). No studies have
found the use of a single IMA to be predictive of medias-
tinitis. Two reports identified the use of both IMAs to be an
independent predictor (62,62a), while several others have
shown no correlation with the development of mediastinitis
(58,61). Because the use of both IMAs may predispose to
devascularization of the sternum, it seems likely that this
technique promotes infection, especially when combined
with other risk factors such as diabetes and/or obesity.
In summary, deep sternal wound infection after CABG is
an expensive and potentially lethal complication that appears
to have a multifactorial etiology. Strategies to reduce the
incidence of this complication include meticulous aseptic
technique, keeping perfusion times to a minimum, avoidance
of unnecessary electrocautery, appropriate use of periopera-
tive antibiotics, and strict control of blood glucose levels
during and after operation. Each of these is discussed in
greater depth in Section 4.1.4.
3.1.5. Morbidity Associated With CABG:
Renal Dysfunction
The first major multicenter study of renal dysfunction after
CABG surgery was published in 1998 (64). This study of
2222 patients who underwent myocardial revascularization
with CPB defined postoperative renal dysfunction (PRD) as
a postoperative serum creatinine level of greater than or
equal to 2.0 mg/dL or an increase in the serum creatinine
level of greater than or equal to 0.7 mg/dL from preoperative
to maximum postoperative values. PRD occurred in 171
(7.7%) of the patients studied; 30 of these (18%, or 1.4% of
all study patients) required dialysis. The mortality rates were
0.9% among patients who did not develop PRD, 19% in
patients with PRD who did not require dialysis, and 63%
among those who required dialysis. 
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Several preoperative risk factors for PRD were identified,
including advanced age, a history of moderate to severe
CHF, prior CABG, type 1 diabetes mellitus, and preexisting
renal disease (preoperative creatinine levels greater than 1.4
mg/dL). The risk of PRD in patients less than 70 years of age
nearly tripled with 1 preoperative risk factor and increased
further with 2 risk factors. A detailed analysis of the impact
of these preoperative risk factors for PRD for 3 age groups
is presented in Table 4 (64). These findings allow identifica-
tion of high-risk patients for PRD and a general estimation
of the risk for PRD for an individual patient. The reported
risk for patients with moderate renal dysfunction is consis-
tent with previous reports from smaller, single-center studies
(65-67). 
Although data from large, multicenter studies are not avail-
able, it is reasonable to conclude that patients with more
advanced, chronic, preoperative renal failure (but without
end-stage renal disease [ESRD]) would have an even higher
incidence of PRD requiring dialysis. Because their kidneys
have a greater reduction in functioning nephrons than those
in patients with lesser degrees of renal failure in the study
cited above, they would be more vulnerable to the maldistri-
bution of renal blood flow, an increase in renal vascular
resistance, and the decreases in total renal blood flow and
glomerular filtration rate that occur during CABG surgery
(68-70). This conclusion has been supported by a study of 31
patients who underwent CABG with a baseline serum crea-
tinine level greater than or equal to 1.6 mg/dL in the 6
months before surgery and who did not require preoperative
dialysis (71). The mean age of the patients was 71 years, and
nearly 80% were males. The hospital mortality was 19%,
and 26% of surviving patients required chronic dialysis.
Among 19 patients with a creatinine level greater than or
equal to 2.6 mg/dL, 42% of survivors required chronic
hemodialysis, whereas none of the surviving patients with a
creatinine level less than or equal to 2.6 mg/dL required
chronic dialysis. This study suggests that patients greater
than 70 years old with a creatinine level greater than or equal
to 2.6 mg/dL are at extreme risk for dialysis dependency
after CABG, and alternative options for coronary manage-
ment should be strongly considered. 
The importance of perioperative renal function is empha-
sized by a report that correlated acute renal failure sufficient
to require dialysis and operative mortality after cardiac sur-
gery (72). The 42 773 patients who underwent CABG or
valvular heart surgery at 43 Department of Veterans Affairs
medical centers between 1987 and 1994 were evaluated to
determine the association between acute renal failure suffi-
cient to require dialysis and operative mortality. This degree
of acute renal failure occurred in 460 (1.1%) patients.
Overall, operative mortality was 63.7% in these patients,
compared with 4.3% in patients without this complication.
Table 4. Risk of Postoperative Renal Dysfunction (PRD) After Coronary Artery Bypass Graft Surgery 
CHF indicates prior congestive heart failure; Reop, redo coronary bypass operation; DM, type 1 diabetes mellitus; Creat greater than 1.4, preoperative serum creatinine level greater
than 1.4 mg/dL; n, observed number of patients within each clinical stratum; -, risk factor absent; and +, risk factor present.
*Insufficient patient numbers, number is less than five.
Reprinted with permission from Mangano et al. Ann Intern Med 1998;128:194-203 (64).
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Acute renal failure requiring dialysis was independently
associated with early mortality after cardiac surgery, even
after adjustment for comorbidity and postoperative compli-
cations. 
3.1.6. Posthospital Outcomes
The extensive application of CABG has been a consequence
of its effectiveness in the relief of angina and prolongation of
survival in certain subsets. The 1999 Guidelines provided
data that allow a general understanding of expectation after
CABG (1). In a heterogeneous group of patients, survival at
5 years was 92% and at 10 years was 81%. Freedom from
angina was 83% at 5 years and 63% at 10 years. The previ-
ous guidelines provided equations for predicting patient-spe-
cific outcomes, including freedom from unfavorable events,
in a comparison of coronary bypass surgery versus medical
treatment. These detailed predictive instruments remain
appropriate for use and are not presented here. While a dis-
cussion of the comparative benefits of CABG versus med-
ical therapy appears in Section 3.2, a brief description of the
factors that influence the long-term results of the operation
is appropriate here. 
The predictors of long-term survival after CABG have
been analyzed in a number of studies. In an analysis of 23
960 patients from 1977 to 1994 from Emory University,
advanced age, EF, presence of diabetes, number of diseased
vessels, and sex were significant multivariate predictors of
survival, while angina class, hypertension, history of MI,
renal dysfunction, and CHF were other important factors
identified by univariate analysis (Table 5) (73). Other stud-
ies have identified predictors for the recurrence of angina
and for postoperative MI (Table 6). Importantly, untoward
events after coronary bypass tend to increase in frequency
between 5 and 10 years after the operation, apparently coin-
cident with the gradual occlusion of vein grafts.
Approximately 50% of vein grafts are closed by 10 years
after operation. 
The delayed return of angina and the fact that approxi-
mately half of the survivors of CABG eventually die of car-
diac-related causes identifies the “Achilles heel” of the pro-
cedure: late vein-graft atherosclerosis and occlusion. The
most important surgical gain has been verification of excel-
lent late patency with IMA grafts (74). From this encourag-
ing result with the use of a single arterial graft has sprung the
arterial arborization of today, with reports of multiple and
“complete” arterial grafting (75-78). This is discussed fur-
ther in Sections 4.2. and 6.2.
3.2. Comparison of Medical Therapies Versus 
Surgical Revascularization
Since the 1991 Guidelines, relatively little clinical trial
information comparing medical with surgical treatment of
CAD has been published. However, longer follow-up of
patients enrolled in the earlier, major randomized trials has
solidified the appropriate indications for surgical treatment. 
The traditional stratification of patients has been based on
the extent of CAD (i.e., number of vessels with anatomical-
ly significant disease and whether or not the major epicardial
Table 5. Multivariate Analysis Predictors of Late Overall
Mortality and Late Cardiac Mortality
CI indicates confidence interval; EF, ejection fraction; IMA, internal mammary
artery. 
MI indicates myocardial infarction; CI, confidence interval; and IMA, internal mammary artery.
Table 6. Multivariate Analysis Predictors of Anginal Recurrence, Late MI, and Any
Cardiac Event 
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obstruction is proximal) in association with the extent of LV
dysfunction (determined by a simple measure of global
LVEF). The major end point of the studies has been survival.
The major randomized trials studied patients between 1972
and 1984, at which time the predominant medical therapy
was the use of beta-blockers and nitrates. 
There are several important limitations of the randomized
trials in view of current practice (Table 7). In the ensuing
years, calcium channel blockers have been added, particu-
larly for symptomatic patients. The use of aspirin has
become more widespread in all patients with CAD. The role
of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors and other lipid-lowering agents has now been rec-
ognized as important in reducing recurrent ischemic events.
Angiotensin converting enzyme inhibitors are now used rou-
tinely, particularly in patients with symptomatic heart failure
after acute myocardial infarction or those with LV systolic
dysfunction. It is hoped that these agents will be used equal-
ly in patients treated with medications alone and in patients
after CABG surgery, whose revascularization therapy is
complemented by appropriate medical treatment to reduce
ischemic complications. The contribution of advances in
surgical revascularization techniques cannot be fully
assessed. The potential value of arterial conduits for revas-
cularization, particularly the IMA, cannot be evaluated from
these early randomized studies, yet their use is now routine
in CABG surgery. There are also no prospective, random-
ized studies comparing the more recent off-bypass or mini-
mally invasive surgical approaches to medical therapy.
Finally, the randomized trials oversimplify the designation
of 1-, 2-, and 3-vessel disease. Several reports show that
prognosis is also critically related to the location of lesions
within vessels, not simply the number of vessels involved
(9,18). 
3.2.1. Overview
There were 3 major randomized trials (79-81) and several
smaller ones (82-84). These studies addressed similar clini-
cal questions and, as shown in Figure 2 and Figure 3, had
similar outcomes. Much of the primary patient information
for the 2649 patients enrolled in these randomized trials has
been combined in a collaborative meta-analysis, which has
facilitated comparison of outcomes at 5 and 10 years of fol-
low-up (Table 8) (85). Extension of survival is a useful
Table 7. Limitations of Randomized Trials in View of Current Practice 
Patient Selection Surgical Factors Medical/Nonsurgical Therapy
Patients less than or Only 1 trial used arterial grafts Lipid-lowering therapy not 
equal to 65 years of age (CASS) (in only 14% of patients) used or standard
Only 1 trial Newer modalities of Aspirin not widely used
included women (CASS) cardioprotection not used
Predominantly low-risk, Minimally invasive, off-bypass Beta-blockers used in 
stable patients techniques not used only half of patients
Aspirin not routinely given ACE inhibitor not used 
early postoperatively Coronary angioplasty not 
widespread
CASS indicates Coronary Artery Surgery Study; ACE, angiotensin-converting enzyme.
CABG indicates coronary artery bypass graft; CI, confidence interval; VA, Veterans Administration; CASS, Coronary Artery Surgery Study. 
P values for heterogeneity across studies were 0.49, 0.84, and 0.95 at 5, 7, and 10 years, respectively. Reprinted with permission from  Elsevier Science, Inc. (Yusuf et al. The Lancet
1994;344:563-70) (85).
Table 8. Total Mortality at 5 and 10 Years
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measure to compare different treatment strategies and can be
adjusted for patient characteristics (Figure 4). Across all
patients, the improvement in survival with CABG compared
with medical treatment is 4.3 months at 10-year follow-up
(P equals 0.003). In patients with left main disease, the sur-
vival benefit is 19.3 months. Subset analyses for other sub-
groups show statistical benefit for those with 3-vessel dis-
ease, and in those with 1- or 2-vessel disease including LAD
CAD. Relative risk reductions were similar with abnormal
or normal LV function. However, a similar relative risk
reduction is associated with a greater absolute survival ben-
efit in the high-risk population with depressed LV function.
The survival benefit of CABG surgery for individuals with
1- and 2-vessel disease without LAD involvement is small,
particularly in the setting of normal LV function. A higher
clinical risk score, more severe angina, and a positive exer-
cise test are associated with a greater prolongation of sur-
vival after CABG surgery than with medical therapy at 5 and
10 years (Table 8) (85). Two clinical scoring systems have
been used. The Veterans Administration trial used the clini-
cal variables of angina class, history of hypertension, and MI
as well as the degree of ST-segment depression at rest. The
Coronary Artery Bypass Graft Surgery Trialists’
Collaboration (85) developed a stepwise logistic regression
analysis-based risk score that included clinical and angio-
graphic variables as well as EF (Tables 8-10) (85). Patients
can be stratified according to these clinical criteria and by
using these scoring systems. There was little survival bene-
fit in those with a low risk (1% annual mortality) but increas-
ingly significant survival extension in those at moderate
(annual mortality of 2.5%) or high (annual mortality of 5%)
risk. 
The randomized trials provide robust results for the popu-
lations studied. However, there are important limitations in
generalizing the results of these studies to most patients with
coronary disease because of the way patients were selected
for the randomized studies. Specifically, the mean age of
randomized patients was 50.8 years, there were very few
patients greater than 65 years, 96.8% were male, and only
19.7% had an LVEF less than 0.50 (85). The challenge of
choosing a therapeutic option in patients with CAD is that
the clinical course is highly variable, and the “average”
patient does not fit perfectly into 1 of the groups studied.
The large registries (86-88) and other studies (89-91) pro-
vide useful confirmatory information in support of the clini-
cal trials and, if interpreted with appropriate caution, can
help in the subsets not well studied in the randomized trials.
The following discussion combines information from ran-
domized and nonrandomized trials in which the directional
trends are consistent with the randomized information. 
Figure 2. Survival curves of the 3 large studies and several small studies combined. VA indicates Veterans Administration; CABG,
coronary artery bypass graft surgery; CASS, Coronary Artery Subject Study. Reprinted with permission from Elsevier Science, Inc.
(Yusuf et al. The Lancet. 1994;344:563-70) (85).
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3.2.2. Location and Severity of Stenoses 
3.2.2.1. Left Main Disease
The benefit of surgery over medical treatment for patients
with significant left main stenosis is little argued. All of the
trials define significant left main stenosis as being greater
than 50% diameter stenosis as judged by contrast angiogra-
phy. The median survival for surgically treated patients is
13.3 years versus 6.6 years in medically treated patients
(92,93). 
Left main equivalent disease, defined as severe (greater
than or equal to 70%) diameter stenosis of the proximal
LAD and proximal left circumflex disease, appears to
behave similarly to true left main disease. Median survival
for surgical patients is 13.1 years versus 6.2 years for med-
ically assigned patients (92). However, there are few ran-
domized or randomizable patients with this anatomy. By 15
years, there is less survival benefit for patients assigned to
surgery. It is estimated that if all medical patients survived
15 years, 65% would eventually have surgery (85). At 15
years, cumulative survival in the CASS registry for patients
with left main equivalent disease was 44% for surgical
patients and 31% for the medical group (92,94,95). 
3.2.2.2. Three-Vessel Disease
Significant CAD is defined variably in the major studies.
CASS originally reported results with significant stenosis
defined as greater than or equal to 70%. The Veterans
Administration and European studies used 50% as the cutoff
for significant stenosis, and when the studies were combined
for the meta-analysis (85), the 50% criterion defined signifi-
cant disease for all vessels. For the purposes of this guide-
line, unless otherwise specified, the term significant will
indicate greater than 50% reduction in visual stenosis. 
The outcome of patients with 3-vessel CAD assigned to
surgical or medical treatment is similar at the 10-year follow-
up to that reported earlier in randomized trials. The more
severe the symptoms, the more proximal the LAD CAD, and
the worse the LV function, the greater is the benefit from sur-
gery (81,85,96-100). In patients with 3-vessel disease, the
relative risk reduction for surgery at 5 years is 42% and at 10
years is 24%, with an increase in survival of 5.7 months at
10-year follow-up (85). The definitions of single-, double-,
and triple-vessel disease in these guidelines are those from
the Bypass Angioplasty Revascularization Investigation
(BARI) (101,102). 
3.2.2.3. Proximal LAD Disease
Proximal LAD CAD (greater than 50% stenosis) is an
important contributor to outcome. In patients with proximal
LAD disease, the relative risk reduction of CABG is 42% at
5 years and 22% at 10 years. In LAD disease without proxi-
mal involvement, the relative risk reduction is 34% at 5 years
and 10% at 10 years. In the presence of depressed LV func-
Figure 3. Cumulative total mortality from all studies. CABG indicates coronary artery bypass graft. Modified with per-
mission from Elsevier Science, Inc. (Yusuf et al. The Lancet. 1994;344:563-70) (85).
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tion, the absolute benefit of surgery is greater because of the
risk of this population (81,103).
3.2.2.4. LV Function
LV systolic function remains an important predictor of
which patients are likely to benefit from surgery (97-
99,104). In patients with a normal EF, surgical revascular-
ization generally provides little survival benefit. In patients
with mild to moderately depressed function, the poorer the
LV function, the greater is the potential benefit of surgery
(97-99,105,106). The relative benefit is similar, but there is
greater absolute benefit because of the high-risk profile of
these patients. It is important to note that the randomized tri-
als did not include patients with an LVEF less than 0.35.
Thus, many of the patients operated on today were not well
represented in the randomized trials. 
A major growth in our understanding of the potential
reversibility of chronic systolic dysfunction among patients
with CAD has occurred in the past few years. Systolic dys-
function that is a result of chronic hypoperfusion (“hibernat-
ing”) and not a result of infarction can now be identified
noninvasively by positron emission tomographic scanning,
radioisotope imaging, or dobutamine echocardiography.
Patients with large areas of myocardial viability may benefit
from revascularization. Small, observational studies of
patients with hibernating myocardium who are undergoing
coronary revascularization have shown functional and per-
haps survival benefit, especially when LV function is partic-
ularly poor. This is discussed further in Section 5.9. 
There are few data regarding optimal choices for women.
The higher early surgical mortality needs to be weighed
against the lessons derived from the predominantly male
subjects (107), and this as well as other subsets will be dis-
cussed in Section 5. 
It is important to note that the randomized trials did not
include patients with an LVEF less than 0.35. Thus, many of
the patients operated on today were not well represented in
the randomized trials. Results are anticipated from the
Surgical Treatment for Ischemic Heart Failure (STICH)
study that is a randomized, multicenter trial of medical ther-
Figure 4. Extension of survival after 10 years of follow-up in various subgroups of patients, from a meta-analysis of 7 randomized stud-
ies. LV indicates left ventricular; VA, Veterans Administration. Reprinted with permission from Elsevier Science, Inc. (Yusuf et al. The
Lancet. 1994;344:563-70) (85).
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apy versus CABG for patients with heart failure, LVEF less
than 0.35, and coronary artery disease amenable for CABG.
3.2.2.5. Symptoms/Quality of Life
More attention has been paid to improvement in symptoms
and quality-of-life measurements. The findings from ran-
domized trials for these outcomes parallel those of the sur-
vival data. Apart from its effect on survival, CABG is poten-
tially indicated for 2 symptom-based indications: to alleviate
symptoms of angina pectoris over and above medical thera-
py and to reduce the incidence of nonfatal outcomes such as
MI, CHF, and hospitalization. CABG is considered to
improve or to relieve angina pectoris in a much broader
group of patients than the subgroups in which it has been
found to improve survival. Registry studies have suggested a
favorable impact on late MI among highest-risk subsets,
such as patients with 3-vessel disease and severe angina pec-
toris. However, in the pooled data from the randomized tri-
als (85), no overall beneficial impact of CABG on subse-
quent MI could be demonstrated. This may reflect an early
increase in MI perioperatively in patients undergoing CABG
surgery balanced by fewer MIs in the long term. 
At 5 years, patients treated surgically used less antianginal
medicines, with 63% of patients completely symptom-free
compared with 38% of medically assigned patients (96). At
10 years, however, these differences were no longer signifi-
cant. Patients treated surgically and medically used similar
amounts of long-acting nitrates and beta-blockers, with 47%
of surgical patients asymptomatic compared with 42% of
medical patients. Recreational status, employment, frequen-
cy of CHF, use of other medicines, and hospitalization fre-
quency were also similar between the groups (108-115). 
At 10 years, the frequency of angina and other quality-of-
life measurements were similar between surgically and med-
ically treated groups. Those who have multivessel disease
and who receive complete revascularization are less sympto-
matic, and symptom benefit is most apparent in patients with
severe angina and LV dysfunction (EF less than 0.35)
(108,110-116). Perhaps because of the symptomatic relief
associated with surgical revascularization, the “crossover”
from medical treatment to surgery may be of greater signif-
Table 9. Subgroup Results at 5 Years 
CI indicates confidence interval; CABG, coronary artery bypass graft; LAD, left anterior descending coronary artery; and LV, left ventricular.
*Includes only (79,80).
†Excludes (81).
‡Excludes (81-84).
§Excludes (80).
Reprinted with permission from Elsevier Science, Inc. (Yusuf et al. The Lancet. 1994;344:563-70) (85).
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icance in improving quality of life. Medically assigned
patients who had persistent angina despite medical therapy
were able to undergo surgical revascularization and thus
obtain relief of symptoms. 
3.2.2.6. Loss of Benefit of Surgery
The meta-analysis based on individual patient data from all
of the available randomized trials indicates a gradually
increasing reduction in mortality over the first 5 to 7 years
when coronary surgery is compared with medical therapy.
After this period, at about the 10- to 12-year follow-up, there
is a tendency of the survival curves to converge. This dimin-
ished continued benefit has been shown in the individual
studies as well and is likely due to a combination of factors.
First, it is inevitable in studies with long-term follow-up that
survival curves of various treatment groups will eventually
merge. This result has to do with the reduced life expectan-
cy of patients with coronary disease, regardless of treatment. 
Second, there is an increased event rate in late follow-up of
surgically assigned patients because of the progression of
native and graft disease, with a disproportionate increase in
late surgical mortality. Finally, crossover to surgery of med-
ically assigned patients is important. Thus, high-risk, med-
ically assigned patients may gain the “benefit” of surgery
even when assigned to medical therapy. The crossover rate at
10 years is between 37% and 50%, and this may contribute
to the better survival and improved quality of life in such
“medically assigned” patients. 
3.2.2.7. Summary
CABG improves long-term survival in a broad spectrum of
patients at moderate to high risk with medical therapy.
Although a relative risk reduction of around 40% can be
expected overall in comparison with medical therapy,
absolute benefits are proportional to the expected risk with
medical therapy. As such, absolute benefit is greatest among
those at highest risk with medical therapy (5-year mortality
greater than 20%). Clinical and angiographic markers of
risk, including severity of CAD, LV dysfunction, and
myocardial ischemia, can identify patients in various risk
strata. 
3.3. Comparison With Percutaneous Techniques
Although PTCA was initially used only for the treatment of
single-vessel CAD, advances in technique, equipment, and
experience have resulted in its expanded use for patients
with multivessel disease. In general, PTCA is less invasive
and requires a shorter hospitalization and recovery time than
does bypass surgery. However, the disadvantages of PTCA
as initial therapy for coronary disease include restenosis of
treated lesions and, compared with CABG, a lesser ability to
revascularize all lesions in patients with multivessel disease.
Clinical trials comparing PTCA and CABG have further
defined the relative advantages and disadvantages of these
treatments.
Table 10. Subgroup Analysis of 5-Year Mortality by Risk Stratum
CI indicates confidence interval; CABG, coronary artery bypass graft. 
*Veterans Administration-type risk score = (0.70 × presence of Class III/IV angina) + (0.37 × history of hypertension) + (0.83 × ST-segment depression at rest) + (0.39 × his-
tory of myocardial infarction).
†Stepwise risk score = (0.015 × age) + (0.56 × presence of Class III/IV angina) + (0.35 × history of myocardial infarction) + (0.62 × abnormal ejection fraction) + (0.53 × prox-
imal lesion greater than 50% in the left anterior descending coronary artery) + (0.29 × right coronary artery lesion greater than 50%) + (0.43 × history of diabetes) + (0.37
× history of hypertension).
Modified with permission from Elsevier Science, Inc. (Yusuf et al. The Lancet. 1994;344:563-70) (85).
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3.3.1. Overview of Randomized Trials
Nine randomized, clinical trials comparing PTCA and
CABG have been published (Table 11). Before discussing
the results of these trials, it is important to consider what we
can expect to learn from them. A comparative trial must be
large enough to have sufficient statistical power to detect a
difference in survival, the usual primary end point. If no dif-
ference is observed between CABG and PTCA, it can be
concluded that the treatments are equivalent only if trials are
large enough to reliably detect or exclude relative differ-
ences in mortality of around 20% and include a large num-
ber of patients in whom CABG has been shown to improve
prognosis. Because 600 deaths would be needed in the “con-
trol” group to exclude a relative risk difference of 20% with
90% power, trials with 4000 moderate- to high-risk patients
per treatment arm would be needed. However, if a 30% risk
difference is considered the smallest clinically important dif-
ference, trials of about 2000 patients in each group are
required. Unfortunately, all of these trials excluded patients
in whom survival had already been shown to be better with
CABG when compared with medical therapy. Second, fol-
low-up must be long enough (generally 4 to 5 years) to
detect a survival advantage with either approach. Third, to
reliably compare the 2 treatments, there must be a high rate
of compliance with the original treatment allocation; if a
substantial proportion of patients “cross over” (30% to 40%
by 5 years), the ability to detect differences in survival
decreases markedly. Finally, the patients enrolled in the trial
must be similar to those not enrolled to allow generalization
of the findings. All of the randomized trials fall short of 1 or
more of these criteria. However, the largest of the 9 random-
ized trials, BARI, comes closest to fulfilling these criteria
and will be discussed in detail (117). 
In this trial, 1829 patients with multivessel disease were
randomized at 18 centers to PTCA or CABG. The primary
end point was all-cause mortality at 5 years, and predefined
subgroup analyses were performed for the severity of angi-
na, the number of diseased vessels, LV function, and lesion
complexity. In addition, a separate analysis of diabetic
patients was added partway through the trial. Baseline char-
acteristics of the BARI study population included a mean
age of 61 years, mean LVEF of 0.57, a 41% prevalence of 3-
vessel disease, and 26% women; there were no significant
differences between treatment groups. Revascularization
was accomplished by PTCA in a mean of 2.4 lesions per
patient, with a success rate of 88% for at least 1 lesion, and
by CABG with a mean of 2.8 grafts per patient (82% with an
IMA). Stents were not routinely employed (117). The aver-
age postprocedure length of stay was shorter with PTCA (3
versus 7 days). The rate of in-hospital Q-wave MI was high-
er for CABG than for PTCA (4.6% versus 2.1%, P less than
0.05), and 6.3% of PTCA patients required urgent CABG.
At a mean follow-up of 5.4 years, there was no statistically
significant difference in long-term survival or freedom from
MI, but patients initially randomized to PTCA had more
hospitalizations and required more repeat revascularization
procedures (Table 11). Thirty-one percent of patients initial-
ly assigned to PTCA underwent CABG during the trial
(117). Compared with the other randomized comparisons,
overall mortality in BARI was higher owing to the inclusion
of older patients, more women, and more patients with mul-
tivessel disease and other comorbidities. This difference
underscores the importance of comparing the methodology
of these trials before discussing their conclusions. 
The most important limitation of all of the randomized tri-
als relates to the ability to generalize the conclusions. The
findings are not applicable to all patients with multivessel
coronary disease for 2 reasons. First, only around 5% of
screened patients with multivessel disease were enrolled in
the trials (118,119). In the BARI trial, more than 25 000
patients with multivessel coronary disease by diagnostic
angiography were screened for eligibility. About 50% of
these patients were ineligible because of left main disease,
insufficient symptoms, or other reasons. One third of the
remaining patients (4110) had multivessel disease suitable
for both PTCA and CABG, and only half of these (7% of
those screened) were enrolled in the randomized trial (120).
Second, examination of the Emory Angioplasty versus
Surgery Trial (EAST) registry suggests that physician judg-
ment may be an important determinant of outcome that is
eliminated by a randomized design. In this registry of 450
eligible patients who refused randomization, survival was
slightly better than in the 392 randomized patients despite
similar baseline features (121). This may reflect physician
judgment, as CABG was utilized more often in patients with
3-vessel disease and PTCA more often in patients with 2-
vessel disease (121). 
The age range (mean age varied from 56 to 61 years) and
sex distribution (around 20% female) were similar in most
trials, although the Medicine, Angioplasty, or Surgery Study
(MASS) trial had 42% women (122). All of the randomized
trials excluded patients with low EFs and those for whom
CABG was known to provide a survival advantage. Six tri-
als included only patients with multivessel disease and 2,
only single-vessel disease (MASS, Lausanne); the
Randomized Intervention Treatment of Angina (RITA) trial
included both (Table 11). Several trials were conducted in
single centers, whereas RITA, the German Angioplasty
Bypass-surgery Investigation (GABI), the Coronary
Angioplasty versus Bypass Revascularization Investigation
(CABRI), and BARI were multicenter. The CABRI and
EAST trials permitted incomplete revascularization, where-
as the others had a goal of complete revascularization.
CABRI and RITA included vessels with total occlusion,
accounting for the lower success rate of PTCA; the success
rate for these vessels in RITA was only 48%. Asymptomatic
patients were excluded from GABI, and the extent of coro-
nary disease also varied widely. Three-vessel disease was
present in only 12% and 18% of RITA and GABI subjects,
respectively, and present in greater than 40% of BARI and
Estudio Randomizado Argentino de Angioplastia vs Cirugia
(ERACI) patients. The incidence of diabetes mellitus varied
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from 10% to 12% (Toulouse, Goy, ERACI, GABI, and
CABRI) to greater than 20% (EAST and BARI). 
Finally, the trials used different primary end points and fol-
low-up periods. Neither CABG nor PTCA has been shown
to reduce the risk of subsequent nonfatal MI, and therefore
inclusion of such an end point would dilute relative differ-
ences and decrease the likelihood of detecting differences.
End points included survival (BARI), freedom from angina
(GABI and Toulouse), freedom from death and MI (RITA),
and other combinations including symptoms, stress thallium
defects, and repeated revascularization (Table 11). Most
required Q waves and a clinical event to define an MI, but
EAST included “silent” MIs as well. Follow-up ranged from
1 to 5 years, and only MASS required angiography in all
patients (122). Overall, all of the trials except BARI were
underpowered and lacked sufficient follow-up. 
3.3.2. Results of Randomized Trials
3.3.2.1. Acute Outcome
Despite the differences in design and follow-up, the results
of randomized trials comparing PTCA and CABG have been
similar. Procedural complications including death (1% to
2%) and Q-wave MI (up to 10%) were low for both proce-
dures but tended to be higher with CABG (Table 11). A sta-
tistically significant increase in MI rate was present only in
GABI and EAST and in 2 meta-analyses including many of
the trials (118,123). For patients initially randomized to
PTCA, CABG was needed during the initial hospitalization
for 6% (range 1.5% to 10%) and was performed in close to
20% by 1 year (123). 
The cost and length of stay were lower for PTCA than for
CABG. In BARI, the cost of PTCA was 50% of that for
CABG, but over time this was nearly equal (124,125). The
lengths of stay in RITA were 4 and 12 days for PTCA and
CABG, respectively (126). Patients having PTCA returned
to work sooner and were able to exercise more at 1 month
(127). The extent of revascularization achieved with CABG
was higher than with PTCA (117,119). In the EAST trial, the
percentage of revascularizable segments successfully treated
was 99% for CABG versus 75% for PTCA (119). When the
comparison was limited to severe and physiologically
important lesions, the extent of early revascularization was
similar, although this analysis includes the patients who
crossed over from PTCA to CABG (119,128). 
3.3.2.2. Long-Term Outcome
There was no significant difference in survival in 8 of the 9
randomized trials that compared PTCA and CABG at fol-
low-up periods ranging from 1 to 8 years (Table 11). BARI
was the largest trial with the longest follow-up. The com-
bined end point of cardiac mortality and MI was similar at 5
years with both treatments (129). An update of the BARI
trial results with a mean follow-up of 7.8 years has now
demonstrated a survival advantage in the overall study
(84.4% with CABG versus 80.9% with PTCA, P equals
0.043), due to a marked survival benefit in the study subjects
with diabetes who were treated surgically (76.4% versus
55.7% with PTCA, P equals 0.0011) (130). Longer follow-
up analyses of EAST and ERACI have not demonstrated any
differences in mortality (131,132).
None of the trials or meta-analyses were able to demon-
strate a difference in Q-wave MI or the combined end point
of death and MI (Table 11) (118,123). Most trials found that
CABG resulted in greater freedom from angina, and the dif-
ference from PTCA was statistically significant in EAST,
Toulouse, RITA (Figure 5), and CABRI. Exercise time at 2.5
years was assessed in RITA and favored patients initially
treated by PTCA (191 versus 171 minutes) (126). Large
thallium defects (assessed in EAST) were slightly more
common in PTCA patients at 3 years (119). The relative risk
for angina with PTCA tended to be higher early but
decreased with longer follow-up (123) (Figure 5). 
The most striking difference between the treatments was in
the need for subsequent procedures. The rate was 4- to 10-
fold higher for PTCA in every trial (Table 11). Three trials
(Lausanne, MASS, and ERACI) that included repeated
revascularization as part of the primary, composite end point
demonstrated a statistically significant reduction in events
with CABG (122,133,134). Eight percent of CABG patients
required additional revascularization within 5 years in
BARI, compared with 54% of PTCA patients (117).
Additional procedures were needed earlier in PTCA patients
and included PTCA only (23.2%), CABG only (20.5%), or
both (10.8%) (117). 
Several studies have compared quality of life and cost
with various revascularization strategies (124,127,135,136).
In RITA, physical activity and employment were similar for
both procedures after 3 years (127). A BARI substudy
including 52% of enrollees found that functional status
assessed by the Duke Activity Index improved more with
CABG early on but was equivalent by 5 years (124).
Emotional health and employment were also similar in this
study and others (124,127,135). The early cost benefit of
PTCA decreased during follow-up owing to the more fre-
quent need for repeated procedures and hospitalization such
that, over the long term, PTCA approached the cost of
CABG (123,124,135,136). There appeared to be a greater
cost benefit to PTCA in patients with 2-vessel disease (124).
In BARI, it was estimated that the slight survival advantage
of CABG would cost $26 117/year of added life (124). 
Comparison with stents
Since the previous update of these guidelines, several trials
comparing stents with CABG in patients with multivessel
disease have been initiated. The Arterial Revascularization
Therapies Study Group (ARTS) trial enrolled 1205 patients
with multivessel coronary disease in whom a cardiac sur-
geon and interventional cardiologist agreed that they could
achieve a similar extent of revascularization. In this random-
ized comparison, there was no difference at 1 year in the
combined rate of death, MI, and stroke between the 2 revas-
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cularization strategies (137). However, repeat revasculariza-
tion rates were higher with stenting (16.8% versus 3.5%
with surgery), with a net cost savings of $2973 per patient
favoring the stent approach. In diabetic patients (n equals
198), the difference in repeat revascularization rates was
even more disparate (22.3% with stents versus 3.1% with
CABG), although overall event-free survival was similar
(138) (Table 11). 
Similar results were reported by the Stent or Surgery (SoS)
trial investigators. The trial randomized 988 patients with
multivessel disease (57% 2-vessel; 42% 3-vessel) to revas-
cularization with PCI (78% received stents) or CABG (81%
with pedicled left IMA graft). The primary end point of
repeat revascularization occurred in 21% of PCI patients
versus 6% of CABG patients at a median follow-up of 2
years (hazard ratio equals 3.85, P less than 0.0001).
Freedom from angina was also better with surgery (79% ver-
sus 66%). Mortality was higher in the PCI group, but this
was influenced by a particularly low surgical mortality and a
high rate of noncardiovascular deaths in the PCI group
(139). 
In the Angina with Extremely Serious Operative Mortality
Evaluation (AWESOME) study, 454 patients at 16 VA hos-
pitals with high-risk features for adverse outcome with sur-
gery were randomized to either CABG or PCI. High-risk
characteristics included prior open-heart surgery, age greater
than 70 years, ejection fraction less than 0.35, MI within 7
days, and IABP. Stents were used in 54% of PCI patients.
Survival was similar (79% with CABG and 80% with PCI)
at 36 months (140). Finally, in the Stenting versus Internal
Mammary Artery (SIMA) trial, 121 patients with isolated
proximal LAD coronary artery disease were randomly treat-
ed with stenting or CABG (using the IMA). At 2.4 years of
follow-up, there were no differences in the rates of death,
MI, functional class, medications, or change in quality of
life. Repeat revascularization was required more often (31%
Figure 5. Freedom from angina in the Randomized Intervention Treatment of Angina (RITA) trial. Reprinted with permission from
Elsevier Science, Inc. (The Lancet. 1993;341:573-80) (126).
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versus 7%) in the stent group (141). Overall, 6 trials have
now been published comparing CABG with PCI using stents
in single or multivessel disease. Compared to the earlier tri-
als with balloon angioplasty, stent usage and left IMA revas-
cularization rates have increased. The results in terms of
death, MI, and stroke are similar in the more recent trials;
however, the disparity in the need for repeat revasculariza-
tion, which favors surgery, has narrowed (Table 11).
3.3.2.3. Special Subsets
The BARI trial prespecified 4 subsets for analysis. The pri-
mary end point of survival did not differ in these subgroups
based on severity of angina, extent of disease, LV function,
and lesion complexity (117). However, 3-year cardiac mor-
tality was higher with PTCA in several high-risk groups (in
unstable angina and non–ST-elevation MI (NSTEMI),
PTCA 8.8% versus CABG 4.9%; in CHF, PTCA 27.7% ver-
sus 16.4% with CABG) (129). The ERACI trial included a
high proportion (83%) of patients with unstable angina, and
there was no difference in survival at 1 year (133). 
Data from fibrinolytic trials suggesting an adverse effect of
diabetes mellitus on PTCA outcome prompted the addition
of treated diabetes mellitus as a subgroup for analysis part-
way through the BARI trial (117,142). This subgroup of 353
patients (19% of total) was more likely to be women or
members of minorities and belong to a lower socioeconom-
ic class. They also had more severe heart disease and comor-
bidities, but their in-hospital complications were similar to
those in patients without diabetes and were also higher for
CABG than for PTCA (143). 
All-cause mortality and cardiac mortality were both high-
er in patients with diabetes treated with PTCA (34.7% ver-
sus 19.1% and 20.6% versus 5.8%, respectively) (Figure 6)
(142). This benefit of CABG was confined to patients
receiving IMA grafts, which may reflect a selection bias or
the low numbers of patients not receiving IMA grafts. A sim-
ilar result with regard to patients with diabetes was found in
a post hoc analysis of 122 patients with diabetes in CABRI
(143), but no difference was found for patients with diabetes
in EAST (119). 
A separate meta-analysis of the randomized trials for sin-
gle-vessel disease has also been performed (123). As expect-
ed, the overall risk for events was less than in patients with
multivessel disease. Although the risk of death and MI was
lower with CABG, this finding should be interpreted with
caution, since no such difference was found for multivessel
disease. The need for late CABG was lower in patients with
single-vessel disease, and there was less difference in angi-
na frequency (123).
3.3.2.4. Results From Nonrandomized Trials 
and Registries
Much of the debate relating to the finding for a survival
advantage of CABG in treated patients with diabetes is
based on the results of nonrandomized trials and registries.
Treated patients with diabetes in the BARI registry who
Figure 6. Improved survival with coronary artery bypass graft surgery (CABG) versus percutaneous transluminal coronary angioplas-
ty (PTCA) in patients with diabetes mellitus. Results from the Bypass Angioplasty Revascularization Investigation (BARI) showing that
patients with multivessel coronary disease who were being treated for diabetes at baseline had a significantly better survival after coro-
nary revascularization with CABG (solid curve) than with PTCA (dashed curve) (P = 0.003). Modified with permission from Circulation.
1997;96:1761-9 (142).
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refused randomization and selected their form of revascular-
ization did not fare worse with PTCA (144). In a retrospec-
tive cohort study comparing PTCA and CABG for patients
with diabetes with multivessel disease and similar age, sex,
EF, and severity of angina, there was also no difference in
survival after 6 years (145). However, in one comparison of
CABG and PTCA in a nonrandomized, observational data-
base, patients with diabetes requiring insulin had a lower
long-term survival after treatment with multivessel PTCA
(146). Limitations of this conclusion include the unknown
adequacy of glucose control and the absence of a survival
advantage for CABG when patients in the randomized trials
are pooled and in other, nonrandomized registries (147). 
The majority of patients in the randomized trials had angi-
na. A small trial that demonstrated improved outcomes with
revascularization compared with medical therapy in patients
with asymptomatic ischemia also examined the relative ben-
efits of the type of revascularization (148). In this nonran-
domized trial, CABG provided superior relief of exercise-
induced as well as ambulatory ischemia compared with
PTCA (149). 
A more compelling report was published by Hannan et al
(150), which described a 3-year survival analysis of the 30000
patients enrolled in the New York State PTCA registry com-
pared with that of 30 000 patients in the CABG registry from
1993 to 1995. As opposed to the randomized trials, this large
experience showed a survival benefit for patients receiving
CABG when proximal LAD stenosis was greater than 70%,
regardless of whether 1-, 2-, or 3-vessel disease was present
(Figure 7) (Table 12) (150). Patients with 3-vessel disease not
involving the proximal LAD also fared better with CABG than
with PTCA. Patients with 1-vessel disease without severe
proximal LAD stenosis had better survival with PTCA.
Several potential limitations of this experience deserve com-
ment. Unmeasured differences in patient severity not account-
ed for in the risk-adjustment method could have affected the
conclusions. Similarly, physicians’ choice of treatment may
have been based on unmeasured patient factors. Finally, coro-
nary stents were utilized in just 11.8% of the PCI patients. 
3.3.2.5. Conclusions
For patients included in the randomized trials, CABG pro-
vided better relief of angina with a lower need for subse-
quent procedures. Initial complications are higher with
CABG, as are the cost and length of hospitalization. Patients
may return to work sooner after PCI but are subsequently
hospitalized more often, thus generating similar overall
long-term costs. Randomized trials do not show any differ-
ence in late death or rate of MI, except in patients with treat-
ed diabetes mellitus, for whom CABG may be superior.
Conversely, data from large registries, particularly those of
New York State, suggest that patients with severe, proximal
LAD stenosis and/or 3-vessel disease may achieve improved
survival with CABG. Patients with 1-vessel disease not
involving severe proximal LAD disease may do better with
PCI. 
Several important caveats and limitations to these conclu-
sions must be discussed. Since completion of the trials, the
influence of new technology, particularly on PCI, has been
considerable. Intracoronary stents are now used in 70% or
more of PCIs and have reduced the need for both urgent
CABG and subsequent procedures by as much as 50%
(151). Continuing advances in PCI and stent designs, the use
of brachytherapy (local radiation), and drug-eluting stents
have further reduced the need for repeat procedures. Medical
management of atherosclerosis, both before and after revas-
cularization, has continued to evolve, with greater use of
beta-blockers and inhibitors of the renin-angiotensin-aldos-
terone system after MI and the introduction of statins and
other lipid-lowering agents. The ability to select patients for
revascularization procedures by using a methodology that
can separate scarred from viable myocardial segments will
undoubtedly alter the outcomes from these procedures.
Other changes in patient management that may influence
these conclusions include the use of platelet glycoprotein
IIb/IIIa inhibitors and/or direct thrombin inhibitors during
percutaneous interventions, the more frequent use of IMA
grafts, and the emergence of less-invasive surgical approach-
es. 
It is likely that during the progress of their disease, many
patients will benefit from a combined application of percu-
taneous and surgical techniques, taking advantage of the low
morbidity of percutaneous methods and the established
long-term benefit of surgical revascularization with arterial
conduits. 
4. MANAGEMENT STRATEGIES
4.1. Reduction of Perioperative Mortality and
Morbidity
One of every $10 spent on surgical treatment of coronary
disease is related to a complication, a sum of 1 billion dol-
lars annually in the United States (152). Careful evaluation
of patient characteristics should lead to proper risk stratifi-
cation and the identification of areas for risk neutralization.
Some risk factors that at first appear immutable may in fact
be markers or surrogates for conditions that can be modified.
The incremental incorporation of new advances can lead to
coronary bypass results that are superior to those of the past.
The following discussion formalizes this mind-set of risk
neutralization to maximize the margin of safety for coronary
bypass. 
4.1.1. Reducing the Risk of Brain Dysfunction
After CABG
One of the most devastating complications of coronary
bypass surgery is perioperative stroke. In addition to patient
morbidity and mortality, there are indirect costs through lost
productivity; the direct economic cost of a stroke ranges from
$90 000 to $228 000 over a patient’s life span (153-155).
Postoperative stroke is the second most common cause of
operative mortality (after low cardiac output state) (156). The
e238
ACC - www.acc.org
AHA - www.americanheart.org
Eagle and Guyton et al. 2004
ACC/AHA Practice Guidelines
Figure 7. Panel A: 95% Confidence interval for ln (adjusted hazard ratio) of PTCA patient death: CABG patient death within a 3-year
period (excluding patients with myocardial infarction less than 24 hours before the procedure). For the sample size within each anatom-
ic cohort, see Table 11. Panel B: Differences in adjusted percent survival at 3 years: percent CABG survival minus percent PTCA sur-
vival. Solid bars show statistically significant differences. Prox indicates proximal; LAD, left anterior descending coronary artery; PTCA,
percutaneous coronary angioplasty; CABG, coronary artery bypass graft. Reprinted with permission from Elsevier Science, Inc.
(Hannan et al. J Am Coll Cardiol. 1999;33:63-72) (150).
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incidence of stroke after coronary operation is related to
increased age (53,157-159) (Figure 8A), which parallels the
accelerated involvement of the aorta and great vessels with
atherosclerotic plaque (156) (Figure 8B). Age per se is less
important than atherosclerosis, which plays a role in at least
two thirds of adverse events after coronary bypass. 
As discussed in Sections 4.1.1.1 and 4.1.1.2, post-CABG
neurological events can be classified into type 1 injuries,
which are predominantly focal stroke, transient ischemic
attack, and fatal cerebral injuries, and type 2 events, which
reflect a more global/diffuse injury, with disorientation or
immediate (and usually reversible) intellectual decline. 
4.1.1.1. Type 1 Neurological Injury
Type 1 injury occurs in 3.1% of patients, is responsible for a
21% post–coronary bypass mortality rate, 11 days in the
intensive care unit, 25 days in hospital, at least an addition-
al $10 266 in hospital boarding charges, and a cost of 5 to 10
times the in-hospital charge for rehabilitative and outpatient
support (51,148).
4.1.1.1.1. AORTIC ATHEROSCLEROSIS AND MACRO-
EMBOLIC STROKE. The surgeon’s identification of an ather-
osclerotic ascending aorta is the single most significant
marker for an adverse cerebral outcome after coronary
bypass operations (OR 4.5, P less than 0.05) (48), reflecting
the role of aortic atheroembolism as the cause of ischemic
stroke (161-165). Since the early days of the operation,
atheroemboli and calcific debris have been detected in the
cerebral circulation in patients dying after coronary bypass
surgery (166). Since the average age of patients having coro-
nary bypass is increasing, perioperative atheroembolism
from aortic arch plaque is also increasing and is likely
responsible for 1 in 3 strokes after coronary bypass (167).
This risk is particularly increased in patients beyond 75 to 80
years old (49) (Figures 8B and 8C). Most perioperative cere-
bral atheroembolization likely arises intraoperatively from
manipulation of the ascending or transverse aorta during
cannulation, clamping, or placement of proximal anasto-
moses or from the shear effect of the flow from the aortic
cannula (168,169,170). Preoperative, noninvasive testing for
detection of the high-risk patient has limited sensitivity.
Table 12. Three-Year Survival by Treatment in Each Anatomic Subgroup 
LAD indicates left anterior descending coronary artery; CABG, coronary artery bypass graft; and PTCA, percutaneous transluminal coronary angioplas-
ty. 
Comparative observed and adjusted 3-year survival of patients treated with PTCA or CABG in various anatomic subgroups.
Reprinted with permission from Elsevier Science, Inc. (Hannan et al. J Am Coll Cardiol. 1999;33:63-72) (150).
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Computed tomography identifies most severely involved
aortas but underestimates mild to moderate involvement
compared with echocardiography (163,171). TEE is useful
for examination of the aorta, and although evaluation of the
ascending aorta was somewhat limited by the intervening
trachea (159) with earlier monoplane techniques, multiplane
TEE technology allows good visualization of the aorta.
However, the intraoperative assessment of ascending aortic
atheroma by epiaortic imaging (in which the imaging probe
is placed directly on the aorta) is superior to both TEE and
direct palpation (160). 
TEE identification of mobile arch atheroma in patients
undergoing CABG was associated with a 33% stroke rate
versus 2.7% in patients with nonmobile plaque (P equals
0.01) (172). Intraoperative palpation is notorious for its
underestimation of the high-risk aorta (160). Palpation
detected only one third of atherosclerotic lesions identified
by epivascular echocardiography (171). The aortic pattern
with the highest risk is the protruding or mobile aortic arch
plaque, and this eludes intraoperative palpation in 80% of
cases (173). Intraoperative epivascular ultrasound represents
an important advance and is now used in many centers for
intraoperative diagnosis and stroke risk reduction (171,174).
The technique is highly sensitive and specific for identifica-
tion of the high-risk aorta. 
An aggressive approach to managing patients with severe-
ly atherosclerotic ascending aortas identified by intraopera-
tive epiaortic ultrasound imaging appears to reduce the risk
of postoperative stroke (53,175). Twelve hundred of 1334
consecutive open heart surgery patients (88% with coronary
Figure 8. A: Incidence of permanent, focal, central nervous system injury after coronary bypass is strongly correlated with increasing
age. B: Ascending aortic atherosclerosis is a powerful marker of increased risk for perioperative stroke in the coronary bypass popu-
lation and increases directly with age. C: Strong correlation between perioperative atheroembolism and the degree of atherosclerotic
involvement of the ascending aorta. The solid line represents severe atherosclerotic involvement the interrupted line, lesser involve-
ment. D: Extracranial cerebrovascular disease is a significant contributor to stroke after coronary bypass and is strongly correlated
with age, suggesting a population for aggressive preoperative screening. Panels B and C are reprinted with permission from Elsevier
Science, Inc. (Blauth et al. J Thorac Cardiovasc Surg.1992;103:1104-11) (169).
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disease) underwent screening with intraoperative epivascu-
lar ultrasound. These findings led to a change in intraopera-
tive technique in 19.3% of patients. In patients with 3 mm or
less of aortic wall thickening, standard techniques were
used. When the aorta demonstrated a greater than 3-mm
thickening, the cannulation, clamp, or proximal sites were
changed, or a no-clamp fibrillatory arrest strategy (176) was
used. For high-risk patients with multiple or circumferen-
tially involved areas or those with extensive mid-ascending
aortic involvement, the ascending aorta was replaced under
hypothermic circulatory arrest. The 27 high-risk patients had
no strokes and a mortality rate of just 3%. Among patients
with a moderately to severely involved aorta treated with the
less-radical approaches, the incidence of stroke was 6.3%.
When epivascular ultrasound showed no or mild atheroscle-
rotic disease, the stroke incidence was low, 1.1% (53,176). 
In a smaller study of epivascular echo-directed manage-
ment, 195 consecutive coronary patients undergoing CABG
were compared with a control group of the previous consec-
utive 165 patients for whom only the surgeon’s palpation
was used to evaluate the aorta. Ten percent of the epivascu-
lar group had the intraoperative technique modified versus
3% of the control group. The most common change in oper-
ative approach was use of a no-clamp, cold fibrillatory arrest
technique. Three percent of the control group had strokes
compared with none of the epivascular echo-managed group
(P less than 0.02) (51). 
With a no-clamp technique, the surgeon may completely
revascularize the heart with standard in situ IMA and aorti-
cally based SVGs, typically constructing a single, proximal
anastomosis during a brief period of total circulatory arrest
on a safe area of the aorta. Alternatively, the surgeon may
use an all-in situ arterial revascularization approach, or
SVGs may be grafted onto the in situ IMA by using an end
vein to side artery anastomosis (167,177). 
Preoperative risk assessment may identify a small popula-
tion of patients with such extensive aortic atherosclerosis
and poor outlook that the benefit from coronary bypass
would appear to be very small. This population is difficult to
define, but a starting point may include patients with aortic
plaques 4 mm or more or with certain morphologies that are
associated with only a 20% chance at 4 years of freedom
from peripheral embolism, MI, recurrent stroke, or death
(165). This risk, along with an extremely high perioperative
risk, would argue for nonoperative treatment. However, if
the cardiac risk of medical therapy is high (5-year mortality
greater than 20%), alternative forms of revascularization
should be considered. These include off-pump bypass sur-
gery; minimally invasive direct CABG (MID-CAB) without
CPB, with or without concomitant PCI; and exclusive per-
cutaneous revascularization. These techniques may provide
the benefit of revascularization in such high-risk patients
while minimizing the perioperative risk of stroke. There are
few randomized trials that examine the specific impact of
CPB on stroke incidence, but 1 randomized study showed a
comparable stroke rate in patients without CPB (off-pump)
versus those on-pump (56). These patients were not strati-
fied according to high-risk aortic disease, so the relative
value of off-pump surgery in such patients remains
unknown. 
4.1.1.1.2. ATRIAL FIBRILLATION AND
POSTOPERATIVE STROKE.
Class IIa
In post-CABG atrial fibrillation that is recurrent or
persists more than 24 hours, warfarin anticoagulation
for 4 weeks is probably indicated. (Level of Evidence:
C)
Chronic atrial fibrillation is a hazard for perioperative
stroke as a result of cardiac thromboembolism.
Intraoperative surgical manipulation or spontaneous
resumption of sinus rhythm early in the postoperative period
may be associated with embolism of a left atrial clot. One
potential approach to reduce atrial fibrillation-associated
embolism is the performance of preoperative TEE. Absence
of a left atrial clot would suggest that the operation may pro-
ceed with acceptable risk. If a left atrial clot is identified, 3
to 4 weeks of anticoagulation, restudy, and then subsequent
operation is a rational approach if the clinical situation
allows this. Unfortunately, few clinical trial data are avail-
able to assist physicians in the best management for this sit-
uation. 
New-onset postoperative atrial fibrillation occurs in 30%
of patients undergoing CABG (178-180), with the peak inci-
dence on the second to third postoperative day (181). It is
associated with a 2- to 3-fold increase in postoperative risk
for stroke (182,183). Patients at risk for postoperative atrial
fibrillation have been identified and include those with
COPD, proximal right CAD, prolonged cross-clamp time,
atrial ischemia, advanced age, and withdrawal of beta-block-
ers. Identifying at-risk patients and directing treatment to
these patients (see Section 4.1.5) appears to be effective in
reducing the incidence of post-CABG atrial fibrillation and
thus the morbid complication of postoperative strokes asso-
ciated with this arrhythmia. Minimally invasive and off-
pump beating-heart procedures may also reduce the inci-
dence of postoperative atrial fibrillation (184,185). 
The role of anticoagulation in patients who develop post-
CABG atrial fibrillation is unclear. In general, an aggressive
anticoagulation and cardioversion philosophy may reduce
the neurological complications associated with this arrhyth-
mia. However, the risks of pericardial bleeding and tampon-
ade have to be weighed with early use of full anticoagula-
tion. Early (within 24 hours of onset of atrial fibrillation)
attempts at cardioversion can probably be safely performed
without anticoagulation. However, if the arrhythmia persists
beyond this time, it may be advisable to use intravenous
heparin while cardioversion is attempted. In certain patients,
TEE can be used to exclude left atrial appendage thrombus
and help to direct cardioversion. In such patients, it is gen-
erally recommended that anticoagulation be used after the
cardioversion (186). If the atrial fibrillation persists, antico-
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agulation with warfarin on an outpatient basis is probably
indicated when the benefit of anticoagulation in selected
patients (186a-c) exceeds the risk of bleeding in the postop-
erative interval in the judgment of the surgical team. Further
attempts at cardioversion are determined by the individual
patient profile (187).
4.1.1.1.3. RECENT ANTERIOR MI, LV MURAL
THROMBUS, AND STROKE RISK.
Class IIa
Long-term (3 to 6 months) anticoagulation is proba-
bly indicated for the patient with recent anteroapical
infarct and persistent wall-motion abnormality after
CABG. (Level of Evidence: C)
Class IIb
In patients having a recent anterior MI, preoperative
screening with echocardiography may be considered
to detect LV thrombus, because the technical
approach and timing of surgery may be altered.
(Level of Evidence: C)
The patient with a recent anterior MI and residual wall-
motion abnormality is at increased risk for development of
an LV mural thrombus and its potential for embolization.
Keren et al (188) identified LV thrombus in 38 of 124 ante-
rior-infarct patients (31%) and in none of 74 patients with
inferior infarcts (P less than 0.001). Early fibrinolytic thera-
py was not uniformly protective against LV thrombus, and
30% occurred after discharge. Such patients are at risk for
systemic embolization of the LV clot, and the risk is highest
in the first few weeks after the acute infarct. Preoperative
screening with echocardiography may demonstrate the clot
and alter the technical approach and perhaps the timing of
surgery. Also, long-term (3 to 6 months) anticoagulation is
probably recommended for the patient with persistent ante-
rior wall-motion abnormalities after coronary bypass. LV
thrombus may recur in patients receiving short-term (2
months or less) anticoagulation. Apical akinesis at 10 days
after infarction was a strong predictor for subsequent throm-
bus formation, which conferred an increased risk for subse-
quent stroke (189). 
4.1.1.1.4. RECENT ANTECEDENT CEREBROVASCULAR
ACCIDENT. A recent, preoperative cerebrovascular accident
presents another situation in which delaying the operation
may reduce the perioperative neurological risk. Evidence of
a hemorrhagic component to the cerebrovascular accident,
based on the results of a computed tomography scan, identi-
fies those patients at particular risk for extension of the neu-
rological damage due to heparinization and CPB (189). It is
generally believed that a delay of 4 weeks or more is prudent
if coronary anatomy and symptoms permit. 
4.1.1.1.5. CPB TIME AND NEUROLOGICAL RISK.
Increased time on CPB is closely correlated with adverse
neurological outcome, emphasizing the need for an organ-
ized, expeditious operation. On average, patients without
postoperative neurological events have shorter pump times
than those who develop postoperative stroke and/or type 2
deficits (190).
4.1.1.1.6. CAROTID DISEASE AND NEUROLOGICAL
RISK REDUCTION.
Class IIa
1. Carotid endarterectomy is probably recommended
before CABG or concomitant to CABG in patients
with a symptomatic carotid stenosis or in asympto-
matic patients with unilateral or bilateral internal
carotid stenosis of 80% or more. (Level of Evidence:
C)
2. Carotid screening is probably indicated in the follow-
ing subsets: age greater than 65 years, left main coro-
nary stenosis, peripheral vascular disease, history of
smoking, history of transient ischemic attack or
stroke, or carotid bruit on examination. (Level of
Evidence: C)
Extracranial carotid disease is significantly associated with
a type 1 adverse neurological outcome (P equals 0.001) (48).
Hemodynamically significant carotid stenoses are associated
with as many as 30% of early postoperative coronary bypass
strokes (158). Strokes caused by carotid disease are particu-
larly devastating, since they often occur on the second to
ninth postoperative day in the midst of an apparently smooth
recovery (159). The trend for coronary surgery to be per-
formed in an increasingly elderly population underscores the
importance of the issue (Figure 8D) (169,191-193). The
prevalence of significant carotid disease in the current car-
diac surgery population reflects the diffuse nature of the ath-
erosclerotic process: 17% to 22% of patients have 50%
carotid stenosis, and 6% to 12% have 80% carotid stenosis
(191,194). Perioperative stroke risk is 2% when carotid
stenoses are less than 50%, 10% when stenoses are 50% to
80%, and 11% to 18.8% in patients with stenoses greater
than 80% (53,195). Although the patient with untreated,
bilateral, high-grade stenoses or an occluded carotid artery
and contralateral high-grade stenosis is rare, such patients
have a 20% chance of stroke (196,197). 
Conversely, the leading cause of short- and long-term risk
for patients having surgical treatment of carotid disease is
the associated coronary disease (198-201). CABG is the
most effective treatment for many of these patients. Provided
that the surgical team has acceptable results with endarterec-
tomy, prophylactic carotid endarterectomy is superior to
conservative therapy for prevention of stroke in symptomatic
or asymptomatic patients with high-grade carotid stenoses
(202-204). 
With proper teamwork, carotid endarterectomy for high-
grade stenosis preceding or coincident with a coronary oper-
ation can be associated with a low risk for short- and long-
term adverse neurological sequelae (114,196,198,205)
(Figure 9). Carotid endarterectomy done before or concomi-
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tant with coronary bypass carries a low mortality (3.5%),
reduces early postoperative stroke risk to less than 4%, and
confers a 10-year rate of freedom from stroke of 88% to 96%
(196,205,206). Special interest in this problem among care-
givers and careful collaboration between the carotid and
coronary surgical teams are keys to success. Stroke and mor-
tality rates after carotid endarterectomy also are inversely
related to institutional volume (207,208). 
The absence of symptoms referable to carotid disease is
not reassuring because a carotid stenosis of 75% in an
asymptomatic patient is an independent predictor of stroke
risk immediately after CABG (OR of 9.87, P less than
0.005) (158,159). The presence or absence of a cervical bruit
is poorly predictive of a high-grade stenosis even in the set-
ting of known symptomatic carotid disease (sensitivity 63%,
specificity 61%) (209). 
A prospective examination of preoperative carotid duplex
scans in 1087 open-heart surgical patients aged 65 or older
defined the markers associated with important (80%) carotid
stenosis: female sex, PVD, previous transient ischemic
attack or stroke, smoking history, or left main disease (P less
than 0.05) (191). If all patients with at least 1 of these risk
factors were screened, 95% of those with an 80% stenosis
would be detected and 91% of those with a 50% stenosis
would be detected. Unfortunately, this would lead to screen-
ing in 85% of patients aged 65 years or older. This example
illustrates the correlation of carotid stenosis with age and
suggests that the lower limit of age at which carotid screen-
ing will be cost-effective is not yet known. For safety and
simplicity, many centers screen all of those aged 65 or older.
The strong association between left main disease and carotid
stenosis argues that left main patients should be screened at
any age. Similarly, those with a previous transient ischemic
attack or stroke should receive carotid screening independ-
ent of age. Preoperative CNS symptoms suggestive of verte-
brobasilar artery insufficiency should lead to evaluation by
magnetic resonance angiography to allow informed consid-
eration of management options. 
When surgical treatment of concurrent carotid and coro-
nary disease is planned, the procedures may be done in
either a combined (same operative setting, carotid to precede
coronary revascularization) or staged fashion. The staged
approach is most commonly used, particularly in patients
with noncritical coronary anatomy. Postoperative care is
rendered in a telemetry setting, with aggressive monitoring
and treatment to prevent postoperative myocardial ischemia.
CABG follows in 1 to 5 days with the use of standard tech-
niques. The superiority of the combined versus staged
approach has not been established by prospective trials.
Thus, current tactics are best left to local team policies and
preferences based on careful examination of team outcomes.
An individualized, patient-specific, selective approach with
the decision based on symptoms and the relative severity of
extracranial cerebrovascular disease and coronary disease
appears prudent and is used in many institutions. The results
of these approaches in a collation (198) of 7 published
Figure 9. Contemporaneous surgical treatment of carotid and coronary disease is associated with an excellent long-term outcome.
The gap shows freedom from stroke, myocardial infraction, and death over time. Reprinted with permission from Akins et al. Ann
Thorac Surg. 1995;60:311-7) (205).
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series, each with 100 patients, published from the mid-1980s
to the mid-1990s had an overall mortality rate of 4%, with
permanent neurological deficit in 3.4% of patients. 
Some observational series have suggested that combined
carotid/coronary operations carry a higher risk for in-hospi-
tal stroke and mortality compared with patients in the same
institution having a staged procedure (210). These studies
may be confounded by selection bias toward recommending
combined operations in patients with more advanced carotid
and coronary disease. Contrariwise, a recent, single-center
series in which a combined operation for all patients with
concurrent carotid and coronary disease was used suggested
this approach to be safe and to have low overall resource
requirements (205). However, another multicenter study
suggested a considerably higher risk (191a). Thus, some
uncertainty remains, underscoring the need for prospective
appropriately-controlled, randomized study of this method
(191b,191c).
Stroke risk appears to be increased when the so-called
reverse-staged procedure is used. In this strategy, the coro-
nary bypass precedes the carotid endarterectomy by 1 day
during the same hospitalization. A prospective, randomized
trial that evaluated this approach demonstrated an increased
risk of stroke (14% versus 2.8%, P less than 0.05) when
carotid operation followed rather than preceded (2.8%, P
less than 0.05) CABG, whereas mortality rates were similar
(211). It is generally accepted that cerebral revascularization
should precede coronary revascularization when significant
carotid disease is known, except in the uncommon situation
of the true emergency CABG patient, in whom carotid
endarterectomy should then closely follow the heart opera-
tion. 
Most workers in the field have focused on in-hospital neu-
rological outcomes for treatment of combined carotid and
coronary disease. Multicenter trials have shown an advan-
tage of surgical over medical management for significant
carotid stenosis in either symptomatic or asymptomatic
patients (202,212-214). These data argue for an aggressive
surgical approach in this population and demand a longer-
range vision. The long-term outlook for combined treatment
of carotid and coronary disease is shown in Figure 9. The
above-suggested strategy for carotid disease management in
the setting of CABG is in concordance with the Guidelines
for Carotid Endarterectomy: A Multidisciplinary Consensus
Statement From the Ad Hoc Committee, American Heart
Association [Special Report] (215). The success of this
long-term strategy is predicated on assembling a team that
can achieve excellent near-term carotid and coronary surgi-
cal results (207,208,215-217). 
Summary
Epivascular echocardiographic detection of ascending or
transverse aortic atherosclerosis and modification of opera-
tive technique hold great promise for significant stroke risk
reduction. In the current era, important concurrent carotid
and coronary disease should be suspected, sought by screen-
ing, and, when found, managed surgically (Table 13). This
strategy neutralizes the short-term risk of treatment of either
disease alone and enhances long-term quality and length of
life for the patient with generalized atherosclerosis. 
4.1.1.2. Type 2 Neurological Injury
Type 2 neurological complications have been identified in a
percentage of patients after CABG and are associated with
increases in postoperative time in the ICU, length of stay,
hospital costs, and the need for postdischarge transfer to
rehabilitation or extended-care facilities (48,218). Newman
identified abnormal neurocognitive function in 53% of CPB-
CABG patients at the time of hospital discharge. Six months
after surgery, abnormalities could be identified in 24% of
patients, which suggests some reversibility of the injury in
Table 13. Proven Management Strategies to Reduce Perioperative and Late Morbidity and Mortality 
Class
Timing Indication Intervention Comments
Preoperative
Carotid screening I Carotid duplex ultrasound in Carotid endarterectomy if steno-
defined population sis greater than or equal to 80%
Perioperative
Antimicrobials I Prophylactic antimicrobials See Table 14
Antiarrhythmics I Beta-blockers to prevent postoperative Propafenone or amiodarone are 
atrial fibrillation alternatives if contraindication to 
beta-blocker (see Table 15)
Postoperative
Antiplatelet agents I Aspirin to prevent early vein- Ticlopidine or clopidogrel are 
graft attrition alternatives if contraindications to
aspirin
Lipid-lowering therapy I Cholesterol-lowering agent plus 3-Hydroxy-3-methyglutaryl/
low-fat diet if low-density lipoprotein coenzyme A reductase inhibitors 
cholesterol greater than 100 mg/dL preferred if elevated low-density 
lipoprotein is major aberration
Smoking cessation I Smoking cessation education, and offer 
counseling and pharmacotherapies
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some patients. However, they were able to measure cognitive
decline in 42% of patients at 5 years. The strongest predic-
tor of late decline was the presence of an abnormality early
after CABG (218). 
Abnormal neurocognitive function is frequently present
preoperatively in the CABG population (219). There is a fur-
ther decline in neurocognitive function after any major oper-
ation in this population, but this decline is likely worse and
more persistent after operations employing CPB (220). 
4.1.1.2.1. REDUCING THE RISK OF MICRO-
EMBOLIZATION. Microembolization is a major contributor
to postoperative cerebral dysfunction after CABG
(221,222). Transcranial Doppler examination of the middle
cerebral artery of patients on extracorporeal circulation sug-
gests that most emboli occur during surgical manipulation
(clamping, cannulation) of the ascending aorta
(221,223,224). Many of these emboli appear to be gaseous,
either derived from the oxygenator or entrained directly
from the ambient atmosphere. Postmortem examination of
the brains of patients dying soon after CPB has shown dif-
fuse, small, capillary-arteriolar dilatations (225). These vac-
uolated vascular abnormalities have also been seen after
catheter manipulation of the ascending aorta, suggesting an
atheroembolic etiology. Fat droplets in shed mediastinal
blood, which can be returned to the pump circuit via car-
diotomy suction, may contribute (226). Small gaseous
emboli could also be responsible for the findings.
Neuroanatomists have postulated that these could impair cir-
culation and lead to the neurocognitive decline seen after
CPB. 
The number of microemboli delivered during CPB is cor-
related with the postoperative neurocognitive decline seen
immediately and 8 weeks after CPB (221). The use of a 40-
micron arterial-line filter in the heart-lung machine circuit
appears to be protective. Type 2 neurological outcomes may
be further reduced by routine use of the membrane oxy-
genator rather than the less-expensive bubble oxygenator,
which is still used selectively in the United States
(190,227,228). The return of shed mediastinal blood to the
CPB circuit via the cardiotomy suction system may increase
the microembolic load to the brain. Some centers avoid car-
diotomy suction and simply discard shed blood.
Alternatively, shed blood may be scavenged and red blood
cells returned after washing and centrifugation via cell-sav-
ing devices (226). 
Some have believed that off-pump bypass surgery may
reduce the incidence of type 2 neurological injury because
ascending aortic cannulation and cross-clamping are avoid-
ed (229). Reports have demonstrated mixed results (54,56).
In patients with significant ascending aortic atheromatous
disease, it would seem prudent to consider an off-pump and
“no touch” aortic technique. Inflow to graft conduits can be
achieved via in situ left or right IMAs, the right gastroepi-
ploic artery, or innominate and subclavian arteries. 
4.1.1.2.2. CEREBRAL HYPOPERFUSION AND NEURO-
LOGICAL OUTCOME. Intraoperative electroencephalo-
graphic monitoring can detect electrical patterns suggestive
of cerebral hypoperfusion and allow real-time intraoperative
correction. Decreases from 29% to 44% to 4% to 5% in post-
operative neurocognitive and neuropsychological dysfunc-
tion (type 2) have been demonstrated by intraoperative elec-
troencephalographic monitoring (230,231). However, the
level of training necessary for interpretation of the elec-
troencephalogram and the poor suitability of current tech-
nology for the operating room currently preclude its general
clinical use for detection of hypoperfusion. Also, the electri-
cal changes associated with microembolization and
macroembolization are at the limits of resolution. The limi-
tations cited reinforce the importance of strategies to prevent
embolization. 
Cerebral blood flow during CPB is kept relatively constant
over a wide range of systemic arterial pressures with the
alpha-stat extracorporeal circulation acid-base management
technique. The incidence of persistent, postoperative neu-
rocognitive deficits at 2 months with the use of this tech-
nique is significantly less compared with the alternative (pH-
stat) technique (27% of patients versus 44%, P equals 0.047)
(232). 
4.1.1.2.3. POTENTIATORS OF ADVERSE NEUROLOGICAL
OUTCOME. If neuroprotective mechanisms fail, there are
strategies to minimize damage to the marginally perfused
cerebral tissue, which has the potential for recovery.
Cerebral hyperthermia potentiates the damage of an acute
neurological injury. In the evolution of warm-heart surgery,
some centers used techniques that had the potential for intra-
operative cerebral hyperthermia. Techniques that have the
patient “drift” on CPB toward ambient temperatures (34°C
to 35°C or lower) rather than immediate warming (to main-
tain strict normothermia) allow an improved margin of neu-
rological safety (233-236). During rewarming, arterial return
blood temperature should be below 38°C. Hyperglycemia
may also amplify the impairment caused by an acute neuro-
logical event, emphasizing the importance of meticulous
perioperative glucose monitoring and control (236). 
Cerebral edema that may be present in patients immedi-
ately after extracorporeal circulation (237) may also potenti-
ate CNS damage. Efforts to reduce the potential for brain
swelling include maintenance of an unobstructed pathway
for venous drainage to the CPB reservoir while on the pump.
Anti-inflammatory strategies for CPB may reduce interstitial
edema and are discussed subsequently, but pulsatile perfu-
sion does not appear to be protective (238-240). 
4.1.2. Reducing the Risk of Perioperative
Myocardial Dysfunction
Most modern myocardial protection techniques allow the
patient undergoing CABG to leave the operating room with-
out a significant perioperative decrement in myocardial per-
formance. Ideally, the surgeon is familiar with the broad
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range of myocardial protection principles that allow the
adaptation of technique to accommodate varying patient pre-
sentations (241,242). There is no substitute for a well-
orchestrated, technically sound, expeditious operation to
minimize risk. 
4.1.2.1. Myocardial Protection for the Patient With
Satisfactory Preoperative Cardiac Function
The wide latitude of techniques associated with excellent
results for the majority of patients undergoing CABG is tes-
timony to the fact that there is no “ideal” or universally
applicable myocardial protection technique (243). The
greater the myocardial functional reserve in the patient pop-
ulation studied, the more difficult it is to demonstrate differ-
ences in myoprotective techniques. A variety of studies,
including prospective trials, confirm the safety of many vari-
ations of cardioplegic arrest, which is the most widely used
method for intraoperative myocardial protection. A single-
center trial of cold crystalloid versus warm blood cardiople-
gia in 1001 patients undergoing elective CABG demonstrat-
ed a low perioperative MI rate (1.4% warm versus 0.8%
cold, P not significant [NS]), IABP use (warm 1.4% versus
cold, 2.0%, NS), and mortality (1.0% warm versus 1.6%
cold, NS) with either technique (241). Advances in the
understanding of myocardial and endothelial metabolism,
temperature management, chemical/electrolyte composition,
sanguineous or asanguineous delivery media, substrate
enhancement, control of conditions of reperfusion, and
delivery route have all led to important incremental advances
in patient outcome (244-247). Certain techniques, however,
offer a wider margin of safety for special patient subsets. 
4.1.2.2. Myocardial Protection for Acutely
Depressed Cardiac Function
Class I
Blood cardioplegia should be considered in patients
undergoing cardiopulmonary bypass accompanying
urgent/emergency CABG for acute MI or unstable
angina. (Level of Evidence: B)
In contrast to the patient with normal myocardial function,
it is easier to demonstrate benefit from specialized protocols
(248,249) in the patient with an acutely injured ventricle.
One multicenter study of emergency CABG for patients
with acute coronary occlusion (some with cardiogenic
shock) demonstrated that controlled, surgical reperfusion
with prompt, vented CPB and substrate-enhanced san-
guineous cardioplegic technique led to a 96.1% survival,
which approaches that seen in low-risk, elective CABG
series (250). Preoperative regional wall-motion abnormali-
ties improved after bypass in 87% of these patients despite
an average of greater than 6 hours from infarct to revascu-
larization. 
Another observational study compared consecutive
patients receiving cold crystalloid cardioplegia with a warm
blood technique that did not include substrate enhancement
in emergency CABG after failed angioplasty. There was a
significant reduction in MI with the sanguineous technique
(65% infarcts with crystalloid versus 26% for blood, P less
than 0.007) (251). Multivariate analysis confirmed normoth-
ermic blood cardioplegia as an independent predictor of
freedom from infarct in this study (P less than 0.005).
Prospective, randomized trials have shown a survival benefit
for patients treated with blood cardioplegia compared with
crystalloid cardioplegia in the setting of urgent revascular-
ization for unstable angina. In one trial, the operative mor-
tality (0% versus 5%), incidence of MI (4% versus 13.5%),
and low-output syndrome (10% versus 19%) were favorably
reduced in patients receiving blood cardioplegia versus crys-
talloid (252). Multivariate analysis confirmed that crystal-
loid cardioplegia (P equals 0.008) was a significant, inde-
pendent predictor of postoperative morbidity compared with
warm-blood cardioplegia (253). 
4.1.2.3. Protection for Chronically 
Dysfunctional Myocardium
Class IIa
Blood cardioplegia is probably indicated in patients
undergoing cardiopulmonary bypass accompanying
CABG in the presence of a chronically dysfunctional
left ventricle. (Level of Evidence: B)
Severe LV dysfunction is an important risk factor for
patients undergoing CABG (254). Efforts to document
reduction of risk in this cohort are confounded by incom-
plete data on the prevalence of reversible ischemic systolic
dysfunction (hibernating myocardium) and the contribution
of improved function from revascularization of myocardium
as opposed to myocardial protection strategies (255). There
is an emerging consensus, however, that for the chronically
impaired ventricle, there is an added margin of safety pro-
vided by blood cardioplegic techniques (255-257). Its theo-
retical advantages include superior buffering capacity, rheo-
logical considerations at the capillary level, and free-radical
control when compared with crystalloid cardioplegia. 
4.1.2.4. Cardiac Biomarker Elevation and Outcome
Class IIb
Assessment of cardiac biomarkers in the first 24
hours after CABG may be considered, and patients
with the highest elevations of creatine kinase–MB
(greater than 5 times upper limits of normal) are at
increased risk of subsequent events. (Level of
Evidence: B)
The importance of elevation of cardiac biomarkers in the
first 24 hours after CABG has been controversial because
some degree of elevation of creatine kinase–MB (CK-MB)
is very common. New Q-wave MI after CABG occurs in 2%
to 4% of patients and is associated with adverse outcome
(258-260). However, up to 90% of individuals have some
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elevation of CK-MB (261). It has now been demonstrated
that marked elevation of CK-MB (5-10 times upper limits of
normal) is associated with an adverse prognosis. Increased
risk of death and repeat MI in the first 30 days after CABG
correlates with progressive increases in CK-MB elevation,
with the worst outcome in those with levels greater than 5
times normal (262). Six-month (263) and 1-year (262) mor-
tality also correlate with postoperative CK-MB elevation.
Poorer outcomes, including heart failure and death, at an
average of 3 to 5 years also appear to correlate with early
cardiac biomarker elevation (261,264). 
The prognostic value of troponins after CABG is not as
well established, but available studies have suggested that
troponin T is more discriminatory than CK-MB in predicting
early complications (265). For patients with elevated bio-
markers after CABG, it is particularly important that atten-
tion be given to optimal medical therapy, including the use
of beta-blockers, angiotensin converting enzyme (ACE)
inhibitors, antiplatelet agents, and statins in eligible individ-
uals. 
4.1.2.5. Adjuncts to Myocardial Protection
Class IIa
The use of prophylactic intra-aortic balloon pump as
an adjunct to myocardial protection is probably indi-
cated in patients with evidence of ongoing myocardial
ischemia and/or patients with a subnormal cardiac
index. (Level of Evidence: B)
The use of prophylactic IABP as an adjunct to myocardial
protection may decrease mortality and overall resource uti-
lization in certain high-risk patients. A retrospective evalua-
tion of 163 consecutive patients with an LVEF less than or
equal to 0.25 demonstrated a 4-fold reduction in 30-day
mortality in patients treated with IABP. Thirty-day mortality
was 2.7% in patients who received a prophylactic IABP
placed preoperatively versus 11.9% for patients not receiv-
ing a balloon (P less than 0.005). IABP use was also associ-
ated with a shorter hospital stay and lower hospital charges
(266). A randomized trial confirmed the benefit of preoper-
ative IABP support in high-risk patients (35a). Placement of
the IABP immediately before the operation afforded similar
protection to that accompanying placement the day before
CABG (267,268). In patients with severe PVD, a higher
threshold for balloon use is required given the high compli-
cation rate in this patient group.
Appreciation of the role of the activated leukocyte in the
genesis and exacerbation of myocardial reperfusion injury
has led to strategies to remove leukocytes from the coronary
blood flow. Clinical studies of leukocyte depletion have
shown significant benefit to myocardial performance in the
hypertrophied LV and in those with acute or chronic
ischemia (269-273). However, leukocyte depletion as an
adjunct to myocardial protection/reperfusion strategies has
yet to achieve widespread recognition and use among sur-
geons; therefore, no consensus statement is appropriate at
this point. 
The long-term survival benefit afforded by use of the IMA
is well recognized (12,274). Less appreciated is the reduc-
tion in immediate, operative mortality associated with the
use of the mammary artery as opposed to saphenous vein
revascularization. Its use may thus be considered an adjunct
to myocardial protection. Its use should be encouraged in the
elderly (275,276), the urgent/acutely ischemic patient (277),
and other subgroups that previously were thought not to
receive its immediate and long-term benefit. The large
CABG database available to the STS (42) was analyzed for
the influence of use of the IMA on operative mortality. Use
of the IMA was associated with reduced operative mortality
in all subgroups analyzed with regard to age (P less than
0.005), sex (P less than 0.005), priority of operation (P less
than 0.005), normal (P less than 0.01) or reduced (P less
than 0.005) LV function, presence of diabetes (P less than
0.005), obese patients (P less than 0.005), history of previ-
ous infarct (P less than 0.005), previous PTCA (P less than
0.001), and any pattern of coronary anatomy (P less than
0.005). Multivariate analysis also confirmed use of the IMA
as an independent predictor of operative survival (P less than
0.0025). When risk factors were combined, the only groups
found to have similar operative mortality between
use/nonuse of the IMA were elective and nonelective reop-
erative patients greater than 70 years of age. Arterial con-
duits are discussed in more detail in Section 6.2.
4.1.2.6. Reoperative Patients
For patients undergoing repeat CABG surgery who previ-
ously have had a left IMA-to-LAD graft, a concern has been
the accidental transection of the graft during sternotomy.
However, one report from a high-volume center showed that
experienced surgeons rarely encountered this complication
(less than 3%) (278). The risk of death or serious myocardial
dysfunction related to atheroembolism from patent, diseased
SVGs is low in the current era and is attributable to recogni-
tion of the problem and careful operative techniques by
experienced surgeons who encounter an increasing percent-
age of reoperative candidates in their practices (278). A risk-
reducing strategy in this situation is the use of retrograde
delivery of cardioplegia. This procedure allows early exclu-
sion of atherosclerotic SVGs from the coronary circulation,
as they are no longer needed to deliver cardioplegia. 
4.1.2.7. Inferior Infarct With Right Ventricular
Involvement
Class IIa
After infarction that leads to clinically significant
right ventricular dysfunction, it is reasonable to delay
surgery for 4 weeks to allow recovery. (Level of
Evidence: C)
Right ventricular (RV) failure secondary to an ischemic
RV (either infarction or stunning) presents a particularly
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hazardous situation (279). The prototypical patient has an
occluded right coronary artery proximal to the major RV
branches and presents with an inferior MI with or without
recognized RV failure (280,281a,282-284). Angiography
may demonstrate that the coronary anatomy is best treated
surgically, but the opportunity for maximal benefit of an
emergency operation (initial 4 to 6 hours) has often passed.
There is substantial risk in operating after this small window
of opportunity but before the recovery of RV function, which
usually occurs at 4 weeks after injury (285). During this
postinfarct month, the RV is at great risk for severe postop-
erative dysfunction, which often requires extraordinary lev-
els of perioperative pharmacological and mechanical sup-
port and has a very high mortality. The nonsurgical postin-
farction patient can most often be supported with pacing,
volume loading, and judicious inotropic administration
(286). In the surgical setting, the RV takes on different char-
acteristics. There is loss of the pericardial constraint imme-
diately on exposing the heart, which results in acute dilata-
tion of the dysfunctional RV. The RV often fails to recover in
this setting, even when state-of-the-art myocardial protec-
tion schemes and revascularization are employed (287). The
parallel effects of RV dilatation and dysfunction on LV dias-
tolic and systolic function are magnified and may be associ-
ated with the need for high levels of support, inability to
close the chest owing to cardiac dilation, need for ventricu-
lar assist devices, prolonged convalescence, transplantation,
or death (286a). In the acute setting, the potential risk of fur-
ther RV injury must be weighed against the potential benefit
of additional myocardial salvage. If early PCI of the right
coronary artery is indicated, it should be performed (35a).
The best defense is an index of suspicion and recognition
of the RV dysfunction by physical examination (281,288)
electrocardiography (right precordial leads), echocardiogra-
phy, or radionuclide-gated blood pool study (285,288-290).
A successful early PCI may allow recovery of an infarcted
RV in as few as 3 days (285).
4.1.3. Attenuation of the Systemic Sequelae 
of CPB
Extracorporeal circulation elicits a diffuse inflammatory
response that is attended by a transient, multisystem organ
dysfunction that may prolong convalescence (291,292).
Numerous strategies have been shown to blunt this counter-
productive immune response (291). Preoperative corticos-
teroid administration is inexpensive and appears to be effi-
cacious. Corticosteroid administration has favorable effects
on the systemic inflammatory response associated with
extracorporeal circulation. Glucocorticoid, when given
before CPB, reduces complement activation and the levels of
proinflammatory cytokines (293-297). Compared with
placebo, patients receiving glucocorticoid are less febrile
postoperatively, have higher cardiac indexes, require less
inotropic and volume support, and spend less time in the
ICU (298-302). 
Although there is no demonstration of an increased risk for
infection in studies to date, it may be prudent to avoid the
use of steroids in diabetic patients because the studies were
not powered to detect modest increases in infection risk
(301). The proper timing and duration of administration in
this application are incompletely resolved; there is evidence
that steroid delivery more in advance of an insult is more
efficacious (303). Preoperative corticosteroid administration
is inexpensive and appears to reduce the systemic inflamma-
tory response associated with CPB with little downside risk.
Current understanding supports liberal prophylactic use in
patients undergoing extracorporeal circulation (293). 
Aprotinin, a serine protease inhibitor known for its hemo-
static characteristics, also attenuates complement activation
and cytokine release during extracorporeal circulation.
There appears to be an emerging role for its prophylactic use
as an anti-inflammatory agent in patients undergoing CPB.
There was a significant reduction in length of stay and hos-
pital charges when aprotinin therapy was applied to a high-
risk cardiac surgical population (291). By virtue of its effects
on coagulation, aprotinin appears to reduce the need for
transfusion after repeat CPB. However, there are insufficient
data at present to make a strong recommendation for the rou-
tine use of this relatively expensive drug (293,297,304). 
Perioperative leukocyte depletion through hematologic fil-
tration may benefit patients by improving pulmonary func-
tion. One study suggested that low-risk patients benefit from
a strategy of leukocyte depletion during CPB in conjunction
with leukoreduction of homologous blood products (305-
308). Although the literature does support the routine use of
arterial-line filters to minimize microembolization in extra-
corporeal circulation, there is no current consensus on the
value of selective leukocyte filtration for the CPB circuit.
Although blood-surface interface modifications for the CPB
circuit have also been shown to decrease markers of inflam-
mation, translation into clinical benefit in terms of reduced
morbidity, mortality, or resource utilization has been equiv-
ocal. The concern over thrombotic complications tempered
enthusiasm among cardiac surgeons (291,309-313). Surface
modification such as heparin-bonded circuitry for extracor-
poreal circulation holds promise for reduction of the sys-
temic inflammatory response to CPB, but at present the evi-
dence is sufficiently conflicting that firm recommendations
are not at hand. 
4.1.4. Reducing the Risk of 
Perioperative Infection
Class I
1. Preoperative antibiotic administration should be used
in all patients to reduce the risk of postoperative
infection. (Level of Evidence: A)
2. In the absence of complicating circumstances, a deep
sternal wound infection should be treated with
aggressive surgical debridement and early revascu-
larized muscle flap coverage. (Level of Evidence: B)
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Class IIa
The risk for deep sternal wound infection is reduced
by aggressive control of perioperative hyperglycemia
by using a continuous, intravenous insulin infusion
(314). (Level of Evidence: B)
Multiple opportunities exist to reduce infection risk in
patients undergoing CABG. Interval reporting to individual
surgeons of their respective wound infection rates leads to
risk reduction through discipline in adherence to sterile
operative techniques. Skin and nasopharyngeal Gram-posi-
tive organisms are the leading cause of the most threatening
complication: deep sternal wound infection or mediastinitis.
Skin preparation with topical antiseptics (315,316), clipping
rather than shaving the skin (318,319), avoidance of hair
removal (62), reduction of operating room traffic, laminar-
flow ventilation, shorter operations, minimal electrocautery
(320), avoidance of bone wax (321), use of double-gloving
barrier techniques for the operating team (322-326), and
routine use of an easily constructed pleuropericardial flap
(327) have all been shown to be of value in reducing post-
operative infection (314). 
Several newer strategies that are easily integrated into
practice deserve consideration. Diabetes mellitus afflicts 1
of 5 patients undergoing CABG and is an independent risk
factor for wound infection (328). The risk for deep sternal
wound infection is reduced by aggressive control of periop-
erative hyperglycemia (glucose levels greater than 150 to
180 mg/dL) by using a continuous intravenous regular
insulin infusion (0.9% deep sternal wound infection) versus
intermittent subcutaneous insulin treatment (1.9%, P equals
0.04) (314). 
Homologous blood transfusions after CABG are correlat-
ed in a dose-related fashion to increased risk for viral and
bacterial infections, increased length of stay, antimicrobial
use, and mortality through transfusion-related immunomod-
ulation (329,330). A retrospective study of 238 patients
undergoing CABG demonstrated this immunosuppressive
effect of transfusion. Wound and remote infections occurred
in 4% of patients who received less than or equal to 2 U of
red blood cells, in 7% of those transfused with 3 to 5 U, and
in 22% of those having received greater than or equal to 6 U
(329). Leukodepletion strategies have been shown to blunt
the immunosuppressive effect of blood transfusion in surgi-
cal patients (330). The dose-related effect of blood transfu-
sion on increased infection risk has been known for general
surgical and orthopedic operations and is thought to be
caused by the accompanying leukocytes in the red blood cell
transfusion (331). A single-center prospective trial of 3
transfusion protocols in 914 patients undergoing cardiac sur-
gery showed a significant reduction for patients receiving
leukocyte-depleted blood (17.9%) as opposed to nonfiltered
blood (23.5%, P equals 0.04) for all infections (respiratory,
urinary tract, bacteremia, and wound) (330). Most striking
was the reduction in 60-day mortality in transfused patients
having received filtered blood: transfused/nonfiltered patient
mortality was 7.8%; transfused/filtered at the time of dona-
tion, 3.6%; and transfused/filtered at the time of transfusion,
3.3% (P equals 0.019) (330). The reduction in the postoper-
ative rate of noncardiac causes of death (i.e., multisystem
failure) in leukocyte-depleted/transfused patients compared
with patients receiving nonfiltered blood was highly signifi-
cant (P equals 0.001) (330). Leukodepletion can be accom-
plished by regional blood banks at the time of donation or at
the bedside at time of transfusion by using a relatively inex-
pensive in-line transfusion filter. 
Preoperative antibiotic administration reduces the risk of
postoperative infection 5-fold (332). Prophylactic antimicro-
bial efficacy is dependent on adequate drug tissue levels
before microbial exposure (333,334). Multi-institutional
studies suggest that many centers, including those with train-
ing programs in cardiothoracic surgery, are not consistent in
delivering or teaching effective use of perioperative antibi-
otics. 
The cephalosporin class of antimicrobials is currently the
agent of choice for prophylaxis of infection for coronary
operations. There is a trend toward superior efficacy with
cefuroxime compared with the other cephalosporins, but this
difference does not reach statistical significance (Table 14)
(334-338). Institution- or surgeon-specific selection is
appropriate within this class (335). Data suggest that a 1-day
course of intravenous antimicrobials is as efficacious as the
traditional 48-hour (or longer) regimen (339-342). There is
little evidence that prolonging (greater than 2 days) the
antimicrobial prophylaxis even in high-risk patients provides
any benefit (343). A 1-day course of antimicrobial prophy-
laxis is safe and effective (344). There are insufficient data
to suggest that aminoglycosides add substantial benefit to
the antimicrobial prophylactic regimen (335). Usual
cephalosporin pharmacokinetics mandates administration
within 30 minutes of incision and redosing if the operation
exceeds 3 hours (335,345). 
Antimicrobial selection is a moot point if the agent is not
delivered during the optimal 30- to 60-minute window just
before incision. The beneficial effect is negated if the drug is
given after incision. This is a major issue. A multi-institu-
tional study, including those with cardiothoracic training
programs, confirmed the suboptimal use of prophylactic
antimicrobials. In 1994, only 23% of the institutions studied
had a system that assured proper administration of prophy-
lactic antimicrobials in the generous 2-hour period just
before incision for patients undergoing CABG. One year
later, compliance was even worse at 20% (346). A practical,
fail-safe guideline to assure proper timing is the administra-
tion of the cephalosporin by the anesthesiologist after induc-
tion but before skin incision. Then the surgeon confirms
administration before the scalpel is in hand (334,347).
Surgeons should be familiar with the pharmacokinetics of
their preferred cephalosporin to modify initial and subse-
quent dosing based on patient size and duration of operation.
This knowledge can favorably influence plasma, sternal, and
soft-tissue bacteriocidal activity for the individual patient. 
If preventive strategies fail, prompt recognition of deep
sternal wound infection or mediastinitis is critical.
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Morbidity and mortality for deep sternal wound infection or
mediastinitis have decreased over the past 20 years for sev-
eral reasons. Aggressive surgical debridement and early vas-
cularized muscle flap coverage are key to reducing the cost,
length of stay, and mortality (348,349). A prospective trial
has lessened debate on proper management of the deeply
infected sternotomy incision. Treatment by wound explo-
ration, sternal rewiring, and drainage failed in 88.2% of
patients compared with high success in patients treated ini-
tially with muscle flap closure (350). 
4.1.5. Prevention of Postoperative Arrhythmias
Class I
Preoperative or early postoperative administration of
beta-blockers in patients without contraindications
should be used as the standard therapy to reduce the
incidence and/or clinical sequelae of atrial fibrillation
after CABG. (Level of Evidence: B)
Class IIa
1. Preoperative administration of amiodarone reduces
the incidence of postcardiotomy atrial fibrillation and
is an appropriate prophylactic therapy for patients at
high risk for postoperative atrial fibrillation who have
contraindications to therapy with beta-blockers.
(Level of Evidence: B)
2. Digoxin and nondihydropyridine calcium-channel
blockers are useful for control of ventricular rate but
at present have no indication for prophylaxis. (Level
of Evidence: B)
Class IIb
Low-dose sotalol can be considered to reduce the inci-
dence of atrial fibrillation after CABG in patients
who are not candidates for traditional beta-blockers.
(Level of Evidence: B)
Postoperative atrial fibrillation increases the length of stay
after CABG up to 5 days (351), increases the charges by as
much as $10 055 (351), and is associated with a 2- to 3-fold
increase in postoperative stroke (182,183). 
The causal and temporal relationship among atrial fibrilla-
tion after CABG, the incidence of new left atrial thrombus,
and the potential for embolism and stroke remains ill-
defined. However, if atrial fibrillation after CABG persists
into a second day, warfarin anticoagulation with a goal of an
international normalized ratio (INR) of 2.0 to 3.0 should be
considered (352). 
Withdrawal of beta-blockers in the perioperative period
doubles the incidence of postoperative atrial fibrillation after
CABG. One series showed that 40 of 105 patients who had
withdrawal of beta-blockers developed postoperative atrial
fibrillation compared with 18 of 105 patients who had early
postoperative reinstitution of beta-blocker (P equals 0.02).
Virtually every study of beta-blockers administered for the
purpose of reducing postoperative atrial fibrillation has
shown benefit. Most trials have examined the initiation of
prophylaxis in the postoperative period. There appears to be
an even greater benefit if beta-blockers are begun before
operation. For example, in 1 controlled trial, atenolol started
3 days before operation led to a reduction of atrial fibrilla-
tion from 37% in the control group to 3% in the atenolol
group (P equals 0.001) (Table 15) (353,354). 
Low-dose sotalol can also be considered effective for
reduction of atrial fibrillation after CABG. In a prospective,
double-blind, randomized, placebo-controlled study, the
placebo group had an incidence of supraventricular arrhyth-
Table 14. Prophylactic Antimicrobials for Coronary Artery Bypass Graft Surgery
Equivalent Efficacy 
IV Dosing Regimen
Antibiotic Dose and Interval Cost per Dose Comments
Cefuroxime 1.5 g preoperatively $6.33/1.5 g First-line agents; low toxicity;
1.5 g after CPB pharmacokinetics vary; shorter 
1.5 g Q12×48 prophylaxis duration less than 24 h
may be equally efficacious for 
cefuroxime
Cefamandole, cefazolin 1 g preoperatively $6.27/g
1 g at sternotomy $0.90/g
1 g after CPB
1 g Q6×48 (Initial dose to be 
given 30-60 minutes before
skin incision)
Vancomycin 1 g Q12/h/until lines/tubes out $5.77/g Reserved for penicillin-allergic;
At least 2 doses justified in periods of methicillin-
(During 30-60-minute infusion resistant Staphylococcus species 
timed to end before skin incision) outbreaks; vancomycin-resistant 
Enterococcus problem is on horizon; 
more likely to require vasopressor 
agent perioperatively
CPB indicates cardiopulmonary bypass. Data derived from References 334 and 336-338. 
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mias of 43% compared with 26% for sotalol (P equals
0.0012, or a 43% reduction) (355).
Amiodarone administered beginning 1 week before sur-
gery reduces the incidence of postcardiotomy atrial fibrilla-
tion (53% with placebo to 25% with amiodarone, P equals
0.003), reduces hospital costs ($26 000 to $18 000, P equals
0.03), and shortens the length of stay (8 to 6.5 days, P equals
0.04) (356). This represents another option for patients
undergoing elective CABG who have contraindications to
beta-blocker therapy. 
The Atrial Fibrillation Suppression Trial (AFIST) was a
prospective study of patients aged 60 years or older (average
age 73 years) undergoing open-heart surgery who were ran-
domized to oral amiodarone therapy or placebo given in
addition to beta-blockers (357). Patients received up to a
total of 3 grams of oral amiodarone in divided doses 1 to 4
days before to surgery and continued 400 mg by mouth
twice a day for 4 days after surgery. The patients who were
given amiodarone had a lower frequency of any atrial fibril-
lation (22.5% versus 38.0%; P equals 0.01), symptomatic
atrial fibrillation (4.2% versus 18.0%, P equals 0.001), cere-
brovascular accidents (1.7% versus 7.0% P equals 0.04), and
postoperative ventricular tachycardia (1.7% versus 7.0%)
(357).
Digoxin and nondihydropyridine calcium channel blockers
(verapamil has been the most extensively studied) are useful
for control of ventricular rate but have no consistent benefit
for prophylaxis of supraventricular arrhythmias after CABG
(Table 15) (355). Currently, preoperative or early postopera-
tive administration of beta-blockers is considered standard
therapy to prevent atrial fibrillation after CABG except in
patients with active bronchospasm or marked resting brady-
cardia. 
4.1.6. Strategies to Reduce Perioperative
Bleeding and Transfusion
Despite the increasing safety of homologous blood transfu-
sion, patients and their families are often far more concerned
about transfusion risk than MI, stroke, or death after CABG.
Well-publicized cases of transmission of viral illness with
transfusion after cardiac operation in the early 1980s have
sensitized the North American population. A study of donors
who passed current blood donor screens but subsequently
seroconverted suggests a current risk for donation of blood
during an infectious period of 1/493 000 for human immun-
odeficiency virus, 1/641 000 for human T-cell lymphotroph-
ic virus, 1/103 000 for hepatitis C virus, and 1/63 000 for
hepatitis B virus (358). 
Cardiac surgical patients account for 10% of blood trans-
fusions in the United States (359). Twenty percent of
patients having cardiac operations use 80% of the blood
products attributed to cardiac surgical use. Several of the
short-term, deleterious effects of transfusion were discussed
in the section on reducing infection (360). Predisposing risk
factors for transfusion after CABG include advancing age,
lower preoperative red blood cell volume, preoperative
aspirin therapy, priority of operation, duration of CPB,
recent fibrinolytic therapy, reoperative CABG, and differ-
ences in heparin management (361-367). Institutional proto-
cols with thresholds for transfusion lead to an overall reduc-
tion in the number of units transfused and the percentage of
patients receiving any blood (368). 
Aspirin, a very common preoperative medication in
patients undergoing CABG, decreases platelet aggregation
and increases postoperative blood loss. The magnitude of
this effect has been confirmed in prospective, controlled tri-
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als (369). Preoperative aspirin is associated with increased
risk for transfusion, prolonged wound closure time, and an
increase in early reoperation for bleeding (370). The value of
aspirin in the treatment of acute coronary syndromes will
often outweigh the increased risk for perioperative bleeding
should coronary bypass be indicated early in the course of
the acute event. In certain patients in an appropriate clinical
setting, including chronic stable angina, low-risk plaque
morphology, and others, cessation of aspirin and other
platelet inhibitors 7 to 10 days before elective cardiac oper-
ation appears prudent to decrease the risk of postoperative
bleeding and transfusion. For clopidogrel, the recommenda-
tion is to discontinue the agent 5 or more days before surgery
when the clinical situation will permit it (see Section 5.11). 
Aprotinin, a serine protease inhibitor with antifibrinolytic
activity, significantly decreases postoperative blood loss and
transfusion requirements (both units and number of patients)
in high-risk, patients undergoing primary CABG, those on
aspirin, and in particular the population undergoing reopera-
tive bypass (371,372). Aprotinin does not appear to decrease
early graft patency after coronary bypass despite its benefit
in reducing postoperative bleeding and need for blood trans-
fusion (373,374). Mechanical strategies to reduce the need
for homologous blood have been only marginally successful. 
Both epsilon-aminocaproic acid and an analogue, tranex-
amic acid, have antifibrinolytic activity. Both have been
demonstrated to decrease mediastinal drainage after cardiac
operation (375-378). Demonstration of a reduction in trans-
fusion requirements has been inconsistent, however (376).
Although these agents are relatively inexpensive, the data
are insufficient to recommend their routine use. In con-
tradistinction to aprotinin, the safety regarding the throm-
botic potential including graft patency issues is unresolved
(374,379). The concept of risk stratification for transfusion
requirements has been validated (380) and offers a more
rational approach to risk reduction strategies seeking to min-
imize blood requirements (380). 
Efforts to synthesize multiple blood-conservation methods
have proven successful in reducing transfusion (381). The
most fully evolved protocol using multiple mechanical and
pharmacological means achieved a remarkable series of 100
consecutive, selected patients undergoing CABG without
transfusion (382). Intrinsic to this strategy was the concept
of varying risk for transfusion and an individualized, algo-
rithm-driven approach for the patient undergoing elective
CABG. Models for prediction of the need for transfusion
postoperatively allow shepherding of resources and applica-
tion of risk-neutralizing strategies to those more likely to
benefit (383). Comparison was made with a consecutive
series of concurrent patients with the same transfusion crite-
ria. The multi-modality conservation patients had no trans-
fusion compared with 38% of the concurrent control group
who received an average of 2.2 plus or minus 6.7 U of blood.
Mediastinal drainage for the conservation group was half
that of the control group (370 plus or minus 180 versus 660
plus or minus 270 mL, P equals 0.001) (382). Costs were
similar between groups. The liberal use of aprotinin (69% of
patients), exclusion of anemia patients, and minimal hemod-
ilution appear to be the keys to these results. 
Prehospitalization autologous blood donation can be effec-
tive. If a patient has no exclusionary criteria (hemoglobin
less than 12, heart failure, unstable angina, left main disease,
or symptoms on the proposed day of donation) and can
achieve 1 to 3 U of donated blood over 30 days before oper-
ation, the risk of homologous transfusion is significantly
lowered (12.6% versus 46% in a non-preadmission donor
control group, P equals 0.001). An alternative or additional
method of pre-CPB blood “donation” is the removal of
blood from the patient in the operating room immediately
before CPB. This blood is then set aside, not exposed to the
CPB circuitry, and then reinfused into the patient after the
patient is disconnected from CPB. This donation immediate-
ly before CPB yielded a significantly higher platelet and
hemoglobin count in 1 study (P less than 0.01) compared
with similar postoperative levels in patients who did not
undergo harvesting of blood immediately before CPB. In
this study, this technique translated into a 6-fold decrease in
the percentage of patients requiring transfusion (10% trans-
fusion rate in pre-CPB donors versus a 65% transfusion rate
in non–pre-CPB donors, P less than 0.01) (384). 
A multicenter, prospective study of recombinant human
erythropoietin given over a 5-day course failed to demon-
strate a significant reduction in transfusion requirement,
although a significant rise in preoperative hemoglobin (P
less than 0.05) was noted (385). 
A randomized, placebo-controlled trial demonstrated no
advantage of iron supplementation for restoration of red
blood cell mass after coronary bypass, but the patients
receiving iron did have significantly more gastrointestinal
complaints (379,384). 
Autotransfusion has had a generally favorable effect on
decreasing allogeneic blood use, but concerns about stimu-
lation of fibrinolysis with reinfusion of shed mediastinal
blood prevent unequivocal recommendations on its use, par-
ticularly in routine low-risk patients (386). 
4.1.7. General Management Considerations
Acuteness of operation is an important determinant of oper-
ative morbidity and mortality. The need for an emergent or
even urgent operation can often be forestalled by appropri-
ate pharmacological therapy, placement of an IABP, or even
percutaneous revascularization of “culprit” stenoses. In each
instance, the benefit of temporizing therapy must be
weighed against the risk of waiting and the risk of the ther-
apy used to achieve delay. A discussion of this strategy as
applied to the acute coronary syndrome is presented in
Section 5.11. Smoking cessation and improvement of chron-
ic bronchitis before elective coronary operation lessen the
risk for perioperative pulmonary complications (305).
Preoperative pulmonary edema is a particularly hazardous
situation, as extracorporeal circulation will worsen the lung
water and predispose the patient to prolonged, postoperative
mechanical ventilatory support. Ideally, the operation is
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deferred until resolution of the edema is accomplished.
Obesity is an independent risk factor for perioperative respi-
ratory failure, sternal and leg wound complications, periop-
erative MI, and arrhythmias (387). If the patient’s coronary
anatomy and clinical course permit, a concerted effort at
weight reduction is appropriate and operation is deferred.
4.2. Maximizing Postoperative Benefit
4.2.1. Antiplatelet Therapy for SVG Patency
Class I
Aspirin is the drug of choice for prophylaxis against
early saphenous vein graft closure. It is the standard
of care (Table 13) and should be continued indefinite-
ly given its benefit in preventing subsequent clinical
events. (Level of Evidence: A)
Aspirin significantly reduces vein graft closure through the
first postoperative year. A demonstrable effect on arterial
graft patency has not been demonstrated. Aspirin adminis-
tration before operation offers no improvement in subse-
quent vein graft patency compared with early postoperative
initiation (370). Fail-safe mechanisms should exist to ensure
prompt postoperative initiation of aspirin therapy.
Prospective controlled trials have demonstrated a graft
patency benefit when aspirin was started 1, 7, or 24 hours
after operation (388-390). The benefit of postoperative
aspirin on SVG patency is lost when started greater than 48
hours after surgery (391). Dosing regimens ranging from
100 to 325 mg daily appear to be efficacious. As the graft
recipient coronary artery luminal diameter increases, SVG
patency rates improve and the advantage of aspirin over
placebo is reduced (392). Aspirin, given early after CABG
(within 48 hours) has been shown to significantly reduce
subsequent mortality, MI, stroke, renal failure, and bowel
infarction (393).
Ticlopidine is efficacious (394) but offers no advantage
over aspirin except as an alternative in the truly aspirin-aller-
gic patient. Life-threatening neutropenia is a rare but recog-
nized side effect. When ticlopidine is used, white blood cell
count should be periodically monitored in the early months
after initiating treatment. Clopidogrel offers the potential for
fewer side effects compared with ticlopidine as an alterna-
tive to aspirin for platelet inhibition. The incidence of severe
leukopenia is rare and similar to that of aspirin in a con-
trolled trial (395). Indobufen is a reversible inhibitor of
platelet cyclooxygenase, in contradistinction to aspirin, so
platelets recover function within 24 hours of cessation of the
drug. It appears to be as effective as aspirin for saphenous
graft patency over the first postoperative year but with fewer
gastrointestinal side effects (396). 
Dipyridamole adds nothing to the aspirin effect for saphe-
nous graft patency (370). Warfarin has shown no consistent
benefit in maintaining saphenous graft patency (397) and
may be associated with an increased risk for bleeding com-
pared with antiplatelet therapy for this application (398).
Whether the combination of aspirin and clopidogrel is supe-
rior to aspirin alone is not yet resolved.
In summary, aspirin is the drug of choice for prophylaxis
against early saphenous graft thrombotic closure.
Perioperative use and/or administration of aspirin within 48
hours of operation should be the standard of care (Table 13)
and should be continued indefinitely, given its benefit in the
secondary prevention of subsequent clinical events.
4.2.2. Pharmacological Management of
Hyperlipidemia
Class I
All patients undergoing CABG should receive statin
therapy unless otherwise contraindicated. (Level of
Evidence: A)
There is little question that patients with known athero-
sclerotic disease, including patients undergoing CABG for
coronary atherosclerosis, should receive lipid-lowering ther-
apy. If there is no contraindication, statin (3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitor) therapy is
recommended as initial therapy to lower the low-density
lipoprotein cholesterol (LDL-C). How low should the LDL-
C be lowered? The Adult Treatment Panel III of the National
Cholesterol Education Program (NCEP) continues to recom-
mend that the LDL-C goal should be less than 100 mg/dL
(399). This recommendation as applied to the CABG patient
is supported by the Post Coronary Artery Bypass Graft Trial
Investigators. Angiographic progression of atherosclerotic
vein-graft disease was significantly retarded by lovastatin
(with the occasional addition of cholestyramine to achieve
the individualized lipid-lowering goal). Patients having
aggressive cholesterol lowering (achieved LDL-C less than
100 mg/dL) had disease progression in 29% of saphenous
grafts over an average 4-year follow-up compared with 39%
in the moderate treatment group (achieved LDL-C less than
140 mg/dL) (P less than 0.001) (397). The aggressively
treated group had a lower repeated revascularization rate
over the course of the study compared with the moderate
treatment cohort: 6.5% versus 9.2% (29% lower, P equals
0.03). 
The Heart Protection Study, which prospectively studied
20 536 patients in a double-blind trial of simvastatin 40 mg
daily versus placebo, showed significant benefit of statin
therapy even in individuals with LDL-C less than 100 mg/dL
(400). Thus, either the LDL-C goal of 100 mg/dL is too high
(studies are under way to compare the effect of an LDL-
C–lowering goal of 100 mg/dL versus 70 mg/dL) or the
pleomorphic benefits of statin therapy are present regardless
of the LDL-C level. Based upon the results of the PROVE-
IT trial, the NCEP has recently recommended an LDL-C
goal of less than 70 mg/dL in patients deemed to be at very
high risk (399a). Because patients are more likely to contin-
ue on statin therapy begun in the hospital (401), it is recom-
mended that statin therapy be continued or started during
hospitalization for CABG surgery. 
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If the patient is on statin therapy and the LDL-C goal has
been reached prior to CABG surgery, attention should be
directed to elevated triglycerides and low high-density
lipoprotein cholesterol (HDL-C). These dyslipidemias, espe-
cially when combined with an elevated fasting glucose, cen-
tral obesity, and hypertension, constitute the cardiovascular
metabolic syndrome, a syndrome that along with diabetes, is
associated with excess cardiovascular mortality and morbid-
ity. These patients should be treated with diet, weight con-
trol, daily exercise, and drug therapy designed to increase
HDL-C and decrease triglycerides. The recommendations of
ATP-III should serve as a guideline (399). Those patients
with the insulin resistance syndrome or diabetes often need
additional therapy with ACE inhibitors or angiotensin recep-
tor blockers to protect their renal function.
Patients with a strong family history of coronary disease
and patients undergoing CABG surgery with completely
normal or low lipid levels without recent illness or lipid-low-
ering therapy should be screened for elevated novel risk fac-
tors such as homocysteine, lipoprotein(a), hs–C-reactive
protein, and fibrinogen (402). 
4.2.3. Hormonal Manipulation
Class III
Initiation of hormone therapy is not recommended
for women undergoing CABG surgery. (Level of
Evidence: B)
Although more than 30 observational studies have shown a
reduced mortality for coronary disease in postmenopausal
women on hormone replacement therapy, hormone therapy
(HT) is no longer recommended for women undergoing
CABG surgery. 
The Heart and Estrogen/Progestin Replacement Study
(HERS) randomized postmenopausal women less than 80
years of age with CAD to placebo (1a,405) or
estrogen/progestin HT (1a,397). Forty-two percent of the
patients underwent CABG surgery (405). The primary end
point was nonfatal MI and CAD deaths. The patients were
followed up for 4.1 years. There was no statistical difference
in the primary end points, but there were more cardiovascu-
lar disease deaths in the patients receiving HT (71 versus
58). There were significantly more patients with deep vein
thrombosis (P equals 0.004) and any thromboembolic events
(P equals 0.002) in the women receiving HT. 
The reason for the marked discrepancy between the obser-
vational studies and this large controlled trial probably
relates to the fact that although HT does offer long-term pro-
tection from cardiovascular disease, it increases the risk of
clotting. Therefore, patients with MI undergoing PCI or
CABG surgery should not be started on HT. Patients on HT
should have therapy discontinued if undergoing surgery or
prolonged bed rest secondary to an illness such as a stroke. 
4.2.4. Smoking Cessation
Class I
1. All smokers should receive educational counseling
and be offered smoking cessation therapy after
CABG. (Level of Evidence: B)
2. Pharmacological therapy including nicotine replace-
ment and bupropion should be offered to select
patients indicating a willingness to quit. (Level of
Evidence: B)
Smoking is the single most important cause of preventable
premature mortality in the United States (406). There is
strong evidence from the CASS that smoking cessation after
coronary bypass is rewarded by less recurrent angina,
improved function, fewer hospital admissions, maintenance
of employment, and improved survival (84% survival for
quitters versus 68% for persistent smokers at 10 years for
those randomized to operation) (P equals 0.018) (407).
Cessation of smoking after coronary bypass improves the
postoperative survival of successful quitters to that of post-
bypass patients who have never smoked; persistent smokers
have significantly more MIs and reoperations (408). As
expected, smoking leads to angiographically detected deteri-
oration over time: only 39% of smokers’ saphenous grafts
are disease-free at 5 years compared with 52% of nonsmok-
ers (409). 
Failure to attempt cessation and recidivism are the difficult
issues. Treatment individualized to the patient is crucial.
Smoking is an addictive disorder and should be treated as
such and not as an indication of self-destructiveness or weak
willpower (410). 
Depression is an important complicating factor in smoking
and may account for a significant number of cessation fail-
ures (411,412). Behavioral treatments alone are not as effec-
tive as drug therapy (413). 
The nicotine transdermal patch is effective in smoking ces-
sation treatment. The average cost per year of life saved
ranges from $965 to $2360 (406). A transdermal nicotine
patch in conjunction with a behavioral modification program
sustained continuous abstinence for 20% of patients receiv-
ing the patch versus 9% for those receiving behavioral mod-
ification alone (414). Nicotine gum added to transcutaneous
patch therapy significantly increased abstinence rates above
that of the active patch alone at 52 weeks (415). 
A sustained-release form of the antidepressant bupropion
is effective for smoking cessation in a dose-related fashion.
The agent reduces the nicotine craving and anxiety of smok-
ers who quit. Three hundred milligrams per day led to a 44%
smoke-free rate at 7 weeks and 23% at 1 year, double that of
the placebo group (P less than 0.001) (412). The results at 1
year parallel those seen with nicotine replacement strategies.
As with any drug, the patient started on bupropion should be
monitored for adverse side effects.
In summary, all smokers should receive educational coun-
seling and be offered smoking cessation therapy, including
pharmacological therapy if appropriate, after coronary
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bypass (Table 16) (416). Pharmacological therapy including
nicotine replacement and bupropion should be offered to
patients indicating a willingness to quit.
4.2.5. Cardiac Rehabilitation
Class I
Cardiac rehabilitation should be offered to all eligible
patients after CABG. (Level of Evidence: B)
Cardiac rehabilitation including early ambulation during
hospitalization, outpatient prescriptive exercise training,
family education (417), and sexual counseling (418) have
been shown to reduce mortality (419,420). Cardiac rehabili-
tation beginning 4 to 8 weeks after coronary bypass and con-
sisting of 3-times-weekly educational and exercise sessions
for 3 months is associated with a 35% increase in exercise
tolerance (P equals 0.0001), a slight (2%) but significant (P
equals 0.05) increase in HDL-C, and a 6% reduction in body
fat (P equals 0.002) (421). Exercise training is a valuable
adjunct to dietary modification of fat and total caloric intake
in maximizing the reduction of body fat while minimizing
the reduction of lean body mass (422). A significant hurdle
appears to be initiation of rehabilitation. In a prospective
study of recruitment for a comprehensive cardiac rehabilita-
tion program for patients having just undergone coronary
bypass, only 52 of 393 elected to participate. Participation
was lower for women (26% of nonparticipants versus 12%
of enrolled, P equals 0.02), unemployed patients (63% of
those declining versus 45% of the participants, P equals
0.02), those with a lower income and educational level (both
P equals 0.001), and those with a greater functional impair-
ment (P equals 0.001) (423). If the barriers to enrollment can
be overcome, benefits seem to accrue to all special groups
studied. The benefits of cardiac rehabilitation extend to the
elderly and to women (424,425). Despite the fact women
have a generally higher risk profile and a relatively lower
functional capacity than men at initiation of a rehabilitation
period (426), there were similar compliance and completion
rates, and women achieved a similar or greater improvement
in functional capacity (women increased peak metabolic
equivalents by 30%, men by 16%, P less than 0.001) (427).
Medically indigent patients appear to have rehabilitation
compliance and benefit rates on par with insured/private-pay
patients if rehabilitation is initiated and appropriately struc-
tured (428). 
In a long-range trial focused exclusively on a coronary
bypass population, postoperative patients were randomized
to standard posthospital care (n equals 109) or standard care
plus rehabilitation (n equals 119). At 5 years, the groups
were similar on measures of symptoms, medication use,
exercise capacity, and depression scores. However, rehabili-
tated patients reported more freedom of physical mobility
(Nottingham Health Profile, P equals 0.005), perceived bet-
ter health (P equals 0.03), and a perceived better overall life
situation (P equals 0.02). A larger proportion of the rehabil-
itated patients were working at 3 years (P equals 0.02). This
difference disappeared with longer follow-up (429). Patients
who sustained an infarct followed by coronary bypass had
greater improvement in exercise tolerance after rehabilita-
tion (change in exercise capacity 2.8 plus or minus 1.4 meta-
bolic equivalents) than did those having infarct alone (0.8
plus or minus 2, P less than 0.02). Improvement was sus-
tained to 2 years (430). 
In addition to benefiting a sense of well-being, there is an
economic benefit that accrues from participation in cardiac
rehabilitation programs. During a 3-year follow-up (mean of
21 months) after coronary events (58% of events were coro-
nary bypass operations), per capita hospitalization charges
were $739 lower for rehabilitated patients compared with
nonparticipants ($1197 plus or minus $3911 versus $1936
plus or minus $5459, P equals 0.022) (431). 
After CABG, the patient is more likely to resume sexual
activity and to a greater degree than is the patient postinfarct.
Anticipatory and proactive advice by the physician or sur-
geon on the safety of resumption of sexual activity as the
patient reengages in other daily activities is beneficial (432). 
In summary, cardiac rehabilitation should be offered to all
eligible patients after coronary bypass surgery. 
4.2.6. Emotional Dysfunction and 
Psychosocial Considerations
The 2 most important independent psychosocial predictors
of death in a multivariate analysis of elderly patients post-
CABG are a lack of social participation and religious
strength (433). Social isolation is associated with increased
mortality and coronary disease (434), and successful treat-
ment may improve outcomes (435). Depression is generally
poorly recognized by the cardiac specialist (421). Mood for
Table 16. Smoking Cessation for the Primary Care Clinician
Strategy 1. Ask—systematically identify all tobacco users at
every visit.
• Implement an office-wide system that ensures that for EVERY
patient at EVERY clinic visit tobacco-use status is queried
and documented.
Strategy 2. Advise—strongly urge all smokers to quit.
• In a clear, strong, and personalized manner, urge every smoker
to quit.
• Ask every smoker if he or she is willing to make a quit attempt at
this time.
Strategy 3. Assist—aid the patient in quitting.
• Help the patient with a quitting plan.
• Encourage nicotine replacement therapy or bupropion except in
special circumstances.
• Give key advice on successful quitting.
• Provide supplementary materials.
Strategy 4. Arrange—schedule follow-up contact
• Schedule follow-up contact, either in person or via telephone.
From the ACC/AHA 2002 Guideline Update on the Management of Patients With Stable
Angina that was modified from Fiore MC, Bailey WC, Cohen JJ, et al. Smoking Cessation.
Clinical Practice Guideline Number 18. AHCPR publication No. 96-0692. Rockville, MD:
Agency for Health Care Policy and Research, Public Health Service, U.S. Department of
Health and Human Services, 1996.
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up to 1 year after coronary bypass is correlated most strong-
ly with mood before coronary bypass. The prevalent opinion
that depression is a common result of coronary bypass is
challenged by several reports (436). Half of patients who
were depressed before operation were not depressed after-
ward, and only 9% of patients experienced new depression
postoperatively. The overall prevalence of depression at 1
month and 1 year was 33%, which was similar to that in
reports of patients undergoing other major operations. Some
have argued that preoperative screening simply sensitizes
the healthcare team and family to postoperative mood prob-
lems, rather than there being a more direct pathophysiologi-
cal association of coronary bypass and depression per se.
Coronary disease and psychiatric disorders are highly preva-
lent and frequently concurrent. Anxiety and depression are
often encountered around the time of coronary bypass oper-
ation. Anxiety may intensify the autonomic manifestations
of coronary disease and complicate patient care. Realization
of one's mortality, physical limitations, limitations of sexual
activity, survival guilt after successful operation, and devel-
opment of nihilism regarding modification of risk factors
play a role in recovery. Denial has adaptive value during hos-
pitalization and can enhance care, but its persistence in the
early home convalescence may be counterproductive.
Clinical depression is correlated with subsequent mortality
(437). 
Eighteen percent of patients are depressed after major car-
diac events, including coronary bypass (421). Cardiac reha-
bilitation has a highly beneficial effect on these patients,
whether moderately or severely depressed. In a prospective
but uncontrolled study of 3 months of rehabilitation on
measures of depression, anxiety, hostility, somatization,
mental health, energy, general health, bodily pain, function-
al status, well-being, and a total quality of life score, patients
were improved from 20% to 57% (P value for the scores
ranged from 0.001 to 0.004) (421). 
4.2.7. Rapid Sustained Recovery After Operation
Rapid recovery and early discharge, the “fast-track”
approach, for the patient post-CABG should become the
standard goal of care. The shortest postoperative stays in the
hospital are followed by the fewest rehospitalizations (438).
There is very little evidence of a rise in morbidity, mortality,
or readmission rates in systems employing fast-track proto-
cols. Longer initial hospitalizations generally are recognized
not to prevent rehospitalizations. Prevention or prompt cor-
rection of noncardiac disorders allows rapid recovery after
coronary operations. Important components of the fast-track
system are patient selection, patient and family education,
short-acting narcotic or inhalational anesthetic agents allow-
ing early extubation and transfer from the intensive care set-
ting, prophylactic antiarrhythmic therapy, dietary considera-
tions, early ambulation, early outpatient follow-up by tele-
phone, and a dedicated fast-track coordinator (439,440). 
4.2.8. Communication Between Caregivers
A primary care physician frequently refers patients who
undergo CABG to a cardiologist and/or surgeon.
Maintaining appropriate and timely communication between
treating physicians regarding care of the patient is crucial.
The primary care physician’s request for referral may well
be verbal but should also be documented in writing and
accompanied by relevant medical information. Ideally, the
primary care physician follows the patient with the other
treating physicians during the perioperative course in the
hospital if circumstances and geography permit. The referral
physician(s) needs to provide written reports of findings and
recommendations to the primary care physician, including a
copy of the discharge summary from the hospital. Discharge
medications that are likely to be required for the long term
should be clearly identified. The decision about the degree
of responsibility for postoperative care and prevention
strategies needs to be made by mutual agreement among the
patient, the primary care physician, the cardiologist, and the
surgeon in each individual case. The primary care physician
can emphasize and continue to implement secondary pre-
vention strategies, frequently begun by the cardiologist and
surgeon, since most of these strategies involve lifestyle
changes or pharmacological therapies over an extended peri-
od of time. 
5. SPECIAL PATIENT SUBSETS
5.1. CABG in the Elderly: Age 70 and Older
The evolution in surgical techniques and changing demo-
graphics and patient selection for CABG surgery have led to
its application in older and sicker patients with more com-
plex disease (441). Nearly all reports during the past 10
years define “elderly” in the context of coronary surgery as
age 70 years or older. However, the definition of elderly in
the literature has gradually increased from 65 years or older
to 80 years or older. The greatest increase in numbers has
occurred in the oldest group, persons 85 years or older (442).
This group has a higher incidence of left main disease, mul-
tivessel disease, LV dysfunction, and reoperation as the indi-
cation for surgery, and for many, concomitant valvular sur-
gery. These patients generally have more comorbid condi-
tions, including diabetes, hypertension, COPD, PVD, and
renal disease. This combination of more advanced coronary
disease and worse comorbidity leads to increased fatal and
nonfatal complications. Higher rates of intraoperative or
postoperative MI, low-output syndrome, stroke, gastroin-
testinal complications, wound infection, renal failure, and
use of an IABP may occur (443,444). In Figure 10, operative
mortality (%) is shown as a function of age. A near-linear
slope increases abruptly at age 75. Similarly, in Figure 11
the OR for operative mortality is shown as a function of age
(21). The effects of these factors on patient outcomes and
institutional resources have significant implications for peer
review, quality assurance screening, institutional reporting to
external sources, and reimbursement (443). 
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Operative mortality in the elderly has ranged from 5% to
20% during the past 20 years for isolated CABG, averaging
8.9%. In a large study from Ontario, Canada, Ivanov et al
(442) found a 34% reduction in risk-adjusted operative mor-
tality (1982 to 1996) while confirming a time-related
increase in the prevalence of older patients and an increase
in the preoperative risk profile in these patients. They report-
ed an overall mortality of less than 5% for elderly patients,
with a 3% mortality for low- and medium-risk patients. 
Preoperative predictors of hospital mortality and morbidi-
ty (30 days) in elderly patients include a near-linear relation
to New York Heart Association (NYHA) class and/or
reduced LVEF (particularly if less than 0.20). Other corre-
lates of increased risk include increasing age; recent MI (less
than 30 days), especially in the presence of unstable angina,
left main disease, or 3-vessel disease; emergency or urgent
coronary bypass; reoperation; reduced renal function; cere-
brovascular disease; COPD; a smoking history; obesity; and
female sex (21,445-452). A higher operative mortality
occurs for all identified risk factors in patients aged 75 years
or older than for those less than 65 years old. However, in
particular, emergency surgery confers up to a 10-fold
increase in risk (3.5% to 35%), urgent surgery a 3-fold
increase (3.5% to 15%), hemodynamic instability a 3- to 10-
fold increase, and an LVEF less than 0.20 up to a 10-fold
increase (21,453,454). Predictors of postoperative low car-
diac output syndrome are, in descending order of impor-
tance, LVEF less than 0.20, repeat operation, emergency
operation, female sex, diabetes mellitus, age greater than 70
years, left main disease, recent MI, and/or 3-vessel disease
(455). The greatest risk is in the acutely ill, elderly patient
for whom the CABG operation may be the best of several
high-risk options (456). 
Operative factors that have been reported to adversely
influence hospital mortality in the elderly include the use of
bilateral IMA grafts, prolonged pump time and/or cross-
clamp time, an increased number of grafts required, right
IMA grafting, and any postoperative complication
(448,449,457,458). Obesity has been identified as a risk fac-
tor for infection in patients receiving bilateral IMA grafts
(457). Contrariwise, improved hospital mortality and long-
term survival have been reported when the left IMA is used
along with 1 or more vein grafts as opposed to vein grafting
alone. Thus, use of the left IMA as a conduit appears to be a
predictor of improved early and late survival
(41,42,276,459). CABG without cardiopulmonary pump
assistance may be advantageous in high-risk patients, partic-
ularly those with an LVEF less than 0.35 (460,461). 
Postoperative atrial fibrillation is a particular problem in
elderly patients undergoing CABG. Correlates of postopera-
tive atrial fibrillation include age greater than 70 (especially
age greater than 80), male sex, postoperative pulmonary
complications, ventilation time greater than 24 hours, return
to the intensive care unit, and use of the IABP. Atrial fibril-
lation contributes to a substantially prolonged hospital stay
(9.3 plus or minus 19 versus 15.3 plus or minus 28 days)
(351). Patients with preoperative chronic renal failure are at
a particular risk, as they tend to be older and have addition-
al comorbidity (71). Interventions to prevent atrial fibrilla-
tion are discussed in Section 4.1.5. 
Figure 10. Operative mortality (%) for CABG in various age cohorts. Data derived from Hannan et al. Am Heart J. 1994;128:1184-91
(21).
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It should be emphasized that long-term survival and func-
tional improvement can be achieved in the elderly patient
despite severe cardiovascular disease and an urgent indica-
tion for surgery (462). The 5-year survival of such patients
who recover from surgery is comparable to that of the gen-
eral population matched for age, sex, and race (463,465).
Preoperative variables that are correlated with poor long-
term survival in elderly patients include the presence of atri-
al fibrillation, smoking, PVD, and poor renal function (low
creatinine clearance). An unsatisfactory functional outcome
has been influenced by hypertension, cerebrovascular insuf-
ficiency, and poor renal function (low creatinine clearance)
(466). 
Peterson et al (467) analyzed the Medicare database to
assess long-term survival in patients 80 years and older and
found it comparable to the general population of octogenar-
ians. This group was hospitalized significantly longer than
those aged 70 or younger (21.4 versus 14.3 days) and had a
higher hospital mortality (11.5% versus 4.4%) and higher 3-
year mortality (28.8% versus 18.1%). Hospital costs and
charges were also higher. Similar findings are reported by
others, with actuarial survival including hospital death at 80
months of 32.8% versus 37.6% for age-, sex-, and race-
matched populations. These authors concluded that
advanced age alone should not be a contraindication to
CABG if it had been determined that long-term benefits out-
weighed the procedural risk (465,467,468). Although hospi-
talization may be longer for elderly patients, physiological,
psychological, and social recovery patterns through the first
6 weeks postoperatively have been reported to be similar to
those of a younger age group (469). Age 70 and older is an
independent risk factor for stroke after CABG, adversely
affecting hospital mortality, prolonging the hospital stay, and
negatively impacting late death (470). 
In operations combining valve surgery and CABG, inde-
pendent predictors for reduced late survival included NYHA
Class IV, age greater than 70 years, male sex, decreased
LVEF, extent of CAD and use of a small prosthetic valve, but
not necessarily the presence of CAD per se (471-474). 
In summary, the patient aged 70 years or older who may be
a candidate for CABG surgery has, on average, a higher risk
for mortality and morbidity from the operative procedure in
a direct relation to age, LV function, extent of coronary dis-
ease, comorbid conditions, and whether or not the procedure
is emergent, urgent, or a reoperation. Nonetheless, function-
al recovery and an improvement in quality of life may be
achieved in the large majority of such patients. 
The patient and physician together should explore the
potential benefits of improved quality of life with the atten-
dant risks of the procedure versus alternative therapy, taking
into account baseline functional capacities and patient pref-
erences. Age alone should not be a contraindication to
CABG surgery if it is thought that long-term benefits out-
weigh the procedural risk (448,475-477). 
Figure 11. Operative mortality odds ratio (relative to odds for 50-year-old patients). Data derived from Hannan et al. Am Heart J.
1994;128:1184-91(21).
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5.2. CABG in Women
Early studies provided evidence that female sex was an inde-
pendent risk factor for higher in-hospital mortality and mor-
bidity than in males, but that long-term survival and func-
tional recovery were similar to those in males undergoing
CABG surgery (29,478-481). More recent studies have sug-
gested that on average, women have a disadvantageous pre-
operative clinical profile that may account for much of this
perceived difference. This includes the fact that women pres-
ent for treatment at an older age, with poorer LV function,
more frequently with unstable angina pectoris, NYHA Class
IV heart failure, 3-vessel and left main disease, and more
comorbid conditions including hypothyroidism, renal dis-
ease, diabetes mellitus, hypertension, and PVD (25,480-
489). Based on these differences, it has been inferred that
women may be under-referred or referred late for treatment
and/or coronary angiography. These findings are not univer-
sal, as significant differences exist in clinical practice
between institutions (481,482). 
A variety of factors may account for the perception that
female sex is an independent risk factor for in-hospital mor-
tality and morbidity after CABG surgery. For example,
Israeli women were reported to have a 3.2-fold higher hos-
pital mortality than men, but women also received a higher
number of SVGs, suggesting more diffuse disease. When
this consideration was adjusted for, mortality was found to
be similar (490). Others have argued that smaller coronary
arteries in women may contribute to higher risk (26). IMA
grafts have been reported to be used less often in women,
possibly contributing to a higher mortality (25,486).
Kurlansky et al (78) reported favorable results in 327 women
with bilateral IMA grafts plus supplemental vein grafts, with
a hospital mortality of 3% to 4%, low postoperative morbid-
ity, excellent functional improvement, and enhanced long-
term survival. Five-year survival of 90.5% and of 65.6% at
10 years was achieved, with 94% of patients reaching
NYHA Class I and 4.5% NYHA Class II. Hammar et al
(480) reported that when age and body surface area were
taken into account, the relative operative risk between men
and women became similar. Others have also found no dif-
ferences in operative mortality, total postoperative morbidi-
ty, and ICU length of stay (491,492). Comparable findings
were reported for coronary bypass surgery in black male and
female patients (493). 
However, analysis from the CASS registry found a higher
operative mortality for women (493) as did Jaglal et al (494),
even when comorbidities were adjusted for appropriately.
They suggested that the excessive mortality was due to late
treatment (494). Farrer et al (495) found that women had
more severe symptoms with a similar severity of coronary
disease as defined by angiography when compared with
men, suggesting a referral bias with referral occurring later
in the course of the disease. Whether these perceived biases
are real and whether they are practitioner or patient related
or have a biological explanation is not known. They serve as
a challenge for future investigation (496). 
Postoperative complications in women mirror those seen
in all patients undergoing CABG surgery. These include MI,
stroke, reoperation for bleeding, pulmonary insufficiency,
renal insufficiency, sternal wound infection (perhaps related
to obesity), CHF, rhythm other than normal sinus rhythm,
and low cardiac output syndrome (25,78,490). Women
appear particularly vulnerable to postoperative CHF, low
cardiac output syndrome (25,29,482), and blood loss (485).
Although postoperative depression is common in women
and men, its occurrence in women has been reported to be
more common (about 60%) and more commonly unrecog-
nized (484). Nonetheless, at 6 months postoperatively, men
and women report similar psychosocial recovery (100) (see
Section 4).
In the CASS registry, although a higher operative mortali-
ty for women was found, the subsequent 15-year postopera-
tive survival and benefits were similar to those for men.
Greater absolute benefit was achieved in those with the high-
est risk in both male and female groups. For women, inde-
pendent risk factors for poorer long-term survival included
older age, prior MI, prior CABG, and diabetes mellitus
(497). 
Over time, changes in the clinical characteristics of women
undergoing CABG mirror those of the changing characteris-
tics of the general population. One study compared female
patients operated on between 1974 and 1979 to a group
receiving surgery between 1988 and 1999 and showed that
operative mortality had increased from 1.3% to 5.8%. This
rise was attributed to an older cohort of women, more emer-
gency or urgent operations, an increased incidence of
depressed LV function, diabetes mellitus, and more 3-vessel
and left main disease, all suggesting that the female popula-
tion undergoing coronary bypass surgery had changed (498).
In another report, women aged 70 or older were found to be
at no greater risk for operative mortality and postoperative
complications than men of similar age (499). 
Another study based on the STS national database exam-
ined more than 300 000 patients undergoing CABG after
1994. Women were found to have a significantly higher
operative mortality for all risk factors examined even when
normalized for size (body surface area). A logistic risk
model was used to determine the net impact of all risk fac-
tors. The model showed that in risk-matched patients, female
gender was an independent risk factor of operative mortality
in low- and moderate-risk subsets but not in high-risk popu-
lations (28).
In conclusion, it appears that in-hospital mortality and
morbidity and long-term survival are related more to risk
factors and patient characteristics than to sex. Coronary
bypass surgery should therefore not be delayed or denied to
women who have the appropriate indications for revascular-
ization. 
5.3. CABG in Patients With Diabetes
Coronary artery disease is the leading cause of death among
adult patients with diabetes and accounts for about 3 times
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as many deaths among patients with diabetes as among
patients without diabetes (500). Not only is the frequency of
acute MI increased in patients with diabetes (501,502) but
also its treatment is more complicated than in the patients
without diabetes. Patients with diabetes with acute MI,
regardless of the level of control of their diabetes before hos-
pital admission, exhibit significantly higher mortality and
morbidity, with fatality rates as high as 25% in the first year
after infarction in some series. Several factors contribute to
this increase in mortality. The size of the infarct tends to be
greater, and patients with diabetes have a greater frequency
of CHF, shock, arrhythmias, and recurrent MI than do
patients without diabetes. Similarly, patients with diabetes
with unstable angina have a higher mortality than do patients
without diabetes. A prospective study indicated a 3-month
mortality of 8.6% and 1-year mortality of 16.7% in patients
with diabetes versus 2.5% and 8.6%, respectively, in patients
without diabetes (503). 
CABG surgery in elderly patients with diabetes (age 65 or
greater) has been reported to result in a reduction in mortal-
ity of 44% in CASS. The relative survival benefit of CABG
versus medical therapy was comparable in patients with and
without diabetes (503a). Nevertheless, a study from Sweden
has indicated that patients with diabetes of all ages have a
mortality rate during the 2-year period after CABG that is
about twice that of patients without diabetes. Thirty-day
mortality after CABG was 6.7% in patients with diabetes,
and subsequent mortality between day 30 and 2 years was
7.8% compared with 3% and 3.6%, respectively, in patients
without diabetes (504). 
Despite increased morbidity and mortality after coronary
revascularization, results from the BARI trial showed that
patients with multivessel coronary disease who were being
treated for diabetes at baseline had a significantly better sur-
vival after coronary revascularization with CABG than with
PTCA (Figure 6) (117). In this study, patients were followed
up for an average of 5.4 years. Better survival with CABG
was due to reduced cardiac mortality (5.8% versus 20.6%, P
equals 0.0003), which was confined to those patients receiv-
ing at least one IMA graft. Thus, although mortality after
CABG surgery may be increased in patients with diabetes,
CABG surgery when indicated appears to provide a better
chance for survival than does medical therapy or PCI. 
Large randomized trials have now reached 7 to 8 year fol-
low-up (131,130). These updated studies generally show that
7 to 8 year survival is superior for patients with diabetes
undergoing CABG compared with patients with diabetes
undergoing PTCA (131,130). In the BARI trial, the protec-
tive effect of CABG was only seen in insulin-dependent
patients with diabetes (505) who had an IMA graft (131).
There was virtually no difference in survival among patients
without diabetes. 
Patients with diabetes who are candidates for renal trans-
plantation may have a particularly strong indication for
CABG surgery. Approximately 20% to 30% of these patients
have significant CAD, which may be asymptomatic or unas-
sociated with conventional cardiovascular risk factors
(390,506). One study assessed the incidence of coronary dis-
ease via angiography (which was performed independently
of the presence of risk factors or suggestive symptoms) in
105 consecutive dialysis patients with diabetes (390).
Angiographic evidence of significant coronary disease was
found in 38 (36%) patients, only 9 of whom experienced
prior symptoms of angina. The degree of hypercholes-
terolemia, hypertension, and smoking history did not differ
between those with and without documented coronary dis-
ease. Thus, noninvasive testing and, if indicated, cardiac
catheterization should be performed before renal transplan-
tation, because conventional clinical predictors of disease
are unreliable and active intervention may improve patient
outcomes (390,507). This approach is supported by a study
that randomized 26 patients with greater than 75% stenosis
in at least 1 coronary artery and relatively normal LV func-
tion to either revascularization or medical therapy with
aspirin and a calcium channel blocker (506). Both the inci-
dence of cardiovascular end points (2 of 13 versus 10 of 13)
and mortality rate (0 of 13 versus 4 of 13) were lower in the
revascularized patients. 
5.4. CABG in Patients With Pulmonary Disease,
COPD, or Respiratory Insufficiency
For many years, it has been recognized that patients under-
going cardiac surgery develop variable degrees of respirato-
ry insufficiency postoperatively. In these patients, higher
concentrations of oxygen are required to achieve adequate
arterial oxygen tension, primarily as a consequence of intra-
pulmonary shunting. Scattered regions of atelectasis and
alveolar collapse may occur, resulting in some air spaces
receiving pulmonary blood flow that are not being ventilat-
ed. Other contributing factors may occur. Impaired capillary
endothelial integrity may be followed by an increase in inter-
stitial fluid and alveolar edema. Anesthetic agents and
vasodilators may affect pulmonary vasoconstriction. Other
causes of gas exchange abnormalities after cardiac surgery
include central effects from anesthesia and narcotics as well
as CNS embolization of air or blood clots. Impairment of
carbon dioxide elimination may develop from either a rise in
alveolar dead space or a decrease in ventilatory drive from
the effects of general anesthesia and/or narcotics. Inadequate
tidal volume from neuromuscular weakness may occur.
Changes in the mechanics of breathing may occur postoper-
atively as a result of inhalation anesthetics and/or muscle-
paralyzing agents. Pain from the chest incision and thoracic
or mediastinal chest tubes may result in diminished excur-
sion of the chest and diaphragm. Obesity and rare phrenic
nerve injury may also play a role (508). Postoperatively,
early extubation is desirable, appears safe, and does not
increase postoperative cardiac or pulmonary morbidity,
especially if the total bypass time is less than 100 minutes
(509,510). However, longer periods of mechanical ventilato-
ry support postoperatively may be necessary in patients who
develop acute adult respiratory distress syndrome or who
have evidence of severe pulmonary insufficiency postopera-
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tively. In such patients, ventilation with lower tidal volumes
(6 mL/kg) should be considered (511).
Preoperatively, it is important to identify patients with sig-
nificant restrictive or obstructive pulmonary disease. The
former includes patients with pulmonary venous congestion,
large pleural effusions, and a large, dilated heart compress-
ing the lungs, all of which may result in a reduction of lung
compliance. Restrictive lung disease is also found in patients
with interstitial lung disease including pulmonary fibrosis,
sarcoidosis, pneumoconiosis, and collagen vascular dis-
eases. The most common cause of preoperative pulmonary
dysfunction, however, is COPD. Patients with mild COPD
and few or mild symptoms generally do well through cardiac
surgery. However, patients with moderate to severe obstruc-
tive pulmonary disease who are undergoing coronary bypass
grafting, especially those in an older age group, are at an
increased risk for operative mortality and postoperative
complications in relation to the severity of their degree of
pulmonary dysfunction (445,512-514). Identification of
these higher-risk patients is important because preoperative
measures to improve respiratory function may diminish
postoperative complications. These measures include the use
of antibiotic therapy for lung infections, bronchodilator ther-
apy, cessation of smoking, preoperative incentive spirome-
try, deep-breathing exercises, and chest physiotherapy. Such
measures frequently permit patients with obstructive pul-
monary disease to safely undergo cardiac surgery (512). 
The parameter most commonly reported by authors in esti-
mating the degree of pulmonary dysfunction is the forced
expiratory volume in the first second (FEV1). However, there
is little consistency in the literature defining the level of
abnormality for moderate to severe COPD, with values for
FEV1 ranging from less than 70% to less than 50% of the
normal predicted value and/or an FEV1 of less than 1.5 L.
Others measure arterial oxygen tension and carbon dioxide
tension. Any degree of hypercapnia above a normal range
places the patient at least in a moderate-risk category
(508,512,513), as does the need for oxygen at home before
surgery. FEV1 levels as low as 1.0 L would not necessarily
disqualify a candidate for CABG surgery. Clinical evalua-
tion of lung function is likely as important as most spiro-
metric studies. This sentiment is reflected by Cohen et al
(513), who compared 37 patients with COPD who were
undergoing CABG surgery to 37 matched control patients
without COPD. They defined COPD in clinical terms (i.e.,
age, smoking history, presence of preoperative arrhythmias,
history of hospitalization for shortness of breath, and evi-
dence of COPD on X-ray film). Those with COPD had lower
values for FEV1 (1.36 plus or minus 0.032 versus 2.33 plus
or minus 0.49 L) and a lower arterial oxygen tension. This
group had a significantly higher rate of preoperative atrial
and ventricular arrhythmias. Postoperatively, they remained
in the ICU longer, had a longer intubation period and more
frequent reintubations, had more postoperative atrial and
ventricular arrhythmias and complications, and remained in
the hospital twice as long. By 16 months postoperatively, 5
of the COPD patients had died, with deaths related to
arrhythmias. None was functionally improved after coronary
bypass surgery. These investigators concluded that clinical
COPD is a significant factor for morbidity and mortality, in
large part due to more frequent postoperative arrhythmias.
Subsequent long-term clinical benefits were significantly
reduced (513). Kroenke et al (512) reported the results of
107 operations in 89 patients with severe COPD, defined as
an FEV1 less than 50% of predicted and an FEV1 to forced
vital capacity ratio of less than 70%. In this diverse group,
10 patients underwent CABG surgery. Pulmonary complica-
tions occurred postoperatively in 29% of all patients and
were significantly related to the type and duration of surgery.
Mortality clustered primarily around the time of CABG (5 of
10 patients) compared with only 1 death in 97 noncoronary
operations. In this study, noncardiac surgery (as opposed to
CABG) was accompanied by an acceptable operative risk in
patients, even in the presence of severe COPD (512). 
Severe, reversible, restrictive pulmonary function abnor-
malities, which appear not to be caused by advanced age or
preexisting COPD, have been reported to follow coronary
bypass surgery in the early postoperative period. In the early
postoperative period, these changes may delay ventilator
weaning in the first 72 hours, but full recovery is expected
(515). Wahl et al (515) compared pulmonary function in a
group of patients older than age 70 with a group with COPD,
defined as a ratio of FEV1 to forced vital capacity of less
than 70% and total lung capacity less than 80% of predicted,
and a normal group in the preoperative and postoperative
periods. All 3 groups demonstrated comparable decreases in
FEV1, total lung capacity, and forced vital capacity postop-
eratively. Partial recovery occurred by day 7 and returned to
preoperative levels by 3 months (515). Similar findings were
reported by Goyal et al (516) after CABG with saphenous
veins, IMAs, or a combination. Others have reported more
severe abnormalities of pulmonary gas exchange and pul-
monary function through 72 hours postoperatively in
patients receiving left IMA grafts, with normality returning
by hospital discharge (517,518). 
A history of COPD and greater than 2 days on a mechani-
cal ventilator postoperatively have been reported as risk fac-
tors for nosocomial pneumonia in patients post-CABG (519)
and have been documented as a risk factor for mediastinitis
(520,521). Moderate to severe degrees of obstructive pul-
monary disease preoperatively, whether defined by clinical
or laboratory parameters, represent a significant risk factor
for early mortality and/or postoperative morbidity in patients
undergoing CABG. However, with careful preoperative
assessment and treatment of the underlying pulmonary
abnormalities, many patients may be successfully carried
through the operative procedure. 
5.5. CABG in Patients With End-Stage 
Renal Disease
Cardiovascular disease is the single best predictor of mor-
tality in patients with end-stage renal disease (ESRD), as it
accounts for almost 54% of deaths (522). The high rate of
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cardiac morbidity and mortality is occurring at a time when
the prevalence of coronary disease is declining in the gener-
al population and is related in part to the changing nature of
new patients being started on dialysis. At present, more than
one third of such patients have diabetes mellitus, and the
average patient age at initiation of dialysis is greater than 60
years. In addition to the foregoing, patients with ESRD usu-
ally have a number of other risk factors for cardiovascular
mortality, including hypertension, LV hypertrophy, myocar-
dial dysfunction, abnormal lipid metabolism, anemia, and
increased plasma homocystine levels. 
When indicated, patients on dialysis can be treated with
CABG. The indications for CABG are similar to those in
patients without ESRD with coronary disease. Coronary
revascularization with CABG or PTCA is associated with
better survival than is standard medical therapy in several
specific settings. These include patients with a modest
decrease in LV function, significant left main coronary dis-
ease, 3-vessel disease, and unstable angina (523). Although
these patients also are at increased risk for operative mor-
bidity and mortality, they are at even higher risk when treat-
ed with conservative medical management. 
It should be noted that patients with chronic renal failure
clearly differ in several respects from other patients who
undergo surgical coronary revascularization. Patients with
ESRD often have multiple comorbid disorders, including
hypertension and diabetes mellitus, each with its own com-
plications and associated impact on both short- and long-
term survival (524). In addition, infection and sepsis have
been identified as significant causes of morbidity and mor-
tality in patients with ESRD undergoing cardiac surgical
procedures (524). As a result of these factors and others such
as perioperative volume and electrolyte disturbances,
patients with chronic renal failure are at increased risk for
complications after CABG. 
Patients with ESRD have an increased risk with CABG.
The Northern New England Cardiovascular Disease Study
Group reported that after adjusting for known risk factors in
multivariate analysis, dialysis-dependent patients with renal
failure were 3.1 times more likely to die after CABG (adjust-
ed OR 3.1, 95% confidence interval 2.1 to 4.7; P less than
0.001) (525). Dialysis-dependent patients with renal failure
also had a substantially increased risk of postoperative medi-
astinitis (3.6% versus 1.2%) and postoperative stroke (4.3%
versus 1.7%) (525). CABG surgery in patients on dialysis
may be associated with an acceptable mortality, with a sig-
nificant increase in the quality of life for long-term sur-
vivors.
In summary, coronary bypass grafting may be performed
for selected patients with ESRD who are dialysis dependent,
with increased but acceptable risks of perioperative morbid-
ity and mortality. Early after revascularization, patients may
expect relief from coronary symptoms with coincident
improvement in overall functional status. However, long-
term survival remains relatively limited in this patient popu-
lation, suggesting a need for further investigations to estab-
lish the relative costs and benefits of revascularization in
patients with dialysis-dependent ESRD. 
5.6. Valve Disease
Class I
Patients undergoing CABG who have severe aortic
stenosis (mean gradient greater than or equal to 50
mm Hg or Doppler velocity greater than or equal to 4
m/s) who meet the criteria for valve replacement
should have concomitant aortic valve replacement.
(Level of Evidence: B)
Class IIa
1. For a preoperative diagnosis of clinically significant
mitral regurgitation, concomitant mitral correction
at the time of coronary bypass is probably indicated.
(Level of Evidence: B)
2. In patients undergoing CABG who have moderate
aortic stenosis and are at acceptable risk for aortic
valve replacement (mean gradient 30 to 50 mm Hg or
Doppler velocity 3 to 4 m/s) concomitant aortic valve
replacement is probably indicated. (Level of
Evidence: B)
Class IIb
Patients undergoing CABG who have mild aortic
stenosis (mean gradient less than 30 mm Hg or
Doppler velocity less than 3 m/s) may be considered
candidates for aortic valve replacement if risk of the
combined procedure is acceptable. (Level of Evidence:
C)
The coexistence of CAD and valvular disease will vary
throughout the population, dependent on which disease ini-
tiates the patient’s symptoms, their age, sex, and clinical risk
factors. The incidence of aortic valve disease in patients
undergoing CABG is much less than the incidence of CAD
in patients undergoing valve replacement. In general, the
incidence of CAD in patients with typical angina who are
undergoing aortic valve replacement (AVR) is 40% to 50%
and drops to about 25% in patients with atypical chest pain
and to about 20% in those without chest pain (526-533). The
incidence of CAD is generally less in patients with aortic
regurgitation than aortic stenosis owing to the younger
patient population presenting with aortic regurgitation (526-
533). The incidence of CAD in patients with mitral stenosis
is small, owing to the fact that this lesion is more frequently
seen in middle-aged women. 
There is a distinctive relationship between mitral regurgi-
tation (MR) and CAD, especially when the mitral valve is
structurally normal but functionally regurgitant. This MR is
usually caused by ischemia. The quandary this presents is
when the MR requires correction at the time of CABG. The
question is easily answered if there are structural abnormal-
ities in the mitral apparatus. Mitral repair is indicated in the
majority of such circumstances, although occasional patients
require valve replacement. The structurally normal mitral
valve may be regurgitant due to reversible ischemia involv-
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ing the papillary muscles, and the dilemma is, “When is it
necessary to inspect the mitral valve for correction?”
Intraoperative TEE has brought dramatic refinement to this
question by providing a functional and quantitative assess-
ment before and after CPB. When the MR is grade 1 to 2,
this may decrease during anesthesia induction and/or with
complete revascularization, thus eliminating the need to
inspect the valve during cross-clamping of the aorta. An
added finding by echocardiography or direct inspection at
the time of operation is the presence of an enlarged left atri-
um, which generally signifies chronicity of the MR and adds
justification to the consideration of mitral valve repair. This
strategy is further assessed by a final post-CPB TEE in the
operating room. If, under this circumstance, the MR is unac-
ceptable, reinstitution of CPB can be performed and the MR
corrected. For instance, if the MR is grade 3 to 4, it is nec-
essary to inspect the valve and correct the mechanical lesion.
It is important to stress that in this situation, it is imperative
that an intraoperative TEE be performed to see whether the
MR is grade 3 to 4, to assess the reparability of the valve,
and to assess success of the repair. The study by Aklog and
associates (534) concluded that CABG surgery alone for
moderate ischemic MR leaves many patients with significant
residual MR. These authors conclude that a preoperative
diagnosis of moderate MR may warrant concomitant mitral
annuloplasty (534).
For situations in which patients are undergoing mitral
valve surgery and have “incidental” CAD and nonischemic
mitral valve disease, the approach has been to perform
CABG on vessels with greater than 50% stenosis at the same
operation. There are far fewer data on this topic than that of
AVR and CAD, but conventional wisdom has promoted this
policy, and there have not been reports of significant increas-
es in operative mortality. 
The discussion of combined procedures revolves around
overall operative risk, which is dependent on several vari-
ables. The most notable of these are age greater than 70
years, female sex, advanced NYHA class, poor LV function,
and multiple valve procedures (535). There is also a differ-
ence in early and late mortality when the valve lesion is aor-
tic versus mitral and when the mitral lesion is ischemic. The
simple addition of MR to a coronary bypass without valve
correction increases the operative mortality to 3% to 5%.
The operative mortality of rheumatic mitral valve disease
and CAD varies from 3% to 20% (536). The addition of a
valve operation to CABG is also associated with a substan-
tial increase in the risk of stroke (536a).
The results of combined aortic valve and coronary disease
have led to the recommendation to graft obstructed vessels
(greater than or equal to 50%) when an AVR is performed.
The operative mortality for patients undergoing AVR who
have ungrafted CAD approaches 10%, while those patients
having AVR and concomitant CABG for CAD have an oper-
ative mortality approaching that of AVR alone (537). It is
generally accepted that the risk of adding CABG to a valve
replacement or repair will increase the operative mortality
over that of an isolated valve procedure. The additional vari-
ables of age greater than 70 or 80 years and poor LVEF will
further increase this risk. 
Another aspect of this combined condition is the patient
with prior CABG who now requires a valve replacement or
repair. There is inconclusive evidence that the reoperative
risk of late AVR after previous CABG is significantly
increased. Sundt et al (538) stated that the operative risk for
AVR alone was 6.3%, whereas the risk of AVR after previ-
ous CABG was 7.4%. Odell et al (539) found the risk of
reoperative AVR with prior CABG to be 12%. A report from
the same institution identified an operative risk of 3.7% (11
of 297) for isolated AVR (540). The discrepancy may be due
to sample size, in that the article by Sundt et al reviewed 52
patients, whereas Odell et al reported on 145 patients under-
going reoperation for AVR with prior CABG. 
5.7. Reoperation
Patients who have undergone CABG may present with
recurrent ischemic syndromes and be considered for reoper-
ation. The voluntary STS National Database has reported an
incidence of reoperation of 8.6% to 10.4% in isolated bypass
operations since 1987, and in centers experienced with reop-
erations, the percentage of isolated bypass operations con-
stituting reoperations may be 20% to 25%. Reoperative can-
didates represent a distinct subgroup of bypass surgery
patients. Segments of myocardium may be supplied by
patent arterial grafts (at risk for damage during reoperation)
or by atherosclerotic vein grafts. Vein graft atherosclerosis is
a pathology that is different from native-vessel CAD and it
is more prone to cause embolization and thrombosis. In
addition, reoperative candidates are older and often have far
advanced coronary and noncoronary atherosclerosis. Left
ventricular function is commonly abnormal, and conduits to
perform bypass grafts may be lacking (541).
The mortality rate for reoperation is greater than that for
primary surgery, although in experienced centers that risk
differential has narrowed with time. Advanced age, abnor-
mal LV function, number of atherosclerotic vein grafts, the
number of previous bypass operations, and emergency status
are specific variables that have been consistently associated
with an increased in-hospital risk associated with reopera-
tion. Emergency operation, in particular, substantially
increases the risk of reoperation. Third and fourth bypass
operations are increasing in frequency and have all the diffi-
culties associated with a second operation, only more so.
They have been associated with an increased mortality rate,
an increased risk of hospital complications, and increased
cost (541). 
However, despite the difficulties of reoperation, it is often
the best treatment strategy for many patients with recurrent
ischemic syndromes. No randomized studies comparing
treatment options for patients with previous bypass surgery
exist. However, an observational study of patients receiving
coronary angiograms after bypass surgery has shown that for
patients with late (greater than or equal to 5 years after oper-
ation) stenoses in vein grafts, there is a high risk of subse-
quent cardiac events and a relatively high risk of death. A
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subsequent observational comparative study showed that
reoperation improved the survival rate and symptom status
of patients with late vein graft stenoses, particularly if an
atherosclerotic vein graft subtended the LAD coronary
artery. Further studies have identified a positive stress test as
a factor that incrementally defines a group of patients at high
risk without repeat surgery. Percutaneous procedures have
often been effective in the treatment of patients with native
coronary stenoses but have been particularly ineffective in
the treatment of atherosclerotic vein graft stenoses. These
considerations combined with late survival rates after reop-
eration of 90% to 95% at 5 years, and more than 75% at 10
years, indicate that reoperation can be a sound form of treat-
ment for patients with severe symptoms or survival jeopardy
(541). 
As the impact of vein graft atherosclerosis on graft failure
was appreciated in the early 1980s, it appeared as though the
need for coronary reoperation might become overwhelming,
but a number of factors decrease the reoperation rate. One is
the use of arterial grafts. Despite the lack of randomized data
observational studies clearly indicate that use of the left
IMA to LAD graft decreases reoperation rate. Studies also
indicate that the strategy of bilateral IMA grafting may fur-
ther decrease the reoperation rate. Second, vein graft failure
may be delayed by pharmacological treatment. Early vein
graft patency rates are clearly improved by perioperative
treatment with platelet inhibitors, and the use of postopera-
tive statin therapy decreases late vein graft failure rate and
the incidence of late clinical events. Finally, the availability
of percutaneous treatments may further delay the need for
reoperation (541).
5.8. Concomitant PVD
The coexistence of CAD and PVD is well known. It is esti-
mated that the prevalence of serious, angiographic CAD
ranges from 37% to 78% in patients undergoing operation
for PVD (542). CAD is the leading cause of both early and
late mortality in patients undergoing peripheral vascular
reconstruction (543). MI is responsible for about half of all
postoperative deaths in patients undergoing abdominal aor-
tic aneurysm resection (544,545), extracranial revasculariza-
tion (199,546), or lower-extremity revascularization
(545,547). Long-term survival after successful vascular
reconstruction is limited by the high incidence of subsequent
cardiac death (548). On the other hand, the presence of PVD
is a strong, independent predictor of long-term mortality in
patients with stable chronic angina (549). After successful
myocardial revascularization, patients with PVD are at sub-
stantially increased risk for in-hospital (37) and long-term
(550) mortality. 
The importance of preoperative cardiac evaluation was
demonstrated by Hertzer et al (543) in a study of 1000
patients with PVD: abdominal aortic aneurysm, cerebrovas-
cular disease, or lower-extremity ischemia. All 1000 patients
underwent coronary angiography. Severe, surgically cor-
rectable CAD was found in 25% of the patients; 34% of the
patients suspected to have CAD on clinical grounds were
found to have severe, surgically correctable CAD; 14% of
the patients not suspected to have CAD were found to have
severe, surgically correctable CAD. The early postoperative
mortality rate after the peripheral vascular procedures was
lower in patients who had preliminary CABG compared
with those who did not. The long-term beneficial effect of
preliminary CABG in patients undergoing peripheral vascu-
lar reconstruction was reported by Eagle et al (549) in their
retrospective cohort analysis of 1834 patients with combined
CAD and PVD. Nine hundred eighty-six patients received
CABG and 848 patients were treated medically. In a mean
follow-up of 10.4 years, 1100 deaths occurred and 80% were
due to cardiovascular causes. The group treated with surgi-
cal coronary revascularization had significant survival bene-
fits at 4, 8, 12, and 16 years compared with patients treated
with medical therapy alone. Subgroup analysis suggested
that the long-term survival benefits of surgical coronary
revascularization were particularly seen in patients with 3-
vessel CAD and depressed LVEFs. 
The predictive value of PVD for short- and long-term clin-
ical outcomes of patients receiving CABG was also exam-
ined by the Northern New England Cardiovascular Disease
Study Group (37,550). In-hospital mortality rates with
CABG in patients with PVDs were 7.7%, a 2.4-fold higher
incidence than in patients without PVD (3.2%). After adjust-
ing for higher comorbidity scores associated with patients
with PVD, patients with PVD were 73% more likely to die
in hospital after CABG. The excess risk of in-hospital mor-
tality associated with PVD was particularly notable in
patients with lower-extremity occlusive disease (adjusted
OR 2.03). The presence of cerebrovascular disease had a
small but nonsignificant effect on CABG-related in-hospital
deaths (adjusted OR 1.13). 
Excess mortality rates in patients with PVD were due pri-
marily to an increased incidence of heart failure and dys-
rhythmias rather than cerebrovascular accidents or peripher-
al arterial complications. The difference in mortality rate
was also apparent at long-term follow-up. Five-year mortal-
ity after CABG was substantially higher in patients with
PVD than in those without PVD, with a crude hazard ratio
of 2.77 and an adjusted hazard ratio of 2.01 after multivari-
ate adjustment for comorbid conditions. Significantly ele-
vated adjusted hazard ratios occurred in patients with overt
cerebrovascular disease, clinical and subclinical lower-
extremity occlusive disease, abdominal aortic aneurysm, and
combined PVDs. Asymptomatic carotid bruit or stenosis
conferred a small, nonsignificant increased adjusted hazard
ratio of 1.47. In summary, the presence of clinical and sub-
clinical PVD is a strong predictor of increased in-hospital
and long-term mortality rate in patients undergoing CABG.
5.9. Poor LV Function
See Section 9.2.5 for recommendations.
LV function is an important predictor of early and late
mortality after coronary artery surgery. LV dysfunction is
associated with an increased risk of perioperative and long-
term mortality in patients undergoing coronary bypass sur-
e266
ACC - www.acc.org
AHA - www.americanheart.org
Eagle and Guyton et al. 2004
ACC/AHA Practice Guidelines
gery compared with patients with normal LV function. Both
low EF and clinical heart failure are predictive of higher
operative mortality rates with CABG (551). In 6630 patients
who underwent isolated CABG surgery in the CASS reg-
istry, the average operative mortality was 2.3%, ranging
from 1.9% in patients with an EF greater than or equal to
0.50 to 6.7% in patients with an EF less than 0.19 (552). An
operative mortality of 6.6% in patients with an EF less than
0.35 in comparison with 2.6% in patients with an EF greater
than 0.50 was reported (553). Compared with patients with
an EF of 0.40 or higher, patients whose EF was less than
0.20 or between 0.20 and 0.39 had 3.4 and 1.5 times higher
perioperative mortality rates, respectively (17). Reports of
perioperative mortality rate varied widely, ranging from
about 5% in excellent centers in patients of a younger age,
with fewer symptoms, and having no comorbid conditions,
to greater than 30% in patients who were older, with severe
ventricular dysfunction, and having several comorbid condi-
tions (551). A trend toward lower operative mortality rates in
recent years compared with those in early years has been
reported, perhaps due to better myocardial protection tech-
niques and perioperative management in the contemporary
period. 
Analysis of patients with an EF less than 0.35 from the
CASS registry showed 5-year survival rates of 73%, 70%,
and 62% in patients with an EF from 0.31 to 0.35, 0.26 to
0.30, and less than 0.25, respectively (554). A comparison
between surgically treated and medically treated groups
revealed the greatest surgical benefit in patients with an EF
of 0.25 or less. The medically treated patients had a 5-year
survival rate of 43% compared with 63% for those treated
with coronary bypass surgery. A comparison study of 5824
patients who underwent medical or surgical therapy for
ischemic heart disease in the Duke University
Cardiovascular Database showed that patients with the worst
LV function (EF less than 0.35) had the greatest 10-year sur-
vival benefit from bypass surgery (46% versus 27%).
Patients with an EF of 0.35 to 0.50 had a 10-year survival
rate of 62% in the surgical group versus 50% in the medical
group (87). Patients with severe LV dysfunction have
increased perioperative and long-term mortality compared
with patients with normal LV function. However, the benefi-
cial effects of myocardial revascularization in patients with
ischemic heart disease and severe LV dysfunction are clear-
ly evident when compared with medically treated patients in
terms of symptom relief, exercise tolerance, and long-term
survival (87,551,555,556). Coronary artery bypass graft sur-
gery is recommended in patients with severe multivessel dis-
ease and poor ventricular function but with a large amount
of viable myocardium. Patient selection is crucial for achiev-
ing the beneficial effects of myocardial revascularization in
this subset of patients and is discussed in Section 9. 
5.10. Transplantation Patients
Cardiac transplantation is an accepted treatment for end-
stage heart failure, with greater than 30 000 cardiac trans-
plantations performed worldwide to date (557). Allograft
CAD is the leading cause of death after the first year of
transplantation (558-560). This type of occlusive CAD is
diffuse, often rapidly progressive, and affects a substantial
number of heart transplant recipients. The incidence of
angiographic transplant vasculopathy is estimated at 40% to
45% at 3 to 5 years after transplantation with a yearly attri-
tion rate of 15% to 20% (561,562). Angina pectoris is rarely
the presenting symptom in patients with allograft CAD
owing to the lack of afferent autonomic innervation,
although partial reinnervation of the allograft can occur.
Silent MI, heart failure due to loss of allograft function, and
sudden cardiac death are the common signs of cardiac allo-
graft vasculopathy (561). Analysis of coronary angiograms
of affected cardiac allografts has revealed unique morpho-
logical features consisting of diffuse, concentric narrowing
in middle and distal vessels with distal vessel obliteration
and a paucity of calcium deposition (563). The underlying
pathophysiology of allograft vasculopathy is largely
unknown, but it is likely a common final pathway of a con-
stellation of immunologic and nonimmunologic injuries,
namely chronic rejection, cytomegalovirus infection, hyper-
lipidemia, and older donor age (563-565). Treatment of
hyperlipidemia with pravastatin (566) or weekly LDL
apheresis (567) has been reported to lower the incidence of
coronary vasculopathy or even lead to regression. Currently,
retransplantation is the only definitive therapy for advanced
allograft vasculopathy. Good results have been reported with
PCI and directional coronary atherectomy in selected
patients with discrete and proximal coronary focal lesions
(568-569a). In general, coronary bypass surgery is not an
option because of the diffuse type of coronary disease in
patients with cardiac allograft vasculopathy. Isolated cases
of successful coronary bypass grafting have been reported
(570,571). In a report of 5 patients who underwent CABG
for cardiac allograft vasculopathy, 3 patients died during the
perioperative period and 1 died at 50 days. 
It is well known that ESRD is associated with an increased
risk of CAD (572). The safety and efficacy of coronary
bypass grafting were reported in 31 renal transplant patients
who underwent isolated coronary bypass surgery (573).
Perioperative mortality was 3.2%, and no renal allograft
function was impaired. Overall, 1- and 5-year survival rates
for patients undergoing open heart surgery were 88% and
85%, respectively (573). The safety and efficacy of CABG
were also reported in a small series of 3 patients with trans-
planted livers, with no deaths or hepatic decompensation and
good improvement of cardiac symptoms (574). (See Section
5.5. on ESRD.)
5.11. CABG in Acute Coronary Syndromes
Class I
If clinical circumstances permit, clopidogrel should
be withheld for 5 days before performance of CABG
surgery. (Level of Evidence: B)
The acute coronary syndromes represent a continuum from
severe angina to acute MI. Various classifications are based
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on the presence or absence of Q waves associated with evi-
dence for myocardial necrosis, the elevation or depression of
ST segments on the electrocardiogram, and clinical defini-
tions based on the pattern of angina. Historically, a clinical
definition encompassing progressive, rest, and postinfarction
angina and Q-wave and non–Q-wave MI has been used to
examine the effects of surgery. More recent nomenclature
defines the spectrum of acute coronary syndromes from
unstable angina to non–ST-segment elevation MI (NSTEMI)
to ST-segment elevation MI (STEMI). Where appropriate,
we use the new classification in this document, recognizing,
however, that many of the cited trials categorized the patient
subgroups according to the older nomenclature.
The effectiveness of CABG for unstable angina was first
demonstrated in a randomized Veterans Administration trial
comparing medical therapy with CABG initiated in 1976
(575). Although there was no overall difference in survival
between medically and surgically treated patients, an
improvement in survival with CABG occurred in patients in
the lowest tertile of EF (0.3 to 0.58) at 3, 5, and 8 years of
follow-up (105), in those with 3-vessel disease (576), and in
those with LV dysfunction presenting with electrocardio-
graphic changes (577). At 5 years of follow-up, surgically
treated patients had less angina and improved exercise toler-
ance and required fewer antianginal medications than did the
medically treated patients (110). It is difficult to interpret the
results of this study because surgical and medical therapies
have both evolved substantially, including the routine use of
modern techniques for myocardial preservation, arterial
bypass conduits, aspirin, fibrinolytics, and PCI. 
There have been no randomized trials specifically compar-
ing CABG and PCI in patients with unstable angina and
multivessel CAD. The BARI trial prespecified a comparison
subgroup based on the severity of angina. In this trial, 7% of
patients had unstable angina or NSTEMI. There was no dif-
ference in 5-year overall survival for these patients treated
with either CABG (88.8%) or PTCA (86.1%, P equals NS)
(117). However, there was an increased cardiac mortality in
patients treated with PTCA (8.8%) compared with CABG
(4.9%), and this difference was entirely due to a difference
in outcomes in treated patients with diabetes (129). 
In contrast, EAST included a large proportion (60%) of
randomized patients with Canadian Cardiovascular Society
Class IV angina, and there was no difference in mortality at
3 years (119). Similarly, 59% of enrollees in RITA had rest
angina, and this study demonstrated no significant differ-
ences in death or MI at 2.5 years of follow-up (126). There
was a particularly high incidence of unstable angina (83%)
in the small ERACI trial (133). These patients had mostly
complex lesions (50% type B2 and 13% type C), which are
associated with greater angioplasty complications (578).
However, in-hospital mortality was higher with CABG
(4.6% versus 1.5%), and 3-year survival and freedom from
STEMI were similar for both forms of revascularization
(133). 
No studies have addressed the important subset of patients
with unstable angina after prior CABG. The culprit lesion in
these patients is often located in a vein graft, where both
angioplasty and reoperative CABG have less success (412).
Several early studies performed before 1990 demonstrated
an increased surgical mortality ranging from 4.6% to 7.3%
in patients with unstable angina (414,579-581). More stud-
ies have confirmed this finding (582,583). In the series of
Louagie et al (582), 474 patients admitted with prolonged
rest angina and requiring surgery during the same hospital-
ization had an operative mortality of 6.8% and a periopera-
tive MI rate of 7.2%, and 19% required placement of an
IABP. A study examining early revascularization versus con-
servative therapy for patients with NSTEMI had a much
higher 30-day surgical mortality (12%) in patients undergo-
ing early CABG compared with those managed conserva-
tively (5%) (418). 
In patients with post-infarct angina, a higher mortality has
been observed, particularly with early operation after
STEMI (409,579,584). Braxton et al (585) compared 116
patients operated on within 6 weeks of MI with 255 patients
without prior MI. Mortality was highest (50%) in 6 patients
with STEMI undergoing surgery less than 48 hours after
infarction versus 7.7% in 52 patients undergoing surgery 3
to 42 days after infarction and versus 2% to 3% when CABG
was performed even later and in patients without prior
infarction. Factors associated with adverse outcomes during
CABG for unstable angina are listed in Table 17. 
A new issue that has arisen concerns the risk of CABG in
patients with acute coronary syndrome treated with new and
Table 17. Factors Associated With Adverse Outcome During Coronary
Artery Bypass Grafting for Unstable Angina 
Relative Risk of 
Factor (Reference) Mortality (Range)
Clinical
Recent MI: less than 24 h (777), 2.1-1.8
less than 48 h (585),
less than 30 d (451)
Female (451,582,584,777) 1.4-1.7
Age (451,452,584,779) 2.9-5.3*
IDDM (779) 8.3†
Angiographic/hemodynamic
No. of diseased vessels (582,584) 1.9-2.3
(EF 0.20-0.39)
LV dysfunction (451,452,584) 5.9-10.7 
(EF less than 0.20)
Hypotension (452,777) 6.5-7.8
Surgical
Aortic cross-clamp time (582,779) 2.25‡
Urgent surgery (584,777) 1.8-1.9
Bypass time (779) ...
IABP support (779) 4.1
MI indicates myocardial infarction; IDDM, insulin-dependent diabetes mellitus; LV, left
ventricular; IABP, intra-aortic balloon pump; and EF, ejection fraction. 
*Age greater than 70 years.
†Relative risk for perioperative MI.
‡Relative risk of major adverse outcome greater than or equal to 100 versus less than 100
minutes. 
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more potent antithrombotic and antiplatelet therapies.
Several studies have demonstrated a greater risk for postop-
erative hemorrhage in patients treated with low-molecular-
weight heparin (586), abciximab (587), and clopidogrel
(588). It is important to understand the pharmacokinetics of
these agents to reduce the risk. For instance, no increased
bleeding was observed when the short-acting glycoprotein
IIb/IIIa inhibitor eptifibatide was discontinued at least 2
hours before bypass (589), when platelet transfusions were
appropriately administered after abciximab (590), and when
clopidogrel was withheld for 5 days before surgery (588). In
some instances, the need for urgent surgery supercedes the
risk.
The use of CABG for primary reperfusion during STEMI
has largely been superseded by fibrinolysis and primary
PTCA. Early coronary bypass for acute infarction may be
appropriate in patients with residual ongoing ischemia
despite nonsurgical therapy and if other conditions warrant
urgent surgery, including left main or 3-vessel disease, asso-
ciated valve disease, mechanical complications, and anato-
my unsuitable for other forms of therapy. 
In conclusion, CABG offers a survival advantage com-
pared with medical therapy in patients with unstable angina
and LV dysfunction, particularly in those with 3-vessel dis-
ease. Currently, there is no convincing survival advantage
for surgery over PTCA in patients with unstable angina suit-
able for treatment with either technique. However, the risk of
CABG in patients with unstable angina, postinfarction angi-
na, early after non-STEMI, and during acute MI is increased
several fold relative to patients with stable angina, although
the risk is not necessarily higher than that of medical thera-
py for these patients. 
6. IMPACT OF EVOLVING 
TECHNOLOGY
6.1. Less-Invasive CABG
Patients presenting for CABG are older, have more comor-
bid conditions, and as a group have a higher predicted risk of
mortality than their historical predecessors. Despite these
trends, clinical outcomes after CABG have continued to
improve (591,592).
Before 1995, the vast majority of CABG procedures used
a midline sternotomy incision, CPB, and global cardioplegic
arrest. Cardiopulmonary bypass has adverse effects on many
organ systems and elicits a systemic inflammatory response.
Some have sought to minimize the invasiveness of CABG
through the elimination of CPB or through the use of small-
er incisions or both.
Coronary artery bypass graft surgery on a beating heart
without CPB was first reported by Kolessov in 1967, who
was technically challenged by the motion of the heart, and
access to the posterior surface of the heart was not possible
(10). The technique was largely abandoned in the United
States after the refinement of CPB. However, CABG on a
beating heart was still practiced in several countries, where
much experience was accumulated (593,594). These proce-
dures were primarily reserved for patients needing LAD or
right coronary artery (RCA) bypass because techniques for
safe access to the lateral and posterior wall arteries had not
developed. 
Single LAD bypass on the beating heart through a small
anterolateral thoracotomy (MID-CAB) was reintroduced in
the mid-1990s (595-597). Target coronary artery stabiliza-
tion was initially achieved with pharmacologically induced
bradycardia or intermittent temporary asystole, with small
bolus infusions of adenosine. Early angiographic anastomot-
ic patency rates were inferior to those achieved with con-
ventional CPB-CABG and prompted the development of
various styles of mechanical stabilizers to limit target artery
motion. Patency rates improved with experience and with
the use of mechanical stabilization (598).
Surgeons uncommonly are referred patients with single-
vessel LAD disease, but the results of MID-CAB fostered
interest in the development of techniques for multivessel
OPCAB. Building on the experience of Benetti and Bufolo,
surgeons developed methods to safely access lateral wall and
posterior wall vessels. With mechanical coronary artery sta-
bilizers, devices for clearing the anastomotic field of blood,
intracoronary shunts, and techniques and devices for cardiac
positioning, many centers were able to report sizeable series
in which the large majority of CABG procedures were
achieved without CPB (599-602).
Several retrospective studies have suggested that OPCAB
may reduce morbidity and/or mortality. Nearly all reports
have demonstrated reductions in the need for transfusion of
blood products, shorter ICU stays, and shorter postoperative
lengths of stay. Some of these studies have also suggested
that hospital costs are reduced (603-605). 
Hernandez et al (606) reported on the experience of the
Northern New England Cardiovascular Disease Study Group
comparing 1741 OPCAB and 6126 contemporaneous CPB
patients. The groups differed somewhat in preoperative risk
factors, but their predicted risk of mortality was the same.
They found no differences in crude rates of mortality, stroke,
mediastinitis, or return to the operating room for bleeding.
OPCAB patients had a reduced need for IABP support, less
atrial fibrillation, and shorter median postoperative lengths
of stay.
Magee et al (607) reviewed all multivessel CABG proce-
dures from 2 large institutions from January 1998 through
July 2000. They entered 8449 patients (1983 OPCAB, 6466
CPB) into a multivariate logistic regression analysis to eval-
uate the impact of CPB on mortality, independent of other
risk factors known to affect mortality. They also used
propensity scoring to computer match pairs of OPCAB and
CPB patients in an attempt to remove selection bias from the
analysis. CPB was associated with increased mortality com-
pared with OPCAB by univariate analysis (CPB 3.5%,
OPCAB 1.8 %) even though the OPCAB group had a high-
er predicted mortality. CPB was associated with increased
mortality by multiple regression analysis (OR 1.79, 95%
confidence interval 1.24 to 2.67). The combined computer-
matched groups based on OPCAB-selection propensity
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score also demonstrated an increased risk of mortality for
CPB (OR 1.9, 95% confidence interval 1.2 to 3.1).
Plomondon et al (608) reviewed CABG-only procedures
from the Veterans Affairs Continuous Improvement in
Cardiac Surgery Program records from October 1997
through March 1999. Nine centers were identified that had
completed at least 8% of their CABG procedures as OPCAB
and were designated as study hospitals. OPCAB patients (n
equals 680) from these hospitals were then compared with
CPB patients (n equals 1733) for mortality or morbidity.
Predicted mortality was higher in the OPCAB group
(OPCAB 4.4%; CPB 3.9%; P equals 0.0022), as was pre-
dicted morbidity (OPCAB 13.2%; CPB 11.9%; P equals
0.0008). OPCAB patients experienced lower mortality
(OPCAB 2.7%; CPB 4.0%) and lower morbidity (OPCAB
8.8%; CPB 14%; P equals 0.001). Multivariable OR for
OPCAB versus CPB groups, after risk adjustment for patient
risk factors, were computed. For mortality, the OR for
OPCAB was 0.56 (95% confidence interval, 0.32 to 0.93, P
equals 0.033), and for morbidity the OR was 0.52 (95% con-
fidence interval, 0.38 to 0.70, P less than 0.0001). Observed-
to expected ratios for mortality and morbidity were less than
1.0 for OPCAB patients and more than 1.0 for CPB patients.
The authors concluded that in centers experienced in beating
heart coronary bypass, an off-pump approach for CABG was
associated with lower risk-adjusted morbidity and mortality.
Cleveland et al (609) reported on the largest multicenter
report to date. They retrieved data from the STS National
Cardiac Surgery Database from a 2-year period of time
(January 1998 through December 1999) and identified 126
centers experienced in OPCAB. There were 11 717 (9.9%)
OPCAB patients and 106 423 (90.1%) CPB patients. The
OPCAB patients were older, were more likely female, and
were less likely to be diabetic than the CPB subjects. The
OPCAB group also had more patients with preexisting
COPD, dialysis-dependent renal failure, and cerebrovascular
disease than the CPB group. The CPB patients were more
likely to have 3-vessel disease, and more of them were in
need of urgent or emergency CABG. Predicted mortality
was similar (OPCAB 2.88%; CPB 2.87%). The observed
risk-adjusted mortality in the OPCAB group was 2.31%, and
that of the CPB group was 2.93% (P less than 0.0001). The
risk-adjusted rate of major morbidity in the OPCAB group
was 10.62% compared with 14.15% in the CPB group (P
less than 0.0001). When complications were examined indi-
vidually, the OPCAB group had fewer strokes (OPCAB
1.25%; CPB 1.99%; P less than 0.001), less postoperative
renal failure (OPCAB 3.85%; CPB 4.26%; P equals 0.036),
and fewer patients with postoperative cardiac arrest
(OPCAB 1.42%; CPB 1.74%; P equals 0.010), and fewer
patients returned to the operating room for bleeding
(OPCAB 2.07%; CPB 2.80%; P less than 0.001).
Additionally, in patients with pre-existing COPD or cere-
brovascular disease, OPCAB patients were less likely to
require prolonged mechanical ventilation or to have stroke
or coma, respectively. 
Three randomized, prospective trials have been reported
comparing OPCAB and CPB CABG. None of these trials
were large enough to demonstrate any differences in opera-
tive mortality or the occurrence of postoperative stroke.
Angelini et al (610) pooled data from 2 separate random-
ized trials. OPCAB patients were shown to have reduced
morbidity (e.g., transfusion, chest infection). At midterm
follow-up there were no differences between groups with
regard to cardiac death or cardiac events. 
van Dijk et al (611) randomized relatively low-risk patients
(n equals 281) to OPCAB or CPB CABG. Completeness of
revascularization was equivalent between groups. OPCAB
patients required fewer intraoperative transfusions and had
lower levels of cardiac-specific enzyme release. At 1 month,
no differences were noted in rates of cardiac death or car-
diac-related events.
Puskas et al (612) randomized 201 patients to OPCAB or
CPB CABG. No patients were excluded on the basis of coro-
nary artery anatomy, LV dysfunction, or any comorbidity.
Intended target vessels were identified and recorded preop-
eratively before randomization. OPCAB patients required
fewer transfusions, had less release of cardiac-specific
enzymes, had shorter times to extubation, had shorter ICU
and postoperative lengths of stay, and had lower hospital
costs. Levels of revascularization were identical between
groups.
Patients with significant comorbidity have been reported to
have been revascularized by OPCAB techniques. The elder-
ly, patients with prior CABG, patients with left main CAD,
and those with impaired myocardial, renal, or pulmonary
function have all been reported to have been safely and
effectively approached without CPB.
Larger randomized trials will be necessary to delineate
which patients benefit from the avoidance of CPB and what
the magnitude of that benefit actually is.
The third emerging technique in less-invasive cardiac sur-
gery is the closed-chest, port-access, video-assisted CABG
operation developed at Stanford, Calif (613). CPB and car-
dioplegia of a globally arrested heart are integral parts of this
technology. Vascular access for CPB is achieved via the
femoral artery and vein. A triple-lumen catheter with an
inflatable balloon at its distal end is used to achieve endovas-
cular aortic occlusion, cardioplegia delivery, and LV decom-
pression. With CPB and cardioplegic arrest, CABG can be
performed on a still and decompressed heart, through sever-
al small ports and with the aid of a videoscope. In compari-
son with the MID-CAB approach, the port-access technique
allows access to different areas of the heart, thus facilitating
more complete revascularization, and the motionless heart
allows for accurate anastomosis. The proposed advantage of
this approach compared with conventional CABG is the
avoidance of median sternotomy, with the resultant dimin-
ished incisional pain and faster recovery. The potential mor-
bidity of the port-access technique stems from the multiple
port sites, limited thoracotomy, and groin dissection for
femoral-femoral bypass. The short- and long-term safety,
benefits, and efficacy of the minimally invasive port-access
e270
ACC - www.acc.org
AHA - www.americanheart.org
Eagle and Guyton et al. 2004
ACC/AHA Practice Guidelines
approach must be compared with the conventional operation
in an appropriately controlled clinical trial. As in any new
technology, vigorous scientific scrutiny must be applied
before any conclusions can be made. 
6.1.1. Robotics
Investigational work continues in the development of robot-
ic coronary bypass. Closed-chest multiarterial bypass on the
beating heart would offer the maximum benefit via the least
invasive approach. CPB and thoracotomy would be avoided,
and the durability of arterial CABG would be preserved.
Boyd et al (614) described 4 levels of robotically assisted
coronary bypass currently being investigated.
1. Voice-activated robotic control of an intrathoracic
camera placed through a port and used for video-
assisted manual endoscopic harvesting of the IMA
with standard endoscopic instruments. A manual
beating heart anastomosis is then completed through
a small thoracotomy.
2. Video-assisted port-access telerobotic conduit har-
vesting, in which the surgeon works from a comput-
er-enhanced remote console to harvest the IMA with
port-access telemanipulators (robotic arms). A manu-
al beating heart anastomosis is then completed
through a small thoracotomy.
3. Computer-assisted endoscopic coronary artery anas-
tomoses in which the conduit is harvested manually
via standard sternotomy and the coronary anastomo-
sis is constructed on the arrested or beating heart from
the computer-enhanced master console through tele-
manipulators passed via ports.
4. Totally endoscopic coronary bypass during which
conduit harvesting and preparation, target coronary
artery identification and preparation, vascular control,
and the anastomosis are all accomplished from the
computer-enhanced console via port-access telema-
nipulators without any chest incision.
Successful application of all 4 of these strategies has been
reported from specialized centers (615-618). The major
obstacle to a totally endoscopic CABG has been the techni-
cal difficulty in the construction of an accurate anastomosis.
Considerable effort is under way to develop technology for
a facilitated anastomotic device, perhaps avoiding the need
for a sutured anastomosis. Robotically assisted coronary
artery bypass must be considered a work in progress at this
time.
6.2. Arterial and Alternate Conduits
Class I
In every patient undergoing CABG, the left IMA
should be given primary consideration for revascu-
larization of the LAD artery. (Level of Evidence: B)
The benefits of bypass surgery are related to patent bypass
grafts, and short- and long-term graft patency is associated
with cardiac morbidity and mortality. The most commonly
used bypass grafts have been the in situ IMA and segments
of greater saphenous vein (SVG) used as aorta-to-coronary
grafts. By the early 1980s, serial angiographic studies of
vein grafts made it apparent that SVGs could develop intrin-
sic pathological changes, intimal fibroplasia and vein graft
atherosclerosis, that were progressive and compromised
long-term graft patency rates. Late vein graft patency rates
ranged from 70% to 80% at 5 postoperative years to 40-60%
at 10 postoperative years. Fortunately, similar serial studies
showed that IMA grafts had early patency rates of greater
than 90%, but more importantly, they showed that late attri-
tion of IMA grafts is extremely uncommon, resulting in a
late patency rate of in situ IMA grafts of 90% or more at 10
postoperative years. The clinical importance of the left IMA-
to-LAD graft was emphasized by a long-term follow-up
study that compared patients with left IMA-LAD grafts and
supplemental vein grafts to patients receiving only vein
grafts. The patients receiving left IMA-to-LAD grafts had a
better survival rate, fewer reoperations, and fewer cardiac
events at a 10-year follow-up.
In the modern era, it can be expected that vein graft paten-
cy rates will be improved over the earlier studies.
Randomized trials have shown that perioperative treatment
of patients with platelet inhibitors improves bypass graft
patency rates at 1 postoperative year. Prospective angio-
graphic studies from the BARI trial documented an 87% 1-
year vein graft patency rate compared with 98% for IMA
grafts. Furthermore, aggressive treatment with statins
appears to decrease vein graft attrition rate. However,
although the interventions have decreased vein graft failure,
it has not been eliminated. The prospective study of SVG
patency rates noted a 66% patency rate at 10 postoperative
years.
If 1 IMA graft is good, might 2 be better? The use of the
right IMA in addition to the left IMA (bilateral IMA, or
BIMA, grafting) for bypass grafting has been employed as a
surgical strategy since the early years of bypass surgery.
Despite the apparent logic of using 2 grafts anticipated to
have excellent long-term patency rates, evidence that BIMA
grafting (or any other extension of arterial grafting) provides
incremental clinical benefit over the left IMA-to-LAD graft
in associated vein graft strategy (single IMA, or SIMA,
grafting) has been difficult to document for a variety of rea-
sons. First, there are no randomized studies concerning this
issue. Second, too few institutions have used BIMA grafting
to provide enough patients to allow detailed analysis. Third,
survival rates after SIMA grafting are favorable for the first
postoperative decade, meaning that particularly long-term
follow-up studies are necessary to allow any differences to
become apparent. Fourth, patient selection can confound the
analysis of outcomes. In general, studies of BIMA grafting
have excluded patients undergoing emergency operation and
those with previous bypass surgery and have included
decreased numbers of patients with diabetes. However, there
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are now several nonrandomized, risk-adjusted, comparative
studies that show improved long-term outcomes for patients
receiving BIMA grafts in terms of fewer reoperations and
improved late survival rates. BIMA grafting has not become
a routine strategy even for elective patients for multiple rea-
sons, including increased operative difficulty, increased
operative time, and the risk of wound complications. Most
studies have shown an increase in the risk of wound compli-
cations with BIMA grafting, usually in patients with dia-
betes. The use of techniques for skeletonizing the IMAs dur-
ing preparation, thus minimizing the decrement in sternal
blood supply, may decrease the incidence of sternal compli-
cations, but even modern studies of BIMA grafting have
shown an increased risk of wound complications in obese
diabetic patients.
The use of the radial artery as a conduit for coronary
bypass grafting was first reported by Carpentier et al (619)
in 1973. Its use was quickly abandoned when occlusion rates
up to 30% were reported (620,621). Interest in its use was
revived in 1989 when radial artery grafts were found to be
patent in patients who had undergone their coronary artery
surgery 13 to 18 years earlier. The radial artery is a thick
muscular artery with an average diameter of 2.5 mm and an
average length of 20 cm. It is prone to spasm when mechan-
ically stimulated, and perioperative calcium channel block-
ers or long-acting nitrates are often used to reduce this com-
plication. The technique of minimal manipulation and en
bloc dissection of the radial artery with its surrounding satel-
lite veins and fatty tissue is thought to account for the supe-
rior results in experiences with radial artery grafting.
Brodman et al (622) reported a 95% 12-week patency rate in
175 patients receiving 229 radial artery grafts (54 patients
had bilateral radial artery grafts). Perioperative MI and mor-
tality rates were similar to those of conventional bypass sur-
gery. There was no reported hand ischemia, wound
hematoma, or infection. A 2.6% incidence of transient fore-
arm dysesthesia, which resolved over 1 day to 4 weeks after
surgery, was reported. Acar et al (623) reported an 84% 5-
year radial artery graft patency rate in 100 consecutive
patients receiving the radial artery as a conduit for coronary
revascularization. In the same group of patients, the left IMA
graft patency rate was 90% at 5 years. Thus, the radial artery
appears to be a safe and reliable arterial conduit for coronary
revascularization on the basis of these early clinical experi-
ences. 
Use of the in situ right gastroepiploic artery as a conduit
for CABG was first reported in 1987 (624,625). This artery
can be harvested by extending the median sternotomy inci-
sion toward the umbilicus and dissecting the artery along the
greater curvature of the stomach. A pedicle length of 15 cm
or more can be achieved by mobilizing the artery to the ori-
gin of the gastroduodenal artery. It can be grafted to the right
or circumflex coronary artery by routing it in a retrogastric
fashion or to the LAD in an antegastric fashion. Early graft
patency ranged from 90% to 100% (626-628), but long-term
results have not been published. The inferior epigastric
artery free graft has been used for CABG since 1990
(629,630). This artery can be harvested by retracting the rec-
tus muscle via a paramedian incision. A length of 6 to 16 cm
can be dissected from its origin from the external iliac artery
(631). Short-term patency rates of up to 98% have been
reported (632). Long-term results are not available. 
Cryopreserved homologous SVGs and glutaraldehyde-
treated homologous umbilical veins grafts have been used
for clinical aortocoronary bypass surgery (633,634). Graft
patency was reported to be only 50% at 3 to 13 months.
These grafts should not be used unless other conduits are
unavailable. Similarly, the bovine IMA has been used, again
with about 50% 1-year patency (635,636). Synthetic grafts
that have been used for aortocoronary bypass include
Dacron grafts and polytetrafluoroethylene grafts. Only a few
successful cases of Dacron graft use have been reported, and
these were in patients in whom the graft was used as an
interposition between the ascending aorta and the proximal
end of a coronary artery with resultant high flow (637-639).
The patency of polytetrafluoroethylene grafts is also limited
and has been reported to be about 60% at 1 year (640,641). 
6.3. Percutaneous Technology
Technological improvements have had a great impact on
PTCA and have included new medications and devices that
have reduced both the acute and long-term complications of
percutaneous coronary interventions. The most significant
medication advance has been the introduction of new
platelet inhibitors, which have reduced the incidence of MI
and death during angioplasty and related interventions
(642). 
In the area of devices, intracoronary stents have reduced
complications, including the need for emergency surgery, as
well as the need for repeated interventions due to restenosis
(643,644). New refinements in stent design and adjunctive
pharmacological therapy are further improving patient out-
comes after stenting (645). Directional coronary atherecto-
my has also been shown to reduce restenosis compared with
conventional PTCA, but its role relative to stents is not yet
clear (646). Several new devices, such as the transluminal
extraction catheter (InterVentional Technologies, Inc., San
Diego, CA) and the Angioget thrombectomy catheter (Possis
Medical, Inc., Minneapolis, MN), that remove thrombus
before intervention either have been approved for use or are
undergoing investigation and may reduce complications in
some high-risk subsets of patients. Rotational atherectomy
or rotational ablation has expanded the types of lesions (eg,
calcified or long lesions) that can be treated without surgery
(647). 
Restenosis remains the greatest weakness of PTCA and is
being addressed by mechanical solutions such as stents and
directional atherectomy, which improve the intimal lumen
diameter, and by pharmacological interventions aimed at
preventing intimal hyperplasia. Promising approaches
included in this latter category are medications such as
probucol and folate (648-650), gene therapy, and local radi-
ation therapy (651-653). Finally, the balance between bypass
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surgery and PCI is being further altered as the promise of
new technology offered by drug-eluting stents is realized
(654).
After CABG surgery, failure of the SVG is a major cause
of recurrent cardiac ischemia. Angiographic studies have
shown that 16% to 31% of SVGs fail within 1 year (655-
658), and within 10 years, about half of all vein grafts are
totally occluded or have severe atherosclerotic disease
(74,659,660). It is estimated that vein graft failure is respon-
sible for recurrent angina at an annual rate of 4% to 9% in
patients after aortocoronary artery bypass grafting (661-
663). In these patients, repeated CABG surgery is a satisfac-
tory option. However, in comparison with initial bypass sur-
gery, reoperation is technically more challenging and is
associated with higher perioperative morbidity and mortali-
ty as well as less symptomatic relief (664-666). As alterna-
tives to repeated bypass surgery, various percutaneous tech-
niques have been developed to treat stenotic vein grafts.
These techniques include conventional balloon angioplasty
and the use of newer interventional devices such as coronary
stents and directional coronary atherectomy. 
In general, the results of angioplasty in SVGs are less
favorable than in native vessels, with less procedural success
and a higher rate of restenosis. Several factors influence the
clinical outcome of the procedure: age of the graft, location
of the stenosis within the graft, and the discrete (versus dif-
fuse) morphological features of the atherosclerotic plaques
(667-670). In a randomized comparison with angioplasty,
directional coronary atherectomy was associated with a
higher initial success rate and fewer repeated target-vessel
interventions at 6 months but more periprocedural compli-
cations, most notably distal embolization and NSTEMI
(671,672). 
Intracoronary stents are now commonly used in the man-
agement of SVG stenosis. A multicenter, prospective, ran-
domized trial compared the effects of stent placement with
those of balloon angioplasty on clinical and angiographic
outcomes in patients with obstructive disease of SVGs
(673). Compared with the balloon angioplasty group, stent-
ing of vein graft lesions resulted in a higher rate of proce-
dural efficacy (92% versus 69%) and a greater increase in
luminal diameter immediately after the procedure (1.92 ver-
sus 1.21 mm) and at 6 months (0.85 versus 0.54 mm). The
6-month outcome in terms of freedom from death, MI,
repeat bypass surgery, or revascularization of the targeted
vessel was significantly better in the stent group (73% ver-
sus 58%). Although the difference in the rate of restenosis
between the stent and angioplasty groups did not achieve
statistical significance, it appears that stent placement has
certain advantages over conventional balloon angioplasty in
the initial and short-term angiographic and clinical out-
comes. The use of a balloon-occlusion and aspiration device
has been shown to reduce the risk of adverse cardiovascular
events during SVG interventions by protecting the coronary
circulation from distal embolization of atherosclerotic debris
(674). More operator-friendly filter-type devices are under
investigation and will likely become routine adjuncts for
such procedures. 
With the increasing use of MID-CAB for left IMA-to-
LAD grafting, a combined strategy of MID-CAB and either
balloon angioplasty or stent placement (“hybrid revascular-
ization”) to achieve complete revascularization in patients
with 2-vessel disease has been used in some situations.
PTCA is performed on the second diseased vessel, which
has included the right coronary artery, the left circumflex
artery, and the left main coronary artery. The reverse order of
performing PTCA first with subsequent MID-CAB for the
left IMA-to-LAD revascularization has also been described
(675). The hybrid approach of MID-CAB and percutaneous
intervention provides complete revascularization through
limited incisions without CPB. It also provides a useful man-
agement modality for isolated patients who are at high risk
for either procedure alone. This approach highlights the
potential complementary role of surgery and PTCA in the
management of CAD. However, long-term outcome data for
patients undergoing hybrid procedures are not yet available.
Also, if coronary stenting is performed, then aspirin and
clopidogrel are indicated for at least 30 days, which may
affect the timing of coronary surgery. Thus, the theoretical
benefits of combining procedures must be matched by sci-
entific proof of efficacy before this strategy is likely to
become commonplace. 
6.4. Transmyocardial Laser Revascularization
Class IIa
Transmyocardial surgical laser revascularization,
either alone or in combination with CABG, is reason-
able in patients with angina refractory to medical
therapy who are not candidates for PCI or surgical
revascularization. (Level of Evidence: A)
Intracavitary arterial blood in the LV is only millimeters
away from ischemic areas of myocardium. Indeed, commu-
nicating channels between the cavity and the myocardium
occur in reptilian hearts and in fetal hearts during the first 7
weeks of gestation until the coronary arterial system devel-
ops. This network of communicating channels between the
heart chambers and the coronary arteries, the myocardial
sinusoids, the arterial-luminal and venous-luminal connec-
tions, were described in a study by Wearn et al in 1933
(676). Early attempts to use these connections to supply the
ischemic myocardium included implantation of the left IMA
directly into the heart muscle (677) and direct-needle
acupuncture to the ischemic myocardium to create commu-
nicating channels (678,679). Sen and colleagues (678,679)
used direct acupuncture and found that these acupuncture
channels were protective from acute infarction after ligation
of the LAD. These channels appeared to be open and
endothelialized at 8 weeks but appeared to close within sev-
eral months due to fibrosis and scarring secondary to local
tissue injury. This technique was abandoned with the arrival
of aortocoronary artery bypass surgery in the late 1960s. 
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Use of the carbon dioxide laser for transmyocardial revas-
cularization was attempted in the early 1980s by Mirhoseini
and coworkers (680,681). A high-energy laser beam was
used to create channels from the epicardial to the endocar-
dial surface of an arrested or beating heart, thus allowing
oxygenated blood from the LV to perfuse the ischemic
myocardium. Brisk bleeding from the channels due to ven-
tricular perforation could be easily controlled with light epi-
cardial pressure. It was postulated that a high-energy laser
beam would minimize local tissue injury and prevent pre-
mature fibrotic closure of the newly created channels and
thus lead to improved channel patency (682). Long-term
channel patency on histological examination has been
reported in animal experiments and in sporadic clinical case
reports (682-684). The principal utility of transmyocardial
laser revascularization (TMLR) is directed toward patients
with severe angina pectoris refractory to medical therapy
and who are unsuitable for surgical revascularization, PCI or
heart transplantation. These patients often have diffuse
small-vessel disease and are not appropriate candidates for
another PCI or CABG. The use of TMLR for the manage-
ment of cardiac allograft vasculopathy has also been report-
ed (685,686). 
The results of a multicenter trial with TMLR as the sole
therapy for 200 patients with refractory, end-stage CAD and
documented reversible ischemia was reported by Horvath
and colleagues (687). The perioperative mortality rate was
9%. Postprocedure angina class according to the Canadian
angina classification was significantly decreased from their
preoperative status at 3, 6, and 12 months of follow-up.
Hospital admissions for angina were decreased from an
average of 2.5 admissions in the year before treatment to an
average of 0.4 admissions in the year after treatment. The
number of perfusion defects in the treated LV free wall was
also significantly decreased as assessed by radionuclide per-
fusion scan or positron emission tomographic scan per-
formed after TMLR. A multicenter randomized, prospective
study comparing TMLR with continued medical manage-
ment demonstrated improved event-free survival in 160
patients with symptomatic, end-stage CAD. In the TMLR
group, 72% of patients improved by at least 2 angina class-
es, while 69% of patients in the medical therapy group had
no change of angina class; the remaining 31% experienced
greater angina. Survival free of death, unstable angina, or
class IV angina at 6 months was 73% for the TMLR group
versus 12% in the medical management group. Quality of
life indexes also improved in the TMLR group. 
Five prospective, controlled, randomized trials have been
reported (689-693). In each study, TMLR patients demon-
strated a statistically significant improvement in angina
compared with patients treated with medical therapy alone.
None of the trials demonstrated a significant survival bene-
fit, and only 1 study found a significant improvement in
myocardial perfusion (692). One of the studies (689) con-
cluded that TMLR “cannot be advocated.” This trial from the
United Kingdom was the only one of the randomized stud-
ies that was not a multicenter study. Their recommendation
came in spite of finding a statistically significant (P less than
0.001) improvement in angina for TMLR patients compared
with patients receiving medical therapy without TMLR.
Subsequent studies have supported the initial findings of
these early reports. Compared with medical therapy, there
appears to be consistent and sustained improvement in angi-
na class for at least the first year after TMLR (694-700).
Thereafter, the beneficial effects of TMLR decline some-
what (694,695,699), but Horvath et al (694), in a follow-up
study to the work cited above, reported that long-term effi-
cacy commonly persists for 5 years. As experience accumu-
lates, it appears that operative mortality is generally less than
5% (696,701,702). The most significant predictors of opera-
tive mortality are unstable angina (703) and compromised
LV function (699).
7. INSTITUTIONAL AND OPERATOR
COMPETENCE
7.1. Volume Considerations
Owing to the availability of hospital and physician-specific
mortality data and because of the perceived economies of
scale in consolidating complex medical procedures into
regional centers, considerable attention has been directed to
relating outcome after CABG to the number of procedures
performed. Before 1986, administrative data sets were pro-
posed as a means of risk adjustment to compare outcomes
between hospitals of high and low volume (704,705). These
studies found a relationship between mortality after CABG
and the volume of procedures performed annually. A cutoff
at about 200 cases defined high- and low-volume institu-
tions. High-volume institutions were determined to have
superior results. The ability of administrative data sets to
accurately stratify risk has since been questioned, particular-
ly because of their inability to distinguish preoperative
comorbidity data from postprocedure complications data
(706-708). 
Since 1986, in response to these criticisms, primary car-
diac surgical data sets have appeared with sufficient power
to address this question. Hannan et al (709) reported that in
New York State, after adjusting for case mix, the high-vol-
ume institutions that performed greater than 223 cases annu-
ally experienced significantly lower mortality than did insti-
tutions performing fewer than 223 cases annually, with a rel-
ative risk of 0.74 (0.56 to 0.94, 95% confidence interval).
This same relationship was true for individual surgeon vol-
umes, with high-volume surgeons performing more and low-
volume surgeons performing fewer than 116 CABG proce-
dures annually. These cutoff points were determined arbi-
trarily by being above or below the state median, based on
data from only 1 year. 
The relationship between in-hospital mortality rate and
surgical volume was again explored in 1991, when the cut-
off for institutional volume was defined at 200 cases annual-
ly, and the relative risk, while still significant, was reduced
to 0.84 (0.66 to 1.07, 95% confidence interval) (710). This
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report represented data collected over 3 years (1989 to
1992). In addition to showing the protective effect of high-
volume institutions, the study also showed considerable
variation, particularly among the low-volume centers. A fur-
ther analysis of this patient population revealed that a signif-
icant portion of the observed improvement found in the
overall risk-adjusted mortality rates in New York State was a
disproportionate improvement experienced by the low-vol-
ume institutions compared with the high-volume institu-
tions. Hannan et al (710) postulated that this was due in part
to the out-migration of older, low-volume surgeons and the
in-migration of younger, better-trained surgeons. It is also of
interest that the relationship between individual surgeon vol-
ume and outcome reported in 1989 and 1991 had disap-
peared. 
The Department of Veterans Affairs Hospitals reported on
24 394 patients operated on between 1987 and 1992 (711).
While there appeared to be a significant relationship
between volume and mortality rate among the 43 hospitals
examined, when adjusted for case mix the relationship dis-
appeared. Again, low-volume hospitals had a higher varia-
tion in mortality rates compared with the high-volume insti-
tutions. This variation in outcome led the Department of
Veterans Affairs to routinely review low-volume institutions
(fewer than 100 cases annually). 
A report of the STS National Cardiac Database reviewed
124 793 patients operated on by more than 1200 surgeons in
more than 600 institutions. Only in institutions performing
fewer than 100 cases annually (n equals 18) was the
observed mortality rate of 5.0% significantly higher than the
expected rate of 3.0% (2.9% to 3.2%, 95% confidence inter-
val) (712). 
Dudley et al (713) reviewed the literature linking high and
low volumes to better and worse outcomes for a variety of
procedures including CABG. By relying on the highest-
quality studies, they were able to assign ORs for adjusted in-
hospital mortality comparing high-volume hospitals and
low-volume hospitals (fewer than 500 cases annually). By
applying this model to the California Office of Statewide
Health Planning and Development Database, they projected
that there were between 124 and 372 potentially avoidable
deaths in the state of California in 1997. The authors cau-
tioned against drawing too firm a conclusion from these
findings because of the inherent limitations of observational
data, the possibility of inadequate risk adjustment, and the
absence of a direct cause and effect relationship between
volume and outcome.
Birkmeyer et al (714) reviewed Medicare claims data for 6
cardiovascular and 8 cancer-related procedures. Although
they found that a volume/outcome effect was seen in all 14
procedures studied, the degree of difference in adjusted in-
hospital and 30-day mortality between very-low-volume
(fewer than 230 cases annually) and very-high-volume hos-
pitals (more than 849 cases annually) ranged from a high of
12% in pancreatic resections to a low of 0.2% for carotid
endarterectomies. They found that the range of adjusted
mortality rates for CABG between very-low- and very-high-
volume hospitals was 1.3%, which suggests that the rela-
tionship was modest at best. 
The question of whether high-volume institutions per-
formed significantly better than did moderate-volume insti-
tutions was addressed in a study from Canada. The Adult
Cardiac Care Network of Ontario suggested that concentrat-
ing CABG into high-volume regional centers has explained
their low observed mortality rate and the lack of variation
between centers (715). This observation was not confirmed
in the STS report, as Clark (712) found no protective rela-
tionship in high-volume institutions (greater than 900
cases/y). 
Criticism of these reports revolves primarily around the
adequacy of case-mix adjustment and the limitations of
observational studies. Sowden et al (716) performed a meta-
analysis of studies relating volume to outcome and found
that the stronger the relationship between volume and out-
come, the less case mix was accounted for. They postulated
that owing to the observational nature of these studies, con-
founding accounted for most of the difference between high
and low volume, and as confounding was reduced by
improved risk stratification, the volume-outcome relation-
ship disappeared. Sowden et al (716) also found that the vol-
ume-outcome relationship diminished over time, suggesting
that low-volume institutions had “improved” faster than had
high-volume institutions. 
In summary, studies suggest that survival after CABG is
negatively affected when carried out in institutions that per-
form less than a threshold number of cases annually. Similar
conclusions have been drawn regarding individual surgeon
volumes. In states where reporting of outcomes is an accept-
ed practice (e.g., New York State), the relationship between
low volumes at either an institutional or individual level
seems to have diminished over time. This observation
strengthens the argument for outcome tracking and supports
a posture of close monitoring of institutions or individuals
that perform less than 100 cases annually. It must be remem-
bered that these same studies also found a wide variation in
risk-adjusted mortality rates in low-volume situations; ie,
some institutions and practitioners maintained excellent out-
comes despite relatively low volumes. Therefore, credential-
ing policies based on conclusions drawn from these data
must be made with caution. 
7.2. Report Cards and Quality Improvement
Mortality rates after CABG have declined since the 1987
release by the Health Care Financing Administration of hos-
pital-specific mortality data. The Northern New England
Cardiovascular Disease Study Group reported a 24% decline
in regional mortality from 1987 to 1993 (13). Hannan et al
(717) reported that the actual mortality rate in New York
State declined from 3.52% in 1989 to 2.78% in 1992 while
the risk-adjusted rate decreased from 4.17% to 2.45% during
the same period. The STS National Cardiac Surgical
Database reported that the risk-adjusted mortality rate for
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CABG declined from 3.76% to 3.50% between 1990 and
1994 (16). 
There are numerous potential explanations for this reduc-
tion in mortality after CABG. Some authors suggest that the
feedback of outcome data associated with either an organ-
ized or implicit effort at quality improvement has been prin-
cipally responsible for this decline. O’Connor et al (13)
reported that a combination of regular feedback of mortality
data, associated with open discussion and visitation between
competing cardiac surgical programs in Maine, New
Hampshire, and Vermont, was directly responsible for the
24% reduction in mortality observed there. Hannan et al
(717) reported that the simple fact that outcomes were
tracked and reported back to institutions led implicitly to
improvement efforts that accounted for the New York State
decline in mortality rate. Grover et al (718) reported on a
program of data feedback and regular audit of programs by
members of the Audit Committee of the Veterans Affairs
Cardiac Surgery Consultants Committee that led to a
decrease in observed versus risk-adjusted mortality rates
within the Veterans Administration cardiac surgical system.
Omoigui et al (719), a group from the Cleveland Clinic, sug-
gested that the reduction in mortality noted in New York
State was caused by an out-migration of high-risk patients
due to the increased scrutiny provoked by public release of
mortality data. Despite this criticism, Hannan et al (717)
found no consistent bias against selecting high-risk patients
in the state of New York. Ghali et al (720) suggested that the
reduction seen in both northern New England and New York
State would have happened regardless of quality improve-
ment efforts, as similar improvement was found in
Massachusetts where there was neither a statewide, organ-
ized improvement effort nor dissemination of mortality data.
Peterson et al (721) examined Medicare data on both the
total amount of improvement and the ultimate risk-adjusted
mortality rate and found that New York State and northern
New England showed both the lowest overall mortality rates
as well as the greatest improvements of any other state or
region in the country. 
Although it appears clear that outcome tracking has result-
ed in fewer deaths after CABG, Chassin (722) would sug-
gest that it is the public dissemination of this information
that has been responsible for driving that improvement.
While the 1987 Health Care Financing Administration report
of CABG mortality data received widespread media atten-
tion, most newspapers focused on outlier hospitals and thus
provided little guidance to consumers (723). Peterson et al
(721) concluded that reporting of outcomes, whether volun-
tary and anonymous (northern New England) or mandatory
and public (New York State), coupled with initiatives in
quality improvement is indeed effective in improving mor-
tality rates after CABG. 
Besides driving improvement efforts, many suggested that
public reporting of mortality data would initiate market
forces that would drive patients to high-volume “centers of
excellence.” Yet, when clinicians and patients in
Pennsylvania (724,725) and clinicians in New York State
(726) were asked to assess how much the statewide report-
ing of outcome data influenced their referral practices, sur-
prisingly few admitted that these efforts had any effect at all
(724,726). Shahian (727) found that in the State of
Massachusetts, patients preferred hospital reputation, tradi-
tional referral patterns and geographic proximity over pub-
lished outcomes as determinants for selecting a cardiac sur-
gical provider. Finlayson (728) studied a Veterans
Administration population and found that patients anticipat-
ing high-risk surgical procedures would accept a 2-fold to 6-
fold increase risk of mortality to receive their care close to
home. 
An excellent review of the impact of outcomes reporting
on cardiac surgery has been provided by Shahian et al (729).
Outcome reporting in the form of risk-adjusted mortality
rates after CABG has been effective in reducing mortality
rates nationwide. While distortion of data (gaming) and out-
migration of patients have been reported, it is doubtful that
these practices have had a meaningful effect on this
improvement. However, public release of hospital and physi-
cian-specific mortality rates has not been shown to drive this
improvement and has failed to effectively guide consumers
or alter clinicians’ referral practices. 
7.3. Hospital Environment 
The context within which coronary surgery is performed
will ultimately influence the outcome experienced by
patients. Because of the highly technical nature of the pro-
cedure and the narrow clinical margin of the patient popula-
tion, strategies to ensure consistent care have evolved. These
strategies include establishing specialized cardiac surgical
centers (heart hospitals), forming multidisciplinary clinical
teams within hospitals, and creating and implementing clin-
ical pathways, care maps, algorithms, and protocols. 
Appropriately implemented clinical guidelines have been
shown to improve the processes of clinical care in 90% of
cases and show measurable improvement of outcome in 20%
of cases (730). Successful application of clinical guidelines
require they be accompanied by unambiguous statement of
purpose, that clinicians for whom they are intended have
some role in their creation or implementation, and that forc-
ing functions, such as clinical pathways, algorithms, or pro-
tocols, be tied to the guidelines (731,732). 
Whereas clinical practice guidelines describe an ideal
treatment strategy for a particular disease process, clinical
pathways (a.k.a. critical pathways, care maps) represent the
optimal sequence of timing of interventions for a particular
diagnosis or procedure. Well-designed clinical pathways
ensure care is delivered as prescribed by a practice guideline
while optimizing resource utilization, minimizing chance of
error, and allowing for the reinvention of these standards
within the context of local culture. They are typically creat-
ed for patient populations that are large in number, relative-
ly homogeneous in appearance, and consume large amounts
of resources and have thus been found ideal for the CABG
population (732,733). 
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8. ECONOMIC ISSUES
8.1. Cost-Effectiveness of CABG
CABG represents a major investment for society, with an
initial hospital cost of around $30 000 applied to more than
300 000 patients annually in the United States alone (around
10 billion dollars) (124). It is most appropriate to consider
the cost of CABG surgery compared with other medical
treatment modalities with regard to cost-effectiveness.
Definitive data for such a comparison are sparse, and multi-
ple assumptions must be made. The most reasonable system
of analysis appears to be an estimation of the dollars spent
per quality-adjusted life-year gained ($/QALY). In general,
a cost-effectiveness of $20 000 to $40 000/QALY is consis-
tent with other medical programs funded by society, such as
hemodialysis and treatment of hypertension. A cost of less
than $20 000/QALY would be considered particularly cost-
effective, whereas a cost greater than $60 000/QALY would
be considered expensive (734).
A widely quoted analysis of the cost-effectiveness of
CABG surgery was compiled by Weinstein and Stason (735)
in 1982 utilizing data gathered from the then-available ran-
domized trials comparing medical therapy with coronary
artery bypass. The cost of coronary bypass is relatively con-
stant, whether it is conducted for left main disease or for sin-
gle-vessel disease. Cost-effectiveness is excellent when the
procedure is applied to patient subgroups for which the ben-
efit in terms of survival or relief of symptoms compared with
medical therapy is great (as it would be, for example, in a
patient with severe angina and triple-vessel disease). The
cost-effectiveness of CABG becomes inordinately poor,
however, when the benefit in terms of survival is marginal
and there are few symptoms in the preoperative patient.
These conclusions are depicted in Figure 12, and examples
are presented in Table 18. Cost-effectiveness for coronary
bypass in patients with left main disease is exceptionally
good at $9000/QALY. It is similarly quite attractive in
patients with 3-vessel disease, at $18 000/QALY. If one con-
siders the cost-effectiveness of coronary bypass in 2-vessel
disease, Weinstein and Stason found that the presence or
absence of LAD disease was very important. Because
CABG surgery is particularly effective in relieving angina,
its cost-effectiveness, even in patients with single-vessel dis-
ease, is not prohibitive if that patient has severe angina. In
the patient without angina or with only mild angina, howev-
er, the cost of coronary bypass per QALY was prohibitive in
this analysis, exceeding $100 000 for patients with 2-vessel
or 1-vessel disease. 
It is not surprising that coronary bypass surgery is cost-
effective in exactly those groups of patients in whom sur-
Figure 12. Cost utility. VD = vessel disease; LMD = left main disease; QALY=quality-adjusted life-year. Modified with permission from
Elsevier Science Inc. (Kupersmith et al. Prog Cardiovas Dis. 1995;37:307-56) (734).
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vival and/or symptomatic benefit is demonstrable. Most
important, within these subsets the cost-effectiveness of
coronary bypass compares favorably with other generally
accepted medical therapies. 
8.2. Cost Comparison With Angioplasty
The cost-effectiveness of angioplasty is dependent on the
preangioplasty symptoms of the patient in the same way that
CABG surgery is so dependent, particularly in subgroups in
whom revascularization cannot be shown to have a survival
benefit compared with medical therapy (i.e., in single-vessel
disease). Because it relieves angina, angioplasty for single-
vessel-disease patients with severe angina is estimated to
have a cost-effectiveness of $9000/QALY. In patients with
only mild angina, however, angioplasty in the setting of
LAD single-vessel disease is estimated to have a poor cost-
effectiveness of $92 000/QALY (736). 
A direct comparison of the cost of angioplasty and coro-
nary bypass surgery for selected patients with multivessel
disease (i.e., those patients for whom either therapeutic
modality was considered appropriate) has been made in the
randomized trials of angioplasty versus CABG. In general,
the cost analyses of randomized trials have revealed that the
initial cost of angioplasty is about 50% to 65% of the initial
cost of bypass surgery. The incremental cost of repeated pro-
cedures during the follow-up period has led to a cumulative
cost of angioplasty that approaches the cumulative cost of
bypass surgery at 3 years. The EAST found that the 3-year
inpatient cost of angioplasty was 94% of that of bypass sur-
gery (135). The RITA trial, which included a large number
of patients with single-vessel disease, found that the 2-year
cumulative cost of angioplasty was 80% of the cost of coro-
nary bypass (136). The BARI trial conducted a prospective-
ly designed analysis of the comparative cost of the 2 proce-
dures from a subgroup of the participating centers, compris-
ing a total of 934 of the 1829 patients enrolled (124). The
mean initial hospital cost of angioplasty was 65% of that of
surgery, but after 5 years the cumulative cost of initial surgi-
cal therapy was only $2700 more than the cost of initial
angioplasty (around a 5% difference). Because the surgical
cohort had a higher overall 5-year survival, the cost of this
survival benefit could be calculated. It was found to be
$26000/y of survival benefit for surgical therapy of 2- and 3-
vessel disease (in patients for whom either angioplasty or
surgery was considered appropriate initial therapy). As con-
sidered in the previous section, this incremental cost for dou-
ble- and triple-vessel disease is within the range of costs for
generally accepted therapies. It is notable that this cost of
incremental benefit does not consider the benefit of coronary
bypass in terms of relief of angina during the follow-up
interval, which was demonstrated in each of these 3 trials
(BARI, EAST, and RITA). If this factor were included, the
cost-effectiveness of CABG for incremental benefit in these
selected patients with multivessel disease ($/QALY) would
be less than $26 000. 
Previous considerations of both patient benefit and cost-
effectiveness have suggested that angioplasty is less effec-
tive for patients with more advanced disease. Data gathered
at Duke University have shown that there is a significant cost
gradient for angioplasty as the extent of disease increases
(related to repeated procedures whose incidence may be
reduced by stents), which is not apparent for coronary
bypass (Figure 13) (737). 
The use of drug-eluting stents in percutaneous revascular-
ization will require a re-evaluation of cost-effectiveness con-
siderations. The initial procedure is considerably more
expensive (equaling the cost of CABG in many patients with
multivessel disease), but the recurring cost of reintervention
for restenosis will be dramatically reduced. Cost-effective-
ness will depend on pricing of stents, utilization rates of the
more expensive stents, and efficacy. All of these factors are
evolving rapidly.
8.3. Cost Reduction in Coronary Bypass
Estimates presented in the previous portion of this section
suggest that coronary bypass has been cost-effective in the
last 2 decades. Initiatives to decrease the length of stay by
using clinical pathways and standardized fast-track proto-
cols have reduced hospital costs. Indeed, the estimates made
by Weinstein and Stason are distinctly dated: improvements
in outcomes and shortened lengths of hospitalization are
likely to have considerably improved the cost-effectiveness
of CABG (and angioplasty) since 1982. 
Studies from the 1980s suggested that by concentrating
CABG procedures into high-volume institutions, the overall
cost of providing coronary surgical revascularization would
be reduced owing to efficiencies of scale (738-740). Shahian
et al (741) studied this question and found no relationship
between either hospital size or annual CABG case volume
and cost of performing bypass surgery. 
Table 18. Cost per Quality-Adjusted Life-Year ($/QALY) of
Revascularization Compared With Medical Therapy* 
CABG for left main stenosis, 9000
with or without angina
CABG for 3VD with or 18 000
without angina 
CABG for 2VD with severe 22 000
angina and LAD stenosis
CABG for 2VD with severe 61 000
angina, no LAD disease 
CABG for 2VD, no angina, 27 000
with LAD stenosis
CABG for 2VD, no angina, 680 000
no LAD disease
CABG for 1VD, severe angina 73 000
PTCA for 1VD, severe angina 9000
PTCA for LAD stenosis, 92 000
mild angina
CABG indicates coronary artery bypass graft; 1, 2, or 3VD, 1-, 2-, or 3-vessel disease;
LAD, left anterior descending coronary artery; and PTCA, percutaneous transluminal
coronary angioplasty.
*Adjusted to 1993 dollars from multiple sources in a review by Kupersmith et al. Prog
Cardiovas Dis. 1995;37:307-56 (734).
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A major innovation has been the introduction of off-bypass
CABG, which has reduced the postprocedure length of stay
to between 2 and 3 days. In some centers, this has led to a
total 3-month cost for single-vessel coronary bypass that is
not significantly different from the total 3-month cost for
angioplasty of single-vessel disease (742). Considering the
favorable long-term patency of an IMA graft to the LAD, the
cost reductions possible with off-bypass CABG may
improve the relative cost-effectiveness of coronary bypass
compared with either medical therapy or percutaneous tech-
niques, particularly for symptomatic, proximal LAD dis-
ease.
9. INDICATIONS
9.1. Introduction
The CABG operation is indicated both for the relief of
symptoms and for the prolongation of life. The 1991
Guidelines focused on survival relative to medical therapy as
the pivotal recommendation for operation. In addition to
extension of the length of life, this operation is an important
therapeutic tool for the relief of disabling symptoms. 
The 1991 Guidelines state that “the evidence is complete
that the coronary artery bypass operation relieves angina in
most patients.” The results of the randomized trials of
CABG versus PTCA have confirmed and extended this con-
clusion (743,744). Not only did CABG effectively relieve
angina in the symptomatic patients enrolled in the random-
ized trials, but also freedom from angina and from antiangi-
nal medications was superior in the CABG cohorts com-
pared with PTCA cohorts. Bypass surgery also relieved
angina better than coronary stents in a randomized trial com-
paring the 2 forms of therapy (137). 
The benefit realized from the use of CABG to relieve dis-
abling symptoms must be balanced against the risk of the
operation and tempered by the potential activity level of the
individual patient. This risk may be very low in selected
groups of patients. In a series of 1386 patients with single-
and double-vessel disease aged less than 66 years, without
CHF, and an EF greater than 0.35 from the early 1980s at
Emory University, a hospital mortality of 0.07% (1 patient)
was reported. Not only did these young, healthy patients
have a very low risk, but their potential for renewal of an
active lifestyle was exceptionally high. CABG in patients
such as these for relief of disabling angina after failure of
medical therapy is an attractive option, even if no survival
benefit can be predicted. If, on the other hand, one were to
consider a 78-year-old patient with limiting arthritis and
Class II angina, then the potential benefit of CABG will be
considerably less and the risk comparably greater. In this
case, the attractiveness of PTCA or continued medical ther-
apy as the appropriate therapy is enhanced. 
Some caution must be expressed in the use of CABG for
relief of symptoms. CABG treats the manifestations of
CAD, not the disease process. As coronary disease progress-
es, therefore, angina often returns. The hazard function for
return of angina is low for the first 5 years after operation
and then begins to rise, seemingly related to late closure of
bypass conduits. So long as the patient and the healthcare
practitioner understand that angina may return after 5 to 10
years, the application of CABG for the relief of angina rather
than for survival benefit is appropriate, particularly in low-
risk patients. If preoperative symptoms are disabling, there is
a high probability for a return to a fully functional lifestyle
and, as discussed in Section 8, the procedure is cost-effective
as well.
Figure 13. Percentage of 1-year costs for PTCA and CABG. PTCA indicates percutaneous transluminal coronary angioplasty;
CABG, coronary artery bypass graft. Reprinted with permission from the Society of Thoracic Surgeons (Mark. Ann Thorac Surg
1996;61:S12-5) (737).
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The second important recommendation for CABG, after
relief of symptoms, is prolongation of life. The randomized
trials of CABG versus medical therapy have defined patient
subsets whose survival is enhanced. These patients tend to
be those with advanced coronary disease: notably left main
disease and triple-vessel disease (or double-vessel disease
including a proximal LAD stenosis) combined with LV dys-
function. The survival benefit of CABG was examined in
detail in the 1991 Guidelines and will be applied to specific
patient subgroups in the following sections.
The explosive growth of PCI in the last decade mandates a
careful examination of CABG survival versus PCI survival.
Large randomized trials generally show that 7 to 8 year sur-
vival is superior for patients with diabetes undergoing
CABG compared with patients with diabetes undergoing
PTCA (131,130). Among patients without diabetes, there
appears to be little difference in survival.
Only short-term results of stent revascularization are avail-
able at this time; however, similar trends favoring surgery in
patients with diabetes are emerging. Definitive conclusions
regarding stent procedures await maturation of ongoing clin-
ical trials.
9.2. Clinical Subsets
9.2.1. Asymptomatic or Mild Angina
Class I
1. CABG should be performed in patients with asymp-
tomatic or mild angina who have significant left main
coronary artery stenosis. (Level of Evidence: A)
2. CABG should be performed in patients with asymp-
tomatic or mild angina who have left main equiva-
lent: significant (greater than or equal to 70%) steno-
sis of the proximal LAD and proximal left circumflex
artery. (Level of Evidence: A)
3. CABG is useful in patients with asymptomatic
ischemia or mild angina who have 3-vessel disease.
(Survival benefit is greater in patients with abnormal
LV function; e.g., EF less than 0.50 and/or large areas
of demonstrable myocardial ischemia.) (Level of
Evidence: C)
Class IIa
CABG can be beneficial for patients with asympto-
matic or mild angina who have proximal LAD steno-
sis with 1- or 2-vessel disease. (This recommendation
becomes a Class I if extensive ischemia is document-
ed by noninvasive study and/or LVEF is less than
0.50.) (Level of Evidence: A)
Class IIb
CABG may be considered for patients with asympto-
matic or mild angina who have 1- or 2-vessel disease
not involving the proximal LAD (If a large area of
viable myocardium and high-risk criteria are met on
noninvasive testing, this recommendation becomes
Class I). (Level of Evidence: B)
For patients with no symptoms or mild angina, the appro-
priateness of coronary bypass surgical therapy is based on
survival advantage therapy compared with nonsurgical ther-
apy. The relative appropriateness of percutaneous versus
surgical therapy is discussed in Section 3.3. To identify
anatomic subsets in which coronary bypass is beneficial,
definition of “important” coronary stenosis is necessary. For
this and all subsequent sections, coronary stenosis will be
defined as a 50% or greater reduction of lumen diameter.
This is the degree of narrowing defined as important in the
majority of randomized trials that have examined the rela-
tionship of coronary anatomy and survival after CABG. It is
important to note that the level of angina in this category is
not considered an indication for surgery. Moderate or severe
angina would represent symptoms that many patients find
unacceptable despite adequate medical therapy.
Contrariwise, in this category, patients are either completely
asymptomatic or have acceptable symptoms such that
bypass surgery for symptom relief is not the issue. 
The indication for bypass surgery in this category relates to
the extent of coronary disease, the demonstration of objec-
tive signs or symptoms of this disease, and consideration for
the risk of nonmedical therapy, which may include either
bypass surgery or angioplasty. As stated in Section 3.2, the
data on which these classifications are assigned are based on
3 randomized controlled trials, several smaller randomized
trials, a subsequent meta-analysis of these data, and several
observational studies. The limitations of these data are dis-
cussed in Section 3.2 and listed in Table 7. 
9.2.2. Stable Angina
Class I
1. CABG is recommended for patients with stable angi-
na who have significant left main coronary artery
stenosis. (Level of Evidence: A)
2. CABG is recommended for patients with stable angi-
na who have left main equivalent: Significant (greater
than or equal to 70%) stenosis of the proximal LAD
and proximal left circumflex artery. (Level of
Evidence: A)
3. CABG is recommended for patients with stable angi-
na who have 3-vessel disease. (Survival benefit is
greater when LVEF is less than 0.50.) (Level of
Evidence: A)
4. CABG is recommended in patients with stable angina
who have 2-vessel disease with significant proximal
LAD stenosis and either EF less than 0.50 or demon-
strable ischemia on noninvasive testing. (Level of
Evidence: A)
5. CABG is beneficial for patients with stable angina
who have 1- or 2-vessel CAD without significant prox-
imal LAD stenosis but with a large area of viable
myocardium and high-risk criteria on noninvasive
testing. (Level of Evidence: B)
6. CABG is beneficial for patients with stable angina
who have developed disabling angina despite maxi-
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mal noninvasive therapy, when surgery can be per-
formed with acceptable risk. If angina is not typical,
objective evidence of ischemia should be obtained.
(Level of Evidence: B)
Class IIa
1. CABG is reasonable in patients with stable angina
who have proximal LAD stenosis with 1-vessel dis-
ease. (This recommendation becomes Class I if exten-
sive ischemia is documented by noninvasive study
and/or LVEF is less than 0.50). (Level of Evidence: A)
2. CABG may be useful for patients with stable angina
who have 1- or 2-vessel CAD without significant prox-
imal LAD stenosis but who have a moderate area of
viable myocardium and demonstrable ischemia on
noninvasive testing. (Level of Evidence: B)
Class III
1. CABG is not recommended for patients with stable
angina who have 1- or 2-vessel disease not involving
significant proximal LAD stenosis, patients who have
mild symptoms that are unlikely due to myocardial
ischemia, or patients who have not received an ade-
quate trial of medical therapy and
a. have only a small area of viable myocardium or
(Level of Evidence: B)
b. have no demonstrable ischemia on noninvasive
testing. (Level of Evidence: B)
2. CABG is not recommended for patients with stable
angina who have borderline coronary stenoses (50%
to 60% diameter in locations other than the left main
coronary artery) and no demonstrable ischemia on
noninvasive testing. (Level of Evidence: B)
3. CABG is not recommended for patients with stable
angina who have insignificant coronary stenosis (less
than 50% diameter reduction). (Level of Evidence: B)
For patients with stable angina, the recommenation for
CABG is based both on the likelihood of improving survival
and on the likelihood of relief of lifestyle-limiting symp-
toms. Based on the 3 large, prospective, randomized trials
comparing medical with surgical therapy and multiple
observational studies, the patient factors most influencing a
decision to recommend CABG include the presence of
severe proximal multivessel coronary disease, LV dysfunc-
tion, a strongly positive stress test, and comorbid conditions
such as PVD and diabetes. Additional factors that are of crit-
ical importance relate to the perceived immediate risk of
bypass surgery and the long-term prognosis, particularly
whether the patient's potential improvement in longevity or
quality of life due to a successful bypass operation justifies
the short-term risk. 
9.2.3. Unstable Angina/Non–ST-Segment
Elevation MI (NSTEMI)
Class I
1. CABG should be performed for patients with unsta-
ble angina/NSTEMI with significant left main coro-
nary artery stenosis. (Level of Evidence: A)
2. CABG should be performed for patients with unsta-
ble angina/NSTEMI who have left main equivalent:
significant (greater than or equal to 70%) stenosis of
the proximal LAD and proximal left circumflex
artery. (Level of Evidence: A)
3. CABG is recommended for unstable angina/NSTEMI
in patients in whom revascularization is not optimal
or possible, and who have ongoing ischemia not
responsive to maximal nonsurgical therapy. (Level of
Evidence: B)
Class IIa
CABG is probably indicated for patients with unsta-
ble angina/NSTEMI who have proximal LAD stenosis
with 1- or 2-vessel disease. (Level of Evidence: A)
Class IIb
CABG may be considered in patients with unstable
angina/NSTEMI who have 1- or 2-vessel disease not
involving the proximal LAD when percutaneous
revascularization is not optimal or possible. (If there
is a large area of viable myocardium and high-risk
criteria are met on noninvasive testing, this recom-
mendation becomes Class I.) (Level of Evidence: B)
Indications for coronary bypass surgery in this category
relate not only to survival but also to the relief of symptoms.
Thus, in general, all of the survival indications listed for the
asymptomatic patient or the individual with stable angina
apply. However, timing of surgery becomes a critical con-
sideration. Some reports have suggested a high mortality
after CABG in patients with acute unstable angina or
NSTEMI and have shown that one of the independent pre-
dictors of mortality after coronary bypass surgery is the sta-
bility of the patient going to operation. Other investigators
have not found this association (Section 5.11). In the patient
in whom stabilization with aggressive medical therapy may
be achieved, it is advisable to stabilize and reduce ongoing
ischemia before proceeding to bypass surgery. In this regard,
a small randomized trial demonstrated that insertion of an
IABP 2 hours or more before CPB can reduce bypass time,
intubation time, and length of stay, and improve postopera-
tive cardiac output in high-risk patients (745).
9.2.4. ST-Segment Elevation MI (STEMI)
Class I
Emergency or urgent CABG in patients with STEMI
should be undertaken in the following circumstances:
a. Failed angioplasty with persistent pain or hemody-
namic instability in patients with coronary anato-
my suitable for surgery. (Level of Evidence: B)
b. Persistent or recurrent ischemia refractory to
medical therapy in patients who have coronary
anatomy suitable for surgery, who have a signifi-
cant area of myocardium at risk, and who are not
candidates for PCI. (Level of Evidence: B) 
c. At the time of surgical repair of postinfarction ven-
tricular septal rupture or mitral valve insufficien-
cy. (Level of Evidence: B)
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d. Cardiogenic shock in patients less than 75 years
old with ST-segment elevation or left bundle-
branch block or posterior MI who develop shock
within 36 hours of MI and are suitable for revas-
cularization that can be performed within 18
hours of shock, unless further support is futile
because of patient’s wishes or contraindications/
unsuitability for further invasive care (Level of
Evidence: A)
e. Life-threatening ventricular arrhythmias in the
presence of greater than or equal to 50% left main
stenosis and/or triple-vessel disease (Level of
Evidence: B)
Class IIa
1. CABG may be performed as primary reperfusion in
patients who have suitable anatomy and who are not
candidates for or who have had failed fibrinolysis/
PCI and who are in the early hours (6 to 12 hours) of
evolving STEMI. (Level of Evidence: B)
2. In patients who have had an STEMI or NSTEMI,
CABG mortality is elevated for the first 3 to 7 days
after infarction, and the benefit of revascularization
must be balanced against this increased risk. Beyond
7 days after infarction, the criteria for revasculariza-
tion described in previous sections are applicable.
(Level of Evidence: B)
Class III
1. Emergency CABG should not be performed in
patients with persistent angina and a small area of
myocardium at risk who are hemodynamically stable.
(Level of Evidence: C)
2. Emergency CABG should not be performed in
patients with successful epicardial reperfusion but
unsuccessful microvascular reperfusion. (Level of
Evidence: C)
Although early coronary bypass surgery as a primary
reperfusion strategy in patients suffering from a STEMI has
been reported, the widespread use of intravenous fibrinolyt-
ic therapy for this purpose and more primary PCI has large-
ly superceded early application of bypass surgery. Studies
have shown that eventual infarct size and the subsequent risk
of mortality and/or LV dysfunction are related to the time
from the onset of symptoms until coronary reperfusion.
Although, on average, coronary bypass surgery requires a
longer time to establish coronary reperfusion than either of
the nonsurgical techniques, modification of the conditions of
reperfusion that is possible with surgical therapy may offer
some benefit with regard to eventual infarct size relative to
percutaneous or fibrinolytic therapy. Despite this potential
benefit of reperfusion modification, coronary bypass is
rarely performed for this indication except in special cir-
cumstances. The decision to perform surgery requires angio-
graphic demonstration of adequate target vessels in the
region of infarction and usually other regions as well. In
most circumstances, early coronary bypass for acute infarc-
tion is appropriate only in patients with residual ongoing
ischemia despite nonsurgical therapy, be it fibrinolysis, PCI,
or both. As with PCI, the risks of bypass operation in
patients in the midst of a STEMI are substantially higher
than are the risks in elective candidates. 
To determine the benefits and liabilities of treatment of an
acute MI with CABG requires accurately defining the topic.
The definition of acute MI is the resultant ischemic muscle
injury after reduction or interruption of the coronary artery
blood supply. The obvious weakness in this definition is the
variability of the tissue damage. This has been addressed by
sub-classifying MIs into Q-wave and non–Q-wave types. A
Q-wave infarction has been defined as ST-segment changes
that progress to new Q waves in addition to a creatine phos-
phokinase (CPK)-MB isoenzyme elevation of greater than
10 IU/L. Non–Q-wave infarction is defined as ST-segment
and T-wave abnormalities (generally NSTEMI) that do not
progress to pathological Q waves but show abnormal eleva-
tions of CPK-MB isoenzyme of greater than 10 IU/L (585).
The decision or appropriateness to recommend surgical
revascularization in the face of an acute MI depends on the
clinical symptoms and the presence of persistent ischemia
despite maximum medical therapy. This is also the algorithm
that is used to decide to proceed with catheter-based therapy.
It appears that when there is a situation that is not amenable
to medical or catheter-based therapy and persistent ischemia
is present, CABG is indicated. This is presuming that there
is no overwhelming contraindication against operation. 
There are specific conditions that will warrant CABG in
the face of an acute MI: the presence of left main stenosis,
severe 3-vessel disease, associated valve disease (whether
secondary to the MI or unrelated) (35a), and anatomy unsuit-
able for other forms of therapy. The literature is somewhat
vague regarding the categories for surgical intervention.
Some of the reports address STEMI versus NSTEMI while
others address the proximity of MI to operation (i.e., less
than 6 hours, 6 hours to 2 days, 2 to 14 days, 2 to 6 weeks,
and greater than 6 weeks) or unstable angina versus evolv-
ing MI, mechanical complications, acute occlusions, and
control patients. It is best to review these separately and try
to identify a common recommendation and approach. 
Braxton et al (585) studied the comparative effect of oper-
ating on patients with STEMI and NSTEMI versus a con-
trol group. Excluding the patients who require emergency
operation for mechanical complications of an acute MI, the
patients undergoing CABG within 48 hours of the STEMI
had a significantly increased operative mortality which
approached 50%. The data imply that for such patients,
there is much to be gained by waiting more than 48 hours
in most circumstances. The implication is also made study
also suggested that symptomatic patients with a NSTEMI
may undergo surgical revascularization at any time with no
significant increase in mortality over elective patients
(585). This is substantiated in an article by Goodman et al
(583), wherein MI after fibrinolytic therapy was evaluated
in relation to events with STEMI versus NSTEMI. The
NSTEMI was more likely to be nonanterior, distally locat-
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ed, and have better global and regional LV function. In the
setting of fibrinolysis after MI, patients with a NSTEMI
were more likely to have early, complete, and sustained
infarct-related artery patency and better LV function. This
identification of anatomic and functional differences
between STEMI and NSTEMI should also translate into
operative risk for these 2 patient cohorts and verifies the
worse operative risk with surgery in the early STEMI peri-
od. 
Creswell et al (581) retrospectively reviewed 2296 patients
who underwent CABG after an acute MI. A generalization
that was made was that the operative mortality decreased as
the time between the acute MI and operation increased.
Patients who underwent operation less than 6 hours after MI
had an operative mortality of 8.4% and those who underwent
operation greater than 6 hours, 4.3% (P equals 0.02) (Table
19). Additional findings were that despite the urgency of
operation, operative mortality was greater for those patients
with a preoperative MI than those without an MI. It is impor-
tant to note that when the independent risk factors of
urgency of operation, increased patient age, renal insuffi-
ciency, number of previous MIs, and hypertension were
adjusted for, the time interval between MI and CABG was
not a significant predictor of death. 
A third way to examine the impact of an MI on operative
mortality was reported by von Segesser et al (579). In this
series, 641 of 3397 patients had stable or unstable angina,
respectively, and underwent CABG. These 641 patients were
divided into 5 groups. Group A patients had unstable angina
that involved the inclusion of 2 of 6 criteria including
impending infarction, electrocardiographic ST-segment
modifications, minimal increases in CPK values, prolonged
angina at rest, angina resistant to intravenous medication,
and postinfarction angina. Group B patients were sustaining
an evolving MI defined as either a new electrocardiographic
Q wave; electrocardiographic ST-segment modifications;
and CPK-MB values greater than 8% of total CPK, CPK
greater than 3 times normal; CPK-MB greater than 10% of
total CPK; or new LV dyskinesis on echocardiography or
scintigraphy. Group C patients had mechanical complica-
tions of acute MI. Group D patients had an acute coronary
occlusion (emergency post-PTCA or angiography), and
Group E patients had stable class IV angina (control). 
In this series, acute CABG in patients with unstable angi-
na, evolving MI, and acute coronary occlusion demonstrated
results comparable to those of CABG in the elective cohort.
Late survival in these 3 cohorts was similar to that of the
group with stable angina. The worst late survival was in
those with mechanical complications, although it was
acceptable. The conclusions of this investigation support
acute revascularizations in unstable angina and selected
patients after acute MI. 
A review of other articles dealing with operation after
acute MI (34,450,580,746) suggests that unless patients are
in cardiogenic shock or have mechanical complications of
acute MI, early CABG can be performed with little or no
increase in risk of perioperative mortality. 
Mechanical complications of acute MI include ventricular
septal defect, MR secondary to papillary muscle infarction
and/or rupture, and LV free-wall rupture (747-754). There is
general agreement that cardiogenic shock associated with a
mechanical complication of an MI warrants emergency
operation to correct the defect as a life-saving procedure.
Although there is less consensus as to the timing of opera-
tion for patients with ventricular septal defect or MR after
acute MI with hemodynamic stability, most cardiac surgical
centers proceed promptly to surgery. 
There does not appear to be clear documentation of the
best timing for stable patients with a mechanical complica-
tion. There has been the argument to delay operation to
allow the friable tissue to “mature” and hold sutures; this
invokes some Darwinian selection process and prompted
Norell et al (747) to approach all of these types of problems
acutely. Their results did not demonstrate a statistical differ-
ence between acute and subacute operation. It must be stat-
ed, however, that the numbers in many of these series were
small or included patient enrollment extending over several
decades while techniques, understanding of physiology, and
philosophy have advanced. 
9.2.5. Poor LV Function
Class I
1. CABG should be performed in patients with poor LV
function who have significant left main coronary
artery stenosis. (Level of Evidence: B)
2. CABG should be performed in patients with poor LV
function who have left main equivalent: significant
(greater than or equal to 70%) stenosis of the proxi-
mal LAD and proximal left circumflex artery. (Level
of Evidence: B)
3. CABG should be performed in patients with poor LV
Table 19. Coronary Artery Bypass Graft Surgery Mortality After Acute Myocardial Infarction: Effect of Timing of Operation
Outcome Less than Greater than 
6 Hours 6-48 Hours 2-14 Days 2-6 Weeks 6 Weeks No MI
Op mort 9.1% 8.3% 5.2% 6.5% 2.9% 2.1%
Periop MI 9.1% 9.8% 2.8% 2.7% 4.0% 3.9%
Trans CVA 0.0% 3.0% 1.3% 0.4% 0.8% 0.8%
Perm CVA 9.1% 3.8% 2.9% 1.5% 2.3% 1.2%
AF 27.2% 40.9% 33.0% 39.1% 31.8% 30.7%
MI indicates myocardial infarction; Op mort, operative mortality; Periop, perioperative; Trans, transient; CVA, cerebrovascular accident; Perm, permanent; and AF, atrial fibrillation.
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function who have proximal LAD stenosis with 2- or
3-vessel disease. (Level of Evidence: B)
Class IIa
CABG may be performed in patients with poor LV
function with significant viable noncontracting,
revascularizable myocardium and without any of the
above anatomic patterns. (Level of Evidence: B)
Class III
CABG should not be performed in patients with poor
LV function without evidence of intermittent
ischemia and without evidence of significant revascu-
larizable viable myocardium. (Level of Evidence: B)
As discussed in Section 5.9, increasing evidence suggests
that chronic LV dysfunction due to viable but hibernating
myocardium in patients with severe multivessel disease is
relatively common. Furthermore, observational studies now
support the notion that coronary bypass surgery can result in
stabilization and often improvement in LV function in
selected patients. Operation on a patient with poor LV func-
tion is particularly appropriate if the patient has signs or
symptoms of intermittent ischemia and minimal or no CHF.
On the other hand, if the patient has prominent signs and
symptoms of CHF with minimal angina, the decision to
operate should be based on objective evidence of hibernating
myocardium (755). There should be demonstration of sub-
stantial regions of myocardial viability that would benefit
from revascularization (756). Such areas must be perfused
by coronary arteries of sufficient size and location to be rea-
sonable targets for bypass surgery (757). 
The concept of operating on patients with poor LV func-
tion for survival advantage comes from the randomized tri-
als that suggested that patients with left main, 3-vessel, and
2-vessel disease and vessel disease involving the proximal
LAD with concomitant LV dysfunction on average had a
greater survival advantage compared with those on medical
therapy. Although the randomized studies did not include
large numbers of patients with EFs less than 0.30, subse-
quent observational data suggest that these patients,
although having a higher immediate risk for bypass surgery,
may achieve a greater long-term gain in terms of survival
advantage, assuming that the concepts discussed above are
applied (755-757). 
9.2.6. Life-Threatening Ventricular Arrhythmias
Class I
1. CABG should be performed in patients with life-
threatening ventricular arrhythmias caused by left
main coronary artery stenosis. (Level of Evidence: B)
2. CABG should be performed in patients with life-
threatening ventricular arrhythmias caused by 3-ves-
sel coronary disease. (Level of Evidence: B)
Class IIa
1. CABG is reasonable in bypassable 1- or 2-vessel dis-
ease causing life-threatening ventricular arrhyth-
mias. (This becomes a Class I recommendation if the
arrhythmia is resuscitated sudden cardiac death or
sustained ventricular tachycardia.) (Level of
Evidence: B)
2. CABG is reasonable in life-threatening ventricular
arrhythmias caused by proximal LAD disease with 1-
or 2-vessel disease. (This becomes a Class I recom-
mendation if the arrhythmia is resuscitated sudden
cardiac death or sustained ventricular tachycardia).
(Level of Evidence: B)
Class III
CABG is not recommended in ventricular tachycar-
dia with scar and no evidence of ischemia. (Level of
Evidence: B)
The benefits of CABG in patients with ventricular arrhyth-
mias have been studied in survivors of out-of-hospital car-
diac arrest and in patients with inducible ventricular tachy-
cardia or fibrillation under electrophysiological study. In
general, bypass surgery has been more effective in reducing
episodes of ventricular fibrillation than ventricular tachycar-
dia, because the mechanism of the latter arrhythmia usually
involves reentry with scarred endocardium rather than
ischemia. 
In survivors of cardiac arrest who have severe and opera-
ble coronary disease, CABG surgery can suppress arrhyth-
mia induction, reduce subsequent cardiac arrest, and result
in a good long-term outcome (758-760). It is particularly
effective when an ischemic cause of the arrhythmia can be
documented, for instance, with exercise (761). However,
because coronary revascularization may not alleviate all of
the factors that predispose to ventricular arrhythmias, con-
comitant insertion of an implantable cardioverter-defibrilla-
tor may be necessary (762). Similarly, continued inducibili-
ty or clinical recurrence of ventricular tachycardia after
CABG usually requires defibrillator implantation. 
9.2.7. CABG After Failed PTCA
Class I
1. CABG should be performed after failed PTCA in the
presence of ongoing ischemia or threatened occlusion
with significant myocardium at risk. (Level of
Evidence: B)
2. CABG should be performed after failed PTCA for
hemodynamic compromise. (Level of Evidence: B)
Class IIa
1. It is reasonable to perform CABG after failed PTCA
for a foreign body in crucial anatomic position. (Level
of Evidence: C)
2. CABG can be beneficial after failed PTCA for hemo-
dynamic compromise in patients with impairment of
the coagulation system and without previous ster-
notomy. (Level of Evidence: C)
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Class IIb
CABG can be considered after failed PTCA for
hemodynamic compromise in patients with impair-
ment of the coagulation system and with previous
sternotomy. (Level of Evidence: C)
Class III
1. CABG is not recommended after failed PTCA in the
absence of ischemia. (Level of Evidence: C)
2. CABG is not recommended after failed PTCA with
inability to revascularize due to target anatomy or no-
reflow state. (Level of Evidence: C)
The decision to proceed with emergency bypass surgery
after a failed PTCA procedure is a complex one. The inter-
ventional cardiologist and consulting cardiac surgeon must
together decide when the procedure cannot be salvaged by
percutaneous techniques, often in the acute setting of
ischemia or infarction. Important considerations include the
mechanisms of the failed procedure, the potential to correct
this situation surgically, the extent of myocardium that is
jeopardized, and the overall clinical status of the patient.
Threatened compared with acute vessel closure poses a par-
ticularly challenging situation, since the physicians must
balance further attempts at percutaneous salvage versus
moving forward with surgery. Factors that influence the out-
come of surgery include patient characteristics such as LV
dysfunction, older age, and previous MI (763,764), as well
as anatomic factors such as complex lesion characteristics,
extent of multivessel disease, and the absence of collaterals
(763-766). Finally, outcome also depends on the total
ischemic time and may be adversely affected by a delay in
transport to the operating room (763,764,767,768). Bypass
surgery is clearly the procedure of choice in the setting of
hemodynamic compromise or for retrieval of a foreign body,
such as a fractured guidewire or undeployed stent in a cru-
cial anatomic position. 
Emergency bypass for failed PTCA is understandably
associated with a higher rate of death and subsequent MI
compared with elective bypass surgery (763,769). It is
encouraging to observe the diminishing need for emergency
bypass surgery in this situation, owing in large measure to
the increasing use and availability of intracoronary stents
(643,645). Among patients who require emergency bypass
after a failed angioplasty in the current era, the rate of com-
plications remains substantial (770-772). This probably
reflects the increased severity of CAD and other comorbidi-
ties in patients currently treated with PTCA. Therefore, a
coordinated approach and cooperative interaction between
the cardiologist, cardiac surgeon, and anesthesia team are
necessary to expedite resuscitation, transfer, and revascular-
ization of patients with failed PTCA (773-775).
9.2.8. Patients With Previous CABG
Class I
1. Coronary bypass should be performed in patients
with prior CABG for disabling angina despite opti-
mal nonsurgical therapy. (If angina is not typical,
then objective evidence of ischemia should be
obtained.) (Level of Evidence: B)
2. Coronary bypass should be performed in patients
with prior CABG without patent bypass grafts but
with Class I indications for surgery for native-vessel
CAD (significant left main coronary stenosis, left main
equivalent, 3-vessel disease). (Level of Evidence: B)
Class IIa
1. Coronary bypass is reasonable in patients with prior
CABG and bypassable distal vessel(s) with a large
area of threatened myocardium by noninvasive stud-
ies. (Level of Evidence: B)
2. Coronary bypass is reasonable in patients who have
prior CABG if atherosclerotic vein grafts with
stenoses greater than 50% supplying the LAD coro-
nary artery or large areas of myocardium are pres-
ent. (Level of Evidence: B)
Reoperation after previous CABG can be successfully per-
formed, but the risk of hospital mortality is increased about
3-fold compared with the primary operation. Moreover,
reoperation is associated with a diminished expectation for
relief of symptoms and a diminished expectation for prolon-
gation of life compared with the primary operation (see
Sections 4.1.2 and 5.7). For this reason, reoperation is gen-
erally reserved for relief of disabling symptoms or for com-
pelling evidence of potentially life-threatening areas of
myocardium at risk objectively quantified by noninvasive
studies. Because many of these patients have had previous
myocardial damage, consideration of the consequences of
infarction of an area of myocardium demonstrated to be at
risk must be weighed against the cumulative effect of the
current threatening situation combined with prior damage. 
The existence of significant late stenoses (greater than or
equal to 5 years after operation) representing atherosclerosis
in vein grafts that are greater than 50% stenosed and that
supply either the LAD coronary artery or large areas of
myocardium represent a potential anatomic indication for
operation.
For a patient with previous bypass surgery, percutaneous
techniques can be effective in treating native-vessel stenoses
and appear to be safe in treating early stenoses in vein grafts.
However, the use of percutaneous techniques to treat late
atherosclerotic stenoses in vein grafts has been much less
successful. 
An increasingly common situation is the presence of a
functioning IMA graft to the LAD artery, with recurrent
ischemia in other regions of the heart. The potential loss of
this conduit consequent to a reoperation represents a major
negative factor in the long-term therapy of that patient and is
cause for additional caution in recommendation of a reoper-
ation. 
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